|
Raffles Medical Group Ltd is an integrated private healthcare provider operating in Singapore, China, Japan, Vietnam, and Cambodia. The company delivers a continuum of care spanning primary, secondary, and tertiary levels through its network of multi-disciplinary clinics, Raffles Hospital, and specialist centers. Key business segments include general and specialist medical services, dental care under the Raffles Dental brand, Traditional Chinese Medicine, and consumer healthcare products such as nutraceuticals and supplements via Raffles Health. The group also provides health insurance solutions through its subsidiary Raffles Health Insurance and offers professional training through Raffles Healthcare Institute. Founded in 1976, the company serves individual patients and corporate clients across the Asia-Pacific region, managing airport medical centers in Singapore and Hong Kong. It operates under the Institutional Group Practice Model, emphasizing peer-reviewed, protocol-driven medical care and integrated electronic records. Summarised from the company's own disclosures, fiscal year ended Jun 2026 |
Industry Medical Care Facilities | Homepage rafflesmedicalgroup.com |
| Sector Healthcare | IR page rafflesmedicalgroup.com/investor-relations | |
|
Tags
private healthcare, tertiary care, primary care, dental care, traditional chinese medicine, health insurance, consumer healthcare, nutraceuticals, corporate wellness, health screening, medical training, RafflesCare, Raffles Airport Medical Centre, Raffles Corporate Wellness, Raffles Dental Surgery, Raffles Healthcare Consultancy, Raffles Healthcare Institute, Raffles Health Screeners, Raffles Longevity, Raffles Medical Management, Raffles Medihelp, Raffles Optica, Raffles Pharmacare, Raffles Pharmacy, Raffles Solitaire, Raffles Solitaire International, Raffles Specialist Centre, Raffles Wellness, Raffles International Medical Assistance LLP, Raffles Medical, Raffles Hospital, Raffles Dental, Raffles Chinese Medicine, Raffles Health Insurance, Raffles Health, Raffles24 Acute & Critical Care, Raffles Health eStore
|
Press page rafflesmedicalgroup.com/our-group/news-room/press-releases |
Metrics
| Valuation | |
|---|---|
| Market cap | S$ 1.537B |
| Market cap (USD) | $ 1.192B |
| P/E | 22.72 |
| PEG | — |
| P/BV | 1.48 |
| P/S | 2.01 |
| P/OCF | 14.06 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 6.7% |
| ROI | 6.4% |
| ROIC | 6.4% |
| Profit margin | 9.2% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | -21.0% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | 4.7% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 5 |
| Quality score | -6.3% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2013 | FY 2012 | FY 2011 | FY 2010 | FY 2009 | FY 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 765.299M | 751.564M | 706.92M | 822.916M | 723.791M | 568.203M | — | — | — | — | — | — | — | — | — | — | — |
| Net profit | 70.57M | 62.243M | 91.09M | 143.214M | 84.171M | 64.67M | 60.522M | 70.803M | 68.661M | 67.946M | 69.031M | 85.295M | 56.881M | 50.226M | 45.639M | 37.916M | 31.526M |
Podcast Mentions
Announcements made on SGXNet, newest first, routine notices (disclosures of interest, daily buy-backs, listing confirmations, coupons) included. The link opens the announcement on SGX. Press releases from the company's own website, newest first.
THE STRATTS TIME
MDODM (P) 046/10/2025
Sph ress
| MONDAY, SEPTEMBER 28 2026 | THE STRAITS TIMES
ADVERTORIAL
50 years of care, built on trust
As Raffles Medical Group marks its 50th anniversary, a doctor-patient relationship spanning decades reflects the value of continuity of care
Yeo Joo Ann has been seeing the same doctor.
From annual health screenings and managing a chronic condition to undergoing a life-saving heart procedure three years ago, the 68-year-old has entrusted his healthcare to Dr Alfred Loh, senior clinical director, and the team at Raffles Medical Group (RMG).
“| was introduced to Dr Loh in 1980. We hit it off and I've been seeing him since,” says Yeo.
Aroutine health screening revealed that Yeo was a Hepatitis B carrier, and Dr Loh has been helping him monitor and manage the condition
Source: Institute for Human Resource Professsionals (https://ihrp.sg). Permission required for reproduction.
Driving Transformation and Impact
Championing People in Healthcare Healthcare is only as strong as the people who deliver it. Technology and infrastructure are essential, but it is people who turn capability into care. Clinical excellence, patient trust, service quality and organisational resilience are all deeply dependent on the workforce. As Dr Loo Choon Yong, Executive Chairman Ʉ̌ɾࢫ-̛࣒k̛ͷ̌ɾʍ͍ࢫ̛ʱࢫþɄʱђʍ͛ࢫ·ʍɾˏɲɄ˵ࢫ n̛͍ͷͅࢫࣜþ·nࣝࢷࢫ͍ʍђʍɲͩ͛ࢷࢫ࣪̌ࢫ˂ʍɄ˵ͩ˂ɲɄ͍ʍࢷࢫ̛ͷ͍ࢫ competitive advantage may begin with strategy, but it is delivered through people.” From his experience, truly effective HR leaders go beyond managing people processes to shaping business outcomes. Early in his leadership journey, Dr Loo valued HR primarily as a functional support mechanism necessary for recruitment, policy management and employee relations. That perspective shifted Ʉ͛ࢫþ·nࢫʳ͍ʍΝࢫˏ̌ࢫ͛ɲɄ˵ʍࢫɄ̌ɾࢫɲ̛̆ͅ˵ʍΦˏͩΩࢶࢫzʍࢫ realised that true transformation could not be executed through operational directives alone. ࣪͛ࢫ̛͍ʳɄ̌ˏ͛Ʉͩˏ̛̌͛ࢫ͛ɲɄ˵ʍࢷࢫͩ˂ʍࢫ˵ʍɄɾʍ͍͛˂ˏͅࢫ question shifts from simply managing people to intentionally building organisational ɲɄͅɄɩˏ˵ˏͩΩࢷ࣫ࢫ˂ʍࢫʍΦͅ˵Ʉˏ̌͛ࢶࢫ࣪zɄΘˏ̌ʳࢫɄࢫ̛͍͛ͩ̌ʳࢫ CHRO helps leadership anticipate workforce risks, strengthen leadership capability, shape culture and ensure the organisation is prepared for the future.” To achieve this level of impact, functional ʍΦͅʍ͍ͩˏ͛ʍࢫɄ˵̛̌ʍࢫˏ͛ࢫˏ̌͛ͷʱёɲˏʍ̌ͩࢶࢫþ·nࢫ-zþÌࢫ Ʉ̌ɾࢫzþöࢫ·Ʉ͛ͩʍ͍ࢫơ͍̈ʱʍ͛͛ˏ̛̌Ʉ˵ࢫėɄ̌ˏʍࢫHˏ̛ࢫ ͷ̌ɾʍ͍͛ͩɄ̌ɾ͛ࢫͩ˂ˏ͛ࢫё͍͛ͩ˂Ʉ̌ɾࢶࢫ8ͷ͍ˏ̌ʳࢫ˂ʍ͍ࢫ HR career, she made a deliberate pivot to become more strategically involved. ࣪ࢫ͍͛ͩʍ̌ʳͩ˂ʍ̌ʍɾࢫͅɄ͍ͩ̌ʍ͍͛˂ˏ͛ͅࢫΝˏͩ˂ࢫɩͷ͛ˏ̌ʍ͛͛ࢫ leaders, aligned my team around operational and organisational priorities, and delivered measurable outcomes that mattered to the enterprise.”
In healthcare, our competitive advantage may begin with strategy, but it is delivered through people.
- Dr Loo Choon Yong Igniting Workforce Transformation This evolution in perspective for both Dr Loo and Tanie has proven crucial, especially since workforce challenges today are far more complex than a decade ago. As ͩʍɲ˂̛̌˵̛ʳˏɲɄ˵ࢫɾˏ͍͛ͷͩͅˏ̛̌ࢫ͍ʍɾʍё̌ʍ͛ࢫ̛͍˵ʍ͛ࢫ and capabilities, workforce planning has transitioned from headcount management to workforce reinvention. Employee expectations have also evolved, with ʳ͍ʍɄͩʍ͍ࢫʍ̆ͅ˂Ʉ͛ˏ͛ࢫ̛̌ࢫђʍΦˏɩˏ˵ˏͩΩࢷࢫΝʍ˵˵ɩʍˏ̌ʳࢷࢫ purpose and meaningful leadership. At the same time, tighter labour markets and the structural challenges of an ageing population add further demographic pressures. ̌ࢫͩ˂ʍࢫ˂ʍɄ˵ͩ˂ɲɄ͍ʍࢫɄ͍ʍ̌Ʉࢷࢫͩ˂ʍ͛ʍࢫɲ˂Ʉ˵˵ʍ̌ʳʍ͛ࢫ Ʉ͍ʍࢫ̆Ʉʳ̌ˏёʍɾࢶࢫŋ̛͍ˬʱ̛͍ɲʍࢫ͛˂̛͍ͩɄʳʍ͛ࢷࢫɲ˵ˏ̌ˏɲɄ˵ࢫ burnout and retention of specialised talent are constant concerns. Sustaining productivity without compromising quality of care requires deliberate workforce ͍͛ͩɄͩʍʳˏʍ͛ࢶࢫ͛ࢫ8͍ࢫ§̛̛ࢫʍ̆ͅ˂Ʉ͛ˏ͛ʍ͛ࢷࢫ࣪࠴࠳ࢫΩʍɄ͍͛ࢫ ago, workforce discussions were largely operational. Today, they are deeply strategic.” To tackle these complexities, the Executive Chairman and CHRO jointly drive ̛͍ʳɄ̌ˏ͛Ʉͩˏ̛̌Ʉ˵ࢫ͍ͩɄ̌͛ʱ̛͍̆Ʉͩˏ̛̌ࢫɄͩࢫþ·nࢶࢫŋˏͩ˂ࢫ Dr Loo’s full support, Tanie is leading a major organisational review under the Career
59
60
Empowering Change . Championing Progress
Dr Loo Choon Yong Executive Chairman and Co-Founder þɄʱѾʍ͛ࣗ·ʍɾˏɲɄ˵ࣗn̛͍ͷࣗͅ
Architecture project. This initiative provides greater structural clarity, maps out clear job responsibilities and constructs a more robust framework for career development – ultimately tailoring the workforce to align the Group’s strategic vision and power future growth plans and evolving business needs. Another key area is the enhancement of leadership capabilities. Recognising that successful healthcare organisations depend ̛̌ࢫ̛͍͛ͩ̌ʳࢫ˵ʍɄɾʍ͍͛ࢷࢫėɄ̌ˏʍࢷࢫ8͍ࢫ§̛̛ࢫɄ̌ɾࢫþ·n࣭͛ࢫ senior leadership team drive professional growth via the Leadership Framework. By
Ms Tanie Eio ईzþöࣗ·Ʉ͛ͩʍ͍ࣗơ͍̈ʱʍ͛͛ˏ̛̌Ʉ˵उ -˂ˏʍʱࣗzͷ̆Ʉ̌ࣗþʍ̛͛ͷ͍ɲʍ͛ࣗÌʱѽɲʍ͍ þɄʱѾʍ͛ࣗ·ʍɾˏɲɄ˵ࣗn̛͍ͷࣗͅ
explicitly mapping out expected behaviours and leadership standards, this framework forms the bedrock for accountability, performance management, career advancement, succession planning and talent development. öɄ͍Ʉ˵˵ʍ˵ࢫ̛ͩࢫͩ˂ˏ͛ࢷࢫþ·nࢫˏ͛ࢫɲ̛̌ɾͷɲͩˏ̌ʳࢫɄࢫ comprehensive evaluation of its Talent Development programmes. Designed to complement the framework, this review enhances leadership bench strength and
Driving Transformation and Impact
IHRP has helped shift HR from being seen as operational to being recognised as a strategic profession with de˚ned standards and competencies. ࣾࣗ·͛ࣗėɄ̌ˏʍࣗHˏ̛ sharpens succession readiness, creating a sustainable talent pipeline geared towards advancing the Group’s long-term expansion plans. Navigating Technology and AI Disruption As the pace of technology disruption ˂Ʉ͛ͩʍ̌͛ࢷࢫͅɄ͍ͩˏɲͷ˵Ʉ͍˵ΩࢫΝˏͩ˂ࢫࢫɄ̌ɾࢫɾˏʳˏͩɄ˵ࢫ transformation reshaping the future of work, Dr Loo recognises that the challenge extends ɩʍΩ̛̌ɾࢫ̛ͅʍ͍Ʉͩˏ̛̌Ʉ˵ࢫʍʱёɲˏʍ̌ɲΩࢫ̛ͩࢫ͍ʍɾʍё̌ˏ̌ʳࢫ workforce roles and capabilities. ėɄ̌ˏʍࢫˏ̌͛ˏ͛ͩ͛ࢷࢫ࣪ė˂ˏ͛ࢫ̆ʍɄ̌͛ࢫzþࢫ̆ͷ͛ͩࢫɩʍࢫɄͩࢫͩ˂ʍࢫ ʱ̛͍ʍʱ̛͍̌ͩࢫ̛ʱࢫɲ̛̌Θʍ͍͛Ʉͩˏ̛̌͛ࢫɄɩ̛ͷͩࢫࢶ࣫ࢫŋɄ˵ˬˏ̌ʳࢫ ͩ˂ʍࢫͩɄ˵ˬࢷࢫ͛˂ʍࢫͅͷ͍͛ͷʍɾࢫɄɾΘɄ̌ɲʍɾࢫ˵ʍɄ͍̌ˏ̌ʳࢫˏ̌ࢫࢫ leadership in a world-renowned institution to strengthen her ability to connect technology disruption with workforce strategy. By providing strategic guidance on change management, workforce implications and ɲɄͅɄɩˏ˵ˏͩΩࢫɩͷˏ˵ɾˏ̌ʳࢷࢫ͛˂ʍࢫʍ̌͛ͷ͍ʍ͛ࢫͩ˂Ʉͩࢫࢫ adoption balances enterprise goals with people outcomes. This critical advisory work is ɾʍ˵ˏΘʍ͍ʍɾࢫɾˏ͍ʍɲͩ˵Ωࢫͩ˂̛͍ͷʳ˂ࢫ˂ʍ͍ࢫ͛ʍɄͩࢫ̛̌ࢫþ·n࣭͛ࢫ ࢫėɄ͛ˬʱ̛͍ɲʍࢷࢫΝ˂ʍ͍ʍࢫ͛˂ʍࢫɲ̛˵˵Ʉɩ̛͍Ʉͩʍ͛ࢫΝˏͩ˂ࢫ8͍ࢫ Loo and other senior executives to drive the organisation’s future-of-work agenda. Partnering for People ėɄ̌ˏʍࢫɲ͍ʍɾˏͩ͛ࢫzþöࢫʱ̛͍ࢫʍ˵ʍΘɄͩˏ̌ʳࢫͩ˂ʍࢫzþࢫ profession over the last decade, empowering practitioners to become strategic partners of business leaders.
࣪zþöࢫ˂Ʉ͛ࢫ˂ʍ˵ͅʍɾࢫ͛˂ˏʱͩࢫzþࢫʱ̛͍̆ࢫɩʍˏ̌ʳࢫ͛ʍʍ̌ࢫ as operational to being recognised as a ͍͛ͩɄͩʍʳˏɲࢫ̛͍ͅʱʍ͛͛ˏ̛̌ࢫΝˏͩ˂ࢫɾʍё̌ʍɾࢫ͛ͩɄ̌ɾɄ͍ɾ͛ࢫ Ʉ̌ɾࢫɲ̛̆ͅʍͩʍ̌ɲˏʍ͛ࢷ࣫ࢫ͛˂ʍࢫ͛ɄΩ͛ࢶࢫ࣪͛ࢫΝ̛͍ˬʱ̛͍ɲʍࢫ ɲ̛̆ͅ˵ʍΦˏͩΩࢫˏ̌ɲ͍ʍɄ͛ʍ͛ࢷࢫˏ̌͛ͩˏͩͷͩˏ̛̌͛ࢫ˵ˏˬʍࢫzþöࢫ provide the foundation for HR leaders to ɩʍࢫɲ̛̆̆ʍ͍ɲˏɄ˵˵ΩࢫɄ͛ͩͷͩʍࢷࢫɾˏʳˏͩɄ˵˵Ωࢫђͷʍ̌ͩࢫɄ̌ɾࢫ ɲɄͅɄɩ˵ʍࢫ̛ʱࢫˏ̌ђͷʍ̌ɲˏ̌ʳࢫʍ̌ͩʍ͍͍ͅˏ͛ʍࢫ͍͛ͩɄͩʍʳΩࢶ࣫ ͩࢫþ·nࢷࢫͩ˂ʍࢫͅɄ͍ͩ̌ʍ͍͛˂ˏͅࢫɩʍͩΝʍʍ̌ࢫ the Executive Chairman and CHRO ʍΦʍ̆ͅ˵ˏёʍ͛ࢫͩ˂ʍࢫΝɄΩࢫʱ̛͍ΝɄ͍ɾࢫʱ̛͍ࢫ˂ʍɄ˵ͩ˂ɲɄ͍ʍࢫ organisations. Together, they demonstrate that as the industry navigates technological disruption and workforce reinvention, a united front is vital to achieving long-term organisational resilience and capability building while preparing the workforce for a very different future.
61
2026 年 9 月 22 日 _ 星期二
BF
fall 刊 Fukan 8% 4-O dk
LIANHE
) 4h
ZAOBAO
20265F 9A 228
Source: Lianhe Zaobao © SPH Media Limited. Permission required for reproduction.
(EmEs thiG | RARER
[email protected] 攝影 | 陳斌勤
is KA, Prem Ue (質量料將維持在中等至
人不健康水平 即使沒有明。4
醫生提醒 , EA, MA
WA she fy Ay EE Dy A _ 5 Min) ARLE NE. she 1] pia] , WEAK Sy AEB .
IM HE IH 得深入了解
均值
Sz IRSA, SA
AY | 染指數上周創下今年以來最 高紀錄。雖然空
氣素質這兩天略
有改善 , 但加里曼丹和蘇門答腊 火點增加兩倍有祭 , 而盛行風預 料從東偏南方和東南方吹來 , 我 國未來幾天仍可能受煙袁影響。
KK Fe =
eae eae
空氣污染 , 其核心物質是
PR 5 hth BEE eRe, NAR oo 戶外停留
間 , 避免 劇烈戶外活 動 , 並補充 足侈水分。 ( GLE 療提供
在空 Bohes MV HHL 療全科醫生林夸 地指出 , 即使當 下沒出現任何症 K, 有害物質仍 會被吸入人體內 , 因此煙霾與二手 煙一樣 , 都會影 Oo) fF BR
戴上醫用口 SAF Win iw #04? FEA 否要用空氣淨化 器 ? 選購空氣 7》 化器要考慮什 Z? BRAG Hh
一回答幾個常見問題
煥軍如何影響健康 ?
答 : 最常見的短期症狀包括 咳嗽、眼鼻喉受刺激 , 以及其他 呼吸道不適。這些症眉通常較輕 微 , 減少接触煙霾后便會自行緩 解 , 必要時可使用非處方藥。
Rit, 若久咳不愈 , 或出 現哮鳴 (wheezing ) 、呼吸困 難、眼睛或喉距嚴重受刺激等症 狀 , 又或現有病況 (如哮喘、慢 性心臟或肺部疾病 ) 惡化 , 則務 必就醫。
哪些人須特別注意 ?
答 : 容易受煙霾影響的群體 包括兒童、孕婦、年長者 , 以及 患有慢性心臟病或肺病人士 ; 必 須長時間待在戶外的人也要特別 注意。
ree. (尤其是初生多 Fl 48 one ee 因此對空氣污染格 外敏感 ; 慢性心臟病和肺病患者 出現不良反應的風險也比一般人 高 , 藥物務必隨身攜帶。孕婦同樣
WA se 155 St ON |e) — FH WY YB
次看蛋
要格外小心 , 因為空氣污染影響 的不只是自己 , 還有胎兒的健康。
空氣污染嚴重時 , 上述人和群 應盡量減少劇烈戶外活動 , 避免 長時間停留在戶外 ; 如感到不 i, 請盡快就醫。
BEA RB ZT HEP
S: MHMB ATW 做法。可留意官方健康提醒 , 根據 自身健康狀況采取相應措施 , 較 容易受影響的人 , 更要格外小心。 一般來說 , 我們應做的包括 :
‧。定時查看空氣素質
( haze.gov.sg )。空氣素質可 能在一天內不停變化 , 因此應查 看最新數據。
。外出前查看一小時 PM2.5 最浮顆粒洲度 , 了解當下空氣素 質 ; 策划一天行程時查看 24 小時 空氣污染指數 ( PSI ) 。
。如 24 小時 PSI 介於 101 至
200 ( 不健康水平 ), 應減少戶 外停留時間 , 避免劇烈戶外活 動 , 多在室內休息 , 並補充足夠 水分。
‧。如出現咳嗽、哮鳴、呼吸
國 ba a ta 2 1
- 嘿曙 rl ig Se] . = en : ~ i om
rey
3m gi:
困難、眼睛或喉唬受刺激等症
外出時說 ? 戴外科口踢?
答 : 普通外科口罩無法有 效阻擋 PM2.5 這類細微的煙霾 微粒 , N95 口罩若佩戴得當 ( 確 保與臉部足夠密合 ), 可減少 PM2.5 的吸入。在本地 , 一般外 出時無需戴 N95 口罩 , 只有和較容 易受煙霾影響的人群 , FEI 重且須長時間待在戶外時 , 才建 議佩戴
何時該用空氣潑化占 ? 答 : 我們不會因 PSI 達到某 個水平 , 就建議所有人使用空 氣淨化器 , 但 PSI 達到 101 至 200 (不健康水平 ) 時 , 尤其在煙霾持 續不斷的情況下 , 使用適當空氣 淨化器能減少室內的細微顆粒。
選購空气淨化器時 應考慮什麼? 答 : 選擇空氣淨化器時 , 應 意其覆蓋面積是否適合需要滔 化的空間 , 以及去除細和顆粒的
“研究說
濾器 ( HEPA 是 high-efficiency particulate air 的簡寫 , 意即能過 a 大於或相等說 0.3 微米的
闔整個空間 , 可查看 CADNR / Clean Air Delivery Rate ( j47#
城市高溫可能傷腎 imme 研究有助鎖定風險熱區
熱應激 (heat stress ) 是 天和氣相關死亡的主要原因之 —, AKA Bi, WEA 射熱等因素無法有效散熱 , 從 而承受過度熱負荷的狀態。城 市熱島效應會使城市氣溫高 周邊地區 , 增加居民中暑及其 他高溫相關疾病的風險。 hee 影
smEeRnnaeoe (CER. EB. 度 , ARADA, BARSAR,
會影響人們實際感受到的熱度。因此 , 評估高溫健康風險時 , 不能只看氣溫 , 也要考慮其他氣象因素。
美國國家科學基金會國家大氣研究中心 ( NSF NCAR ) 聯合 埃默里大學 (Emory University ) 和北卡毗來納大學教堂山分校 ( University of North Carolina at Chapel Hill) , 以亞特蘭大為 研究對象 , 開發出亞特蘭大都會區高分辨率城市氣象影響數據集 ( HUMID-Atlanta ) 。
NSF NCAR 科學家林祖順指出 , 這項工具能幫助研究人員了解 人們實際感受到的高溫 , 以及風力和濕度等因素對人人體的影響
研究成果發表於最近的《科學數據》(Scientific Data ) 期 刊 , 研究由美國國立糖尿病、消化及腎臟疾病研究所資助。
改進后的數據集涵蓋 2010 年至 2023 年資料 , 可將住院記錄
與高溫數據進行比對 , 幫助研究人員了解哪些天氣和城市環境因 素會增加熱應激風險 , 並協助相關部門識別高溫風險較高的時間 和地區 , 制定應對措施。
未來 , 這項技術也可能應用於其他城市 , 並用於預測氣象變 化和發展高溫預警系統。
參與研究的 NSF NCAR 高級科學家安 ‧ 紐曼 (Andrew Newman ) 利用這項數據集 , sla aoa OAM taf ( acute kidney injury, 即門臟功能迅速下降 )。
過去 , 研究人員分析引臟疾病與高溫的關係時 , 未能充分 考慮市中心、偏遠郊區居民所面對的不同高溫環境。HUMID- Atlanta 有助于找出高溫健康風險較高的地區 , 並制定減少傷害的 措施。
ASW, 這項數據集有助於填補高溫健康研究的空白 , #
支持健康教育 , 改善臨床治療 , 以及評估高溫相關的健康風險和 經濟負擔。
決於氣溫 , 也受
高溫風險不只
; 同時須確保它不會釋放臭 eee ees % ( ozone ) . 標準 , 從中可知道每分鐘每 建議選用裝有高效過濾器方英尺空氣里有多少微粒得到 空氣淨化器 , 例如 HEPA 過 AL),
- 注 : 美國的空氣淨化器 ,
其 HEPA 濾网一般以 CFM ( cubic feet per minute, 即每分鐘立 o AHR) 為流量單位 , 有些品 errr 牌則使用 “每分鐘立方公尺 ”
( cubic metres per minute )。 比較不同空氣淨化器時 , 記得確 認單位是否一 Bo
Lh a6
are 共 24 版 / 售價 $1
LIANHE ZAOQOBAO
CO ah
安歷丙午年八月初因 2026 年 9 月 14 日星期一
FAB) 文稿 Source: Lianhe Zaobao © SPH Media Limited. Permission required for reproduction.
Lt
一次專科醫生之間的轉介 , Medical Group) 近 13 年的醫患
M~ XBR FI—ARA KAS
Ia SRACSRELETRE
Rr. WERAAMAMAEE, MEAS Men A
人與親屬 , 也映照出集團 50 年來堅持的持續照護理念
se LEK (Raffles Hospital) 李愛文醫生 (Dr Lee I~-Wuen) 的診 , 擺放著一盆綠意央然的黃金葛。 點 的一份小心意。當時妹妹看診 , 得知李醫 生喜愛花草 , 全多年過 去 , 每逢复診 , 李生忌會笑看跟她們提 起 : “你們送的植物 , 又長新葉子了 ,。
對蔡女士而言 , 這盆不斷生長的植 和象征著一段隨信月延續的醫患信任。
兌她已 : 孖像朋友了 , 不只是一個看診的 BM
BEART 開店 13 年連貫醫療照護
現年 55 才的蔡女士 (應受訪者隱私要 求 , 文中不公開全名 ) 是一名律師事務所 秘書。13 年前 , 一次專科醫生之間的接力 轉介 , 讓她與茉佛士醫療集團結緣 , 由此 開啟了一段持續至今的健康同行之路。
當時 , 蔡女士因心律不齊前往煙佛 士專科中心 (Baffles Specialist Centre) 檢查 , 遇到了心臟專科黃偉仁醫生 (Dr Ng Wai Lin) 。
fim, 得知蔡女士長期受子宮肌瘤困 擾 , 黃醫生便主動向她推薦了菜佛士婦產 科醫療中 (Raffles Women’s Centre) 的李愛文醫生。他說李醫生也是他太太的 婦產科醫生 , 於是便幫我作了轉介。
DRAB, 讓蔡女士在 同一醫療體系內獲得了不同專科的連貫 照拭 , 也奠定了她與李醫生長期信任的 基礎。
4 已克她已經像朋友了 , 不只是 M7E Taiz SHY RF
一一蔡女士 , 菜佛士醫療集團的病患
蔡女士坦言 , 第一次見到李醫生時 , 曾有些顧慮 ; AW, 經過首次咨詢後 , 她 很快便改觀。李醫生詳細了解她的情冗 , 安排檢查 , 並耐心解說治療方案 , 讓她逐 漸建立信任。
蔡女士面對的是困擾多年的子宮肌 瘤。在持續跟進約兩年後 , 李醫生建議她 不要再拖延。 “她說不能再等了 , 應該盡快 手術取出。當時 , 子宮肌瘤已長至約 16 公分 , Pens B fee 活 , 她回恒首 : 當時晚上不能躺看睡 , aE“ Be
2018 年 , 在與丈夫商量后 , 蔡女士決 定接受子宮切除手術。除了專業的醫術, 術后無微不至的關懷更讓她至今難忘。
Celebrating 50 Years of Care
Re
A PiAB SZ (A=) ve 士醫療集團 50 周年慶 典晚宴 , 與集團代表
te a.
合影。 ( 菜佛士醫療 peas) = MOME xs 監 ga os
配合成立 50 周年 , | 菜佛士醫療集團推出 紀念冊《Moments 2a | that Matter, 50 Years
of Care》。 ( 菜佛士
醫療集團提供 )
住院期間 , 茉佛士的醫拱團隊也 時刻跟進 , 主動關心她是否需要協助。 其實他們并不需要這樣做 , 但是他們還是 來看我 , 我很感動。
她表示 , 術后在家休養期間 , 李醫生 還特地打來電話詢問她的康复進度與复診
需求 : 她親自打給我 , 問我的近況 , 看是 否需要再回去复診 ,。 一份信任傳開從一人到一家人的托付
隨牙時間推移 , 這份建立在專業與溫 度上的信任 , 逐漸延伸到了蔡女士的整個 家庭。
如今 , 蔡女士本人及七名親屬 , 包括 她的兩個妹妹和弟弟、阿姨和表弟 , 以及 妹妹的家婆和小姑 , 均在對佛士醫療集蔭 的不同專科接受長期醫療服務。兩個妹妹 央婦科問題成為李醫生的定期复診患者 ; 弟弟在此進行健康檢查 ; 妹妹的家婆 (70 4) 患有三高 , 也因嚴重膀胱下垂在這裡 mE.
考慮到老人家年事已高 , 加上三高可 能增加手術風險 , 蔡女士一家原本忱心懊 懊。但在她的引工下 , 李醫生不僅迅速協 助安排相關專科會診 , 在兩周內順利完成 手術 , 更耐心地安撫家屬。
從一個人的醫療選擇 , 到親屬間共 信賴的醫療伙伴 , 這段關係體現了長期 療照拭的價值。
連貫醫療 ” 人從急診到長期的依靠
13 年來 , 萊佛士醫院已成為蔡女士應 對各類健康問題的堅實後盾。
2023 年的一天 , 她因身體朴度不宙 直接從公司前往菜佛士 24 急性和重症監護 (Raffles24 Acute & Critical Care) 求醫。醫拱團隊迅速安排驗血 , 確認她患 上骨痛熱症后 , 隨即安排住院兩天 , 讓她 及時獲得妥善治療。
對她而言 , 長期醫患關系的重要 , 不
DRI 5
莉李愛文醫生多年來陪伴侍女 士一家走過不同的人生階段 , 為一家人的健康提供持續照 P. (HHT Rete)
ror
MDDI (P) 025/05/2026
(Raffles
莉侍女士的妹妹送給李愛文 醫生的黃金草 , 見證醫患之 間延續多年的情誼。 ( 菜佛 士醫療集轉提供)
我會四力為患者作出 BRIG AYE AE, FHA. R= 和關懷相待。
一一李愛文醫生 , 菜佛士醫院
只是熟悉 A, 更是醫生熟悉自 Ce “如果 你選對一間醫院和醫生 , 之和后的醫療照護 都會在那里。 thik, 醫生了解她一直以 來的病史 , 也讓她面對不同健康問題時更 安心。
面對蔡女士一家人的長期信任 , 李愛 文醫生說 , 她十分珍惜這份托付 : “能侈照 顧他們 , 是我的榮幸。我會盡力為患者作 出最適切的醫療決定 , 並始終以理解、友 善和關懷相待。
她指出 , 長期的醫患信任讓醫生能更 Teen eee eo ee
貫性的診療 ; 在遇到禾雜病症時 , 跨專 Saleem ete. 而這份跨越幾 代人的信任 , enti STN “RBC 心 , 患者至上 ”
診室里的那盆黃金葛仍在蓮勃生長 , 見證一段歷久彌新的醫患情誼、茉佛士醫 fy RASOFRASHTPOO.
人菜佛士醫院護理團隊以專業協作 , 為病患提供日
常醫療照護與支持。 ( 菜佛士醫療集團提供 )
ERLETSASONS SRAHEAIA
2026 年 8 月 1 日 , set
RT Re
舉行 50 周年慶典晚宴 , 尚達
大曼總統擔任主宇
JA SDF
上兵 ,
社會政策統籌部長兼保健衛生部長王乙康也出席晚宴。
50 個故事回望 50 年
BCA RIZ505 佛士醫療集團推出紀念冊 《Moments that Matter, 50 Years of Care》, 匯 集 50 名創辦人、董事會成 員、員工及集臣 的回憶、重要時刻與珍藏 物件 , 回顧集團從 1976 年 的兩家診所 , 發展為一體 化醫療网絡的曆程, 也重 溫病患、員工、合作伙伴 與社區共同寫下的照護篇 “起
Model),
累計服務逾 5000 萬人次 年 , SK 集團采用團隊行醫 ee 模式 (Group Practice 透過家庭醫生、” 層醫療、牙科及過渡拱理 專科醫生及專職 AME, 以及 友好人士共享醫療紀錄和跨專業洶 通 , 讓病人在 系內獲得更連貫的照護。 50 年來 , 集團不斷擴 大服務規模 , Bi 5000 萬人次 , 也逐步建立 紀隊與病人及加 章。間歷久累積的信任。
協調轉介、
持續拓展服務 持續拓展整合式 ThA, Mee, 基
ETA 等服務領域 , 並著重提升 臨床服務能力、推動醫療 數碼化及完善基礎設施 , 為病人提供更及時的醫療 服務 , 確保整個醫療旅程 享有持續且連貫的照護 ; fa) AY FR ARM WZ Healthier SG 等全國性計劃 , 推動以 預防保健為本的健康管理 模式
a) — ir
服務逾
家庭之
zaobao.com.sg
ARARLETSANMRNOMES. BY 年其中一間診所的所在地 : 絲絲街多層停車場。 ( 菜佛士醫療集團提供 )
50 年友展重點
0 1976 年創立 由兩家診所起步 , 如今已發展
為亞洲領先的綜合私人醫療服 務提供者之一 , 醫療网絡覆蓋 亞洲 12 座城市。
0 1993 年
菜佛士外科中 (Raffles SurgiCentre) 成立 , 成為東南 亞首家獨立日間手術中心。
0 1997 年 集團在新加坡證券交易所第二 板挂牌上市。
0 2002 年
菜佛士醫院正式揭幕 , 由時任 Bl AIBN ERA 幕。
0 2010 年 上海醫療中心開業 , 成為進軍 中國市場的重要里程碑。
0 2015 年 MAKSBETOFITM, SD 生部及民防部隊合作 ,。 = 3k fi 上醫院為最低近且合身的醫療 機構時 , 民防部隊救護車可將 非危及生命的蒜急病患送往 該院接受治療通過跨机構協 fF, ABETRAGUSRN 且更協調地提供給公傘。
0 2019 年 菜佛士醫院新擴建項目一一
菜佛士專科中心 (Raffles Specialist Centre) JAF
年 , 重慶醫院開業。
» 器
掃碼瀏覽菜佛士醫療集 a 50 年的重要里程碑
本文由
RafflesMedicalGroup 呈獻
II
Wi tt
Source: The Business Times © SPH Media Limited. Permission required for reproduction.
THE BUSINESS TIMES
Monday, September 14,2026 | MDD! (P)049/10/2025
sph»
4 |
TOPLINE
COMPANIES © MARKETS
The Business Times
Monday, September 14, 200%
Five decades on, Raffles Medical eyes further regional growth and insurance push
It will focus on expanding its business in Asia as it sees plenty of opportunities in the region
By Tessa Oh [email protected]
RAFFLES Medical is looking to dee- pen its footprint in Asia and grow its insurance business as it marks 50 years since its founding. It has cash on hand for acquisitions and aims to launch a new regional scholarship scheme to build a pi- peline of healthcare managers.
Executive chairman Loo Choon Yong told The Business Times in a recent interview that the group, which now operates in five coun- tries and 12 cities, will continue to focus on Asia. It has no plans to en- ter further markets such as the US or Europe.
Asia is preferred as it is in the same time zone, is easier to travel to and because of the superior eco- nomic growth in the region, said Dr Loo.
“There are plenty of opportuni- ties in Asia. Asia is still growing,” he said, pointing to growth of 4 to 5 per cent in China, 6 per cent in In- dia and 5 to 6 per cent across much of South-east Asia, against 1 to 2 per cent in Europe.
In 2023, the group announced that it had entered into a strategic partnership with My My Trading Services Company to acquire a ma- jority interest in American Interna: tional Hospital, a 120-bed tertiary hospital in Ho Chi Minh City, sub- ject to conditions precedent and regulatory approvals.
The hospital asset was valued at USS45.6 million, and the group al- SO agreed to take ona management services contract for the hospital's operations.
Dr Loo said the group does not always need to build from scratch and can use its financial resources to buy existing hospitals or clinics, including practices in Singapore whose owners wish to sell.
“We do have cash. We candeploy this when the right opportunities come,” he said.
Asked if the group is targeting
Dr Loo Choon Yong, executive chairman of Raffles Medical, says the group has identified several people with the potential to take on more of his responsibilities. PHOTO: RAFFLES MEDICAL GROUP
other markets in Asia, Dr Loo did not elaborate.
Indonesia has amended its laws to allow foreign doctors to prac- tise, but Dr Loo said expansion will have to depend on the local condi- tions.
Markets such as Japan, South Korea and Taiwan, where hospitals must be not-for-profit, present an- other hurdle.
The ability to bring in the group's own doctors is an impor- tant consideration, because it au- dits the clinical work of all its doc- tors through a medical board and independent reviewers.
It has replicated this gover- nance model in its China hospitals in Beijing, Shanghai and Chongqing. Those China hospitals are increasingly being positioned as a lower-cost option under the Raffles brand for patients from Central Asia and Mongolia, since
these locations have more direct flights to Beijing and Shanghai than to Singapore.
Dr Loo said a strong Singapore dollar and higher post-pandemic costs for accommodation, food and transport have made Singa- pore more expensive for medical tourists, and the group can now of- fer “different price points” for the same treatment depending ona pa- tient's budget.
Insurance as adjacency
Aside from international expan- sion, the group has set its sights on the insurance sector as its main ad- jacency for growth over the com- ing decades.
Raffles Medical’s insurance business, which underwrites indi- vidual plans such as Raffles Shield and group policies for corporate clients including DBS, is currently run by a general manager but will
be elevated to a full division with a managing director as it grows.
“You may hear more about us ex- panding our insurance business,” Dr Loo said.
This segment also shows more promise in aiding the group's inter- national ambitions, as it would be more straightforward to expand its insurance arm overseas, subject to capital and regulatory require- ments in each market.
The next 50 years
Raffles Medical Group was found- ed in 1976 when Dr Loo, then 27, and fellow doctor Alfred Loh bought a clinic with eight staff. It now employs about 2,900 people.
Dr Loo said the group had no grand plan at the outset beyond a simple idea: to look after patients properly and charge cost plus a margin so that the practice would be sustainable.
Dr Loo said the group does not always need to build from scratch and can use its financial resources to buy existing hospitals or clinics, including pre actices in Singapore whose owners wish to sell.
He singled out the opening of Raffles Hospital in 2001, 25 years after the group’s founding, as the defining milestone.
The group’s initial public offer- ing in 1997 was undertaken specifi- cally to raise funds for the hospital, he said. Building it required the group to integrate specialists, gen- eral practitioners, nurses, allied health staff and a professional back office for the first time.
Having celebrated its 50th anni- versary, the group is now “talking about our 100th", Dr Loo said. “We are a very strange animal. We don't think like a usual corporation. We are thinking 50 years ahead.”
Part of that horizon is talent. Raffles Medical has committed to awarding 50 scholarships over the next five years, up from about sev- en a year previously, and will for the first time extend them to candi- dates from countries where it oper- ates, including China and Vietnam.
Rather than sending recipients to Singapore, the group will spon- sor study at universities in those markets to build a cadre of health- care Managers who can run its re- gional operations.
Succession
On the issue of succession, Dr Loo, who has said publicly that he hopes to step back, said he is dele-
gating on a regular basis.
The group has a managing di- rector overseeing its three hospi- tals in China, two managing direc- tors for the Singapore business and a full C-suite.
He said the picture will become clearer “in the next couple of years”, and that the group has iden- tified several people with the po- tential to take on more of his re- sponsibilities.
Raffles Medical reported a net profit of S$29 million for the six months to Jun 30, down 9.6 per cent from S$32.1 million in the year-ago period, on revenue of $$353.2 million, a 6.7 per cent de- cline from $$378.4 million.
Earnings per share fell to $$0.0157 from S$0.0173. Its stock ended at $$0.84 on Friday (Sep 11).
The group attributed the profit drop mainly to lower occupancy at its transitional care facilities, after the government reduced the num- ber of step-down beds it contracts from Raffes Medical following the opening of new public hospital ca- pacity.
The impact fell on the health- care services segment, run by its general practitioners, where profit fell to $$15.6 million from S$24.9 million.
The hospital services division, by contrast, grew profit 1] percent to $$19.7 million on stable revenue of $$170.2 million. Revenue at Raf- fles China Healthcare rose 13 per cent to 184.8 million yuan (US$27.5 million).
Dr Loo said transitional-care volumes have since stabilised, and that patient numbers rose in July from June.
Asked about the government's plans to lower private healthcare costs, including the possibility of a lower-cost private hospital, Dr Loo said Raffles Medical had participa- ted in a year-long industry consul- tation and is awaiting clarity on the ministry's specifications. “Current- ly, it’s highly speculative,” he said.
Source: Lianhe Zaobao © SPH Media Limited. Permission required for reproduction.
Fukan
副刊
白内障早期阶段可安全摘除 P2 维护肠道健康别盲目补益生菌 P3 范冰冰首演新加坡短片入围釜山国际电影节 P5 [email protected]
2026年9月8日
星期二
◎
报道|李亦筠
夜深了,身体已经疲惫,脑 子却迟迟停不下来。过去 面对失眠,许多人想到的 是吃安眠药;如今,非药 物治疗正成为另一条重要 途径。专家指出,失眠往 往是身体、心理与生活习 惯交织的结果,失眠认知 行为治疗可帮助患者打破 “越怕睡不着,越难入睡” 的循环。配合瑜伽、太极、 步行等温和运动及穴位按 摩,也能从不同方面帮助 身心放松,重建睡眠。
身体想睡大脑不肯关机
不靠安眠药找回睡眠能力 睡眠能 过去睡不着,一般人选择看 医生、吃安眠药。现在睡
不着,可以接受“失眠认知行为 治疗”(以下简称认知行为治 疗)来重建睡眠。国际睡眠医 学把认知行为治疗列为第一线治 疗。随着公众对长期服用安眠药 产生耐药性和副作用的担忧增 加,医院和诊所开始大力推行这 种非药物的心理与行为干预。受 访心理学家认为,这种疗法适合 每个失眠患者,可以帮助他们找 回身体原有的睡眠能力。
解决根源重建睡觉信心 “我睡不着。”这是莱佛士 健康长寿中心高级首席心理学家 黄婉萍博士在临床上经常听到的 一句话。 无论是因工作压力出现睡眠 问题,还是曾经历中风、脑损 伤,或患有其他慢性疾病,患者 即使病情稳定后,仍可能饱受失 眠困扰。这名钻研睡眠医学的心 理学家,帮助他们寻找药物以外 的解决之道。 黄博士是新加坡及东南亚 首名获行为睡眠医学专科文凭 (Diplomate in Behavioural Sleep Medicine)的心理学家。 取得认证须完成数百小时受监督 的临床训练,接受睡眠科学、睡 眠障碍及各种治疗方法的专业训 练,并通过高难度考试。她花了
三年多准备,在接受《联合早 报》专访时,她形容这是自己人 生中最难的一场考试。对她而 言,这项认证的意义,不只是专 业资格,更在于让她掌握从非药 物角度介入和改善睡眠问题的方 法。 “药物对短期是好的,可以 缓解症状,但真正需要处理的是 根源,帮助一个人重建睡觉的信 心。”
黄婉萍以“睡眠驱动力”和 “清醒驱动力”作进一步解释, 一个人从早上醒来的那一刻起, 睡眠驱动力已经开始累积。随着 清醒时间越来越长,大脑中的腺 苷(adenosine)逐渐增加,想 睡的感觉就越强。但与此同时, 人体也有维持清醒的机制,让人 白天能够保持警觉。两套系统共 同运作,使人白天清醒,而到了
了解睡眠机制是核心
药物对短期是好的, 可以缓解症状,但真正 需要处理的是根源,帮 助一个人重建睡觉的信 心。 ——黄婉萍博士
这也是认知行为治疗的核 心。它并不是简单教人“怎么 睡”,而是帮助患者了解睡眠机 制,找出影响睡眠的想法和行 为,再逐步调整睡眠时间、生活 习惯以及对失眠的焦虑,从而重 新建立健康的睡眠模式。
心理学家黄婉萍博士(右)向求助的失眠患者解释睡眠的自然机制, 以及干扰这一机制的生活习惯。(示意图)(李冠卫摄)
晚上,强大的睡眠驱动力则会帮 我们入睡。 “可是,生活中的一些习惯 会干扰这个自然机制。白天长时 间午睡,会消耗累积的睡眠驱动 力;咖啡因则会阻断腺苷的作 用,使人较难感受到睡意。因 此,有失眠问题的人,睡前7至 9小时应停止摄取咖啡因。酒对 睡眠没有好处,它会影响睡眠品 质。”黄博士说,一个人连续几 晚睡不好后,另一个问题可能随 之出现——开始害怕睡不着。 第一晚睡不好,第二晚又担 心重蹈覆辙;到了晚上,人躺在 床上,脑子不断想着:“今晚会 不会又睡不着?”越想睡,身体 和大脑反而越紧张。这正是认知 行为治疗希望打破的循环。
建立床与睡眠联结关系 黄婉萍常见的一类患者,是 四五十岁的高压职场人士。升 职、失业、工作压力、亲人患 病或离世,都可能成为失眠的 诱因。另有一些患者从白天一直 工作到深夜,关掉电脑后马上上 床,身体虽然疲惫,脑子却仍在 高速运转。“我们不是机器。” 她说。人不可能工作到晚上11点 或12点,关掉电脑后便立即“关 机”,大脑需要1至2小时逐渐减 速。 因此,她会从睡前4小时开
始检视患者的生活节奏,安排足 够的时间,让大脑和身体慢慢安 静下来。同时固定睡觉和起床时 间,减少白天长时间午睡,并控 制咖啡因。 她也特别强调“床与睡眠的 关系”。她说,如果一个人长期 在床上工作、滑手机、开视讯会 议,或者半夜醒来后一直翻来覆 去,床便可能逐渐与清醒、焦虑 和挣扎联系起来。所以,认知行 为治疗会重新建立“床=睡觉” 的联结。如果半夜醒来约15至 20分钟仍无法重新入睡,应暂时 离开床,到另一个地方做些放松 的事,等睡意回来再上床。“我 们不会坐在餐桌前等自己饿,为 什么要躺在床上等自己困?” 她强调失眠也不一定只是心 理问题,“单纯把失眠归咎于心 理因素,并不完整。中风、脑损 伤等神经疾病可能首先扰乱睡 眠;女性进入更年期后,潮热、 盗汗等荷尔蒙变化,也可能让人 无法安睡。然而,即使身体状况 逐渐稳定,患者也可能因为长期 睡眠不佳而产生担忧和焦虑,心 理因素随之介入,并进一步加重 失眠。因此,失眠往往是身体与 心理因素交织的结果。”
年纪大了睡不好很正常? 她认为,新加坡人的急性失 眠,常与工作、家庭、感情及丧
失眠者脑子不断想着 “今晚会不会又睡不 着?”,结果越想睡,身 体和大脑反而越紧张, 以致久久无法入睡。(示 意图)(龙国雄摄)
亲等生活压力有关。白天频频打 瞌睡,开会时不断点头,甚至搭 巴士或地铁时不自觉睡着,也不 应简单归咎于“昨晚没睡够”, 因为背后可能隐藏阻塞性睡眠呼 吸暂停综合征等睡眠疾病。她认 为,这类问题在新加坡仍可能被 低估。 轮班工作者同样面对挑战: 工作时难以保持清醒,下班后却 无法在该睡觉的时候入睡。至于 “年纪大了,睡不好很正常”, 黄婉萍并不认同。她曾治疗一名 84岁女性,患者从40岁起便饱 受失眠困扰,后来又经历中风、 跌倒及活动能力下降等问题。第 一次见面时,她告诉黄婉萍,自 己一晚只能睡一两个小时。“治 疗从生活中的小改变开始:早 上走动、接触阳光,白天保持活 动,限制午睡,并通过园艺、唱 圣诗等活动增加日间活动量。接 受四次治疗后,她已经可以连续 睡约5小时。”这个案例让黄婉 萍更加相信,恢复良好睡眠没有 所谓“太迟”。“失眠是可以治 疗的。”她说。 睡眠不是奢侈品,也不是忙 碌生活中可以随意牺牲的一部 分。认知行为治疗要做的,不只 是帮助患者睡着,更重要的是让 他们重新理解自己的身体,摆脱 对失眠的恐惧,逐步找回原本就 拥有的睡眠能力。
瑜伽练习与穴位按摩放松身心有益助眠 研究指出,瑜伽、太极、 步行、跑步是最有效的助眠运 动。 汤申路上段Healthtinity 的创办人兼瑜伽教练詹凯安指 出:“瑜伽、太极、步行和慢 跑有一个共同点,就是都可以
瑜伽教练詹凯安指导练习者做 婴儿式,放松脊椎,减轻身体 紧绷感。(龙国雄摄)
若家中找不到空墙,可用椅子做双 腿靠墙仰卧姿势。(龙国雄摄)
是比较缓慢的运动。”不过, 相较于步行和慢跑,瑜伽最大 的不同,在于它不仅关注身 体,也强调心念调节。通过动 作、呼吸与专注,练习者能慢 慢从外在活动转向内在感受, 这种过程对失眠者尤其重要。 失眠常伴随“过度唤醒” (hyperarousal),即到了该睡 时间,大脑仍处于高度活跃状 态。人躺在床上,身体已经疲 倦,脑子却不断想着工作、家 庭或明天的事情,反复思考同 一个问题。
睡前选择温和瑜伽练习 瑜伽的缓慢动作配合有意 识的呼吸,可以帮助释放身体 紧张;练习时把注意力带回呼 吸和身体感觉,有助减少反复 思考,让身心逐渐进入较为放 松的状态。 詹教练特别提醒,瑜伽有 不同类型和强度。如果睡前参 加节奏快、动作强度高的课 程,身体虽然疲累,大脑却可 能因为受到刺激而更加清醒。
双腿靠墙,让身体进入较为静止的 状态,有助于放松。(龙国雄摄) 因此,睡前应选择节奏较慢的 温和练习,让身体逐渐进入休 息状态。此外,还应避免过度 拉伸。“痛不是目标,舒服才 是目标。”他说,睡前练习需 要的只是温和伸展,让身体感 觉舒适,而不是追求“拉到最 大”。过度追求动作标准,反 而可能产生压力。“我一定要 做到这个姿势”“我今晚一定 要睡着”,这些想法都会增加 焦虑,对睡眠无益。 他建议在睡前练习几个简 单放松动作,包括婴儿式、双 腿靠墙仰卧姿势,以及仰卧束
角式,每个姿势可维持3分钟。 婴儿式可以让脊椎得到放 松,减轻身体紧绷感;双腿靠 墙姿势则让身体进入较为静止 的状态,有助放松。仰卧束角 式打开髋部,可让下背部舒 展,对于一些因背部不适而影 响睡眠的人,或有所帮助。 他说瑜伽还有一种呼吸练 习,名为“蜂鸣式呼吸法” (Bhramari Pranayama)。练 习时先吸气,然后在呼气时发 出类似蜜蜂振翅的嗡鸣声,让 声音产生轻微震动,“这种练 习可作为帮助身心安静下来的 方法,一般练习约3至5分钟,
仰卧束角式打开髋部,对因背部 不适而影响睡眠的人,或有帮 助。(龙国雄摄)
但时间应视个人情况而定。” 练习瑜伽多久才有望改善 睡眠?视个人情况各有不同, 在他所接触的个案中,从约三 周到一年都有。他强调,瑜伽 是辅助策略,不能取代针对失 眠的医学治疗。若失眠是由焦 虑、疼痛、偏头痛、眩晕或其 他身体及心理问题引起,应找 相应的医生或专业人士评估。 但对于希望从生活方式着手改 善睡眠的人来说,瑜伽可提供 另一种选择。
穴位按摩辅助身心放松 上医馆资 深中医师王栋 受访时透露, 穴位按摩可以 作为放松身心 的辅助方法, 但不能取代必 要的心理支持 或专业治疗。 王栋建 议轻柔按揉 百会、印堂、
按揉内关穴(笔 尖点到处)、神门 穴,有助缓解紧 绷感,可镇静安 神。 (萧紫薇摄)
按揉印堂穴(左图)、百会穴(右 图)有助放松解郁。(萧紫薇摄) 太阳、内关和 神门等穴位。 注意力不集中 时,也可按揉 百会和四神 聪。 按摩时用 拇指或食指 指腹即可,以容易恐慌、焦 局部出现轻微虑,可按揉涌 酸胀感为宜, 泉穴。(萧紫 不需要用力掐薇摄) 压,更不应追 求疼痛。每个穴位按揉约1至3 分钟,每天进行1至2次即可。 按摩时配合缓慢、深长的呼 吸,有助于放松。
1
MEDIA RELEASE
RafflesMedicalGroup Marks 50
Years of Care with
S$5 Million Commitment to Advance Healthcare, Strengthen
Communities, and Award 50 Scholarships
Raffles Medical Group Ltd and its Subsidiaries Registration Number : 198901967K
Condensed Interim Financial Statements For the six months ended 30 June 2026
Table of contents A.
Condensed Interim Consolidated Statement of Profit or Loss and Other Comprehensive Income
1
B.
Condensed Interim Statements of Financial Position
3
C.
Condensed Interim Consolidated Statement of Cash Flows
4
D.
Condensed Interim Statements of Changes in Equity
5
E.
Notes to the Condensed Interim Financial Statements
8
F.
Other Information Required by Listing Rule Appendix 7.2
18
Condensed Interim Consolidated Statement of Profit or Loss and Other Comprehensive Income Period ended 30 June 2026 6 months ended 30 June 2026 S$’000
6 months ended 30 June 2025 S$’000
Change %
353,190
378,447
(6.7)
5,703
729
nm
Inventories and consumables used
(31,271)
(30,321)
3.1
Purchased and contracted services
(19,748)
(16,779)
17.7
Insurance service expenses
(75,864)
(81,918)
(7.4)
Net expenses from reinsurance contracts
(3,221)
(5,854)
(45.0)
Staff costs
(147,274)
(157,464)
(6.5)
Depreciation of property, plant and equipment
(20,890)
(20,564)
1.6
Amortisation of intangible assets
(614)
(867)
(29.2)
Operating lease expenses
(827)
(822)
0.6
Impairment loss on trade receivables
(1,232)
(1,013)
21.6
Other operating expenses
(19,826)
(21,960)
(9.7)
Profit from operating activities
38,126
41,614
(8.4)
Finance income
2,117
4,435
(52.3)
Finance costs
(1,091)
(2,138)
(49.0)
Condensed Interim Consolidated Statement of Profit or Loss
Note
Revenue Other operating income
Profit before tax
6
39,152
43,911
(10.8)
Tax expense
7
(9,865)
(11,450)
(13.8)
29,287
32,461
(9.8)
Owners of the Company
29,020
32,108
(9.6)
Non-controlling interests
267
353
(24.4)
29,287
32,461
(9.8)
Profit for the period
Profit attributable to:
Profit for the period Note: (i) nm denotes not meaningful.
Page 1 of 20
Condensed Interim Consolidated Statement of Profit or Loss and Other Comprehensive Income Period ended 30 June 2026 (cont’d)
Condensed Interim Consolidated Statement of Other Comprehensive Income
6 months 6 months ended ended Change 30 June 2026 30 June 2025 % S$’000 S$’000 29,287
32,461
(9.8)
8,876 38,163
(11,089) 21,372
nm 78.6
37,864 299 38,163
20,967 405 21,372
80.6 (26.2) 78.6
Earnings per share Basic earnings per share (cents) [Note k]
1.58
1.73
(8.7)
Diluted earnings per share (cents) [Note l]
1.57
1.73
(9.2)
Profit for the period Other comprehensive income Item that is or may be reclassified subsequently to profit or loss: Foreign currency translation differences - foreign operations Total comprehensive income for the period Total comprehensive income attributable to: Owners of the Company Non-controlling interests Total comprehensive income for the period
Note: (i) nm denotes not meaningful. Explanatory Notes to the Condensed Interim Consolidated Statement of Profit or Loss and Other Comprehensive Income (a) The Group’s revenue in 1H 2026 decreased by 6.7% mainly due to lower occupancy of transitional care facilities in the Healthcare Services segment and lower insurance revenue. The decline was partially offset by continued growth in the Group’s China operations. (b) Other operating income increased mainly due to foreign exchange gain and non-recurring income recognised during 1H 2026. (c) Purchased and contracted services increased mainly due to higher purchases of medical clinical services to support business operations. (d) The decrease in insurance service expenses in 1H 2026 was mainly attributable to improved claims experience and lower insurance revenue. (e) Net expenses from reinsurance contracts decreased mainly due to lower reinsurance premiums ceded, partially offset by lower claim recoveries from reinsurers. (f)
The decrease in staff costs in 1H 2026 was mainly due to manpower optimisation to support business operations.
(g) The decrease in other operating expenses was mainly attributable to an unfavourable foreign exchange loss recognised in 1H 2025, compared with a favourable foreign exchange gain recognised under other operating income in 1H 2026. (h) The decrease in finance income in 1H 2026 was mainly due to lower interest income from bank fixed deposits, resulting from lower prevailing interest rates compared to 1H 2025. (i)
The decrease in finance costs in 1H 2026 was primarily attributable to lower interest expenses, as the Group has fully repaid its loans.
(j)
Lower tax expense was attributable to a lower current tax provision in 1H 2026.
(k) The calculation of earnings per ordinary share was based on weighted average number of shares 1,840,169,991 (First Half 2025: 1,853,767,122) in issue during the period. (l)
The calculation of earnings per ordinary share (on a fully diluted basis) was based on weighted average number of shares 1,843,775,141 (First Half 2025: 1,856,899,196) in issue during the period.
Page 2 of 20
Condensed Interim Statements of Financial Position As at 30 June 2026
Note Non-current assets Property, plant and equipment Intangible assets and goodwill Investment properties Subsidiaries Deferred tax assets Trade and other receivables
11 10 12
Current assets Inventories Trade and other receivables Reinsurance contract assets Cash and cash equivalents Total assets Equity attributable to owners of the Company Share capital Reserves
14
Non-controlling interests Total equity Non-current liabilities Trade and other payables Lease liabilities Deferred tax liabilities Current liabilities Loans and borrowings Current tax liabilities Trade and other payables Lease liabilities Insurance contract liabilities Total liabilities Total equity and liabilities
13
30 June 2026 S$’000
Group 31 December 2025 S$’000
Company 30 June 31 December 2026 2025 S$’000 S$’000
735,155 13,539 233,600 – 1,979 3,000 987,273
741,397 13,923 233,600 – 2,197 3,017 994,134
12,227 19 – 1,006,709 – 17,010 1,035,965
12,433 68 – 1,001,146 – 16,976 1,030,623
10,681 96,420 26,040 262,298 395,439 1,382,712
11,262 95,984 17,768 310,791 435,805 1,429,939
2,295 71,638 – 57,454 131,387 1,167,352
2,494 94,526 – 86,366 183,386 1,214,009
440,099 602,484 1,042,583 (2,218) 1,040,365
440,099 618,381 1,058,480 (2,517) 1,055,963
440,099 622,222 1,062,321 – 1,062,321
440,099 669,072 1,109,171 – 1,109,171
6,626 22,356 8,073 37,055
5,105 27,430 7,859 40,394
– 2,386 152 2,538
– 1,987 9 1,996
– 21,152 168,037 11,824 104,279 305,292 342,347 1,382,712
49,704 24,347 184,630 10,286 64,615 333,582 373,976 1,429,939
– 4,730 97,146 617 – 102,493 105,031 1,167,352
11,204 6,924 84,194 520 – 102,842 104,838 1,214,009
Explanatory Notes to the Condensed Interim Statements of Financial Position (a)
The increase in Reinsurance contract assets was primarily driven by higher remaining coverage balances resulting from reinsurance premiums ceded on renewed contracts during 1H 2026, in line with the renewal cycle of the underlying insurance policies.
(b)
Trade and other payables decreased due to the settlement of accrued operating expenses and payment to suppliers during 1H 2026.
(c)
The increase in Insurance contract liabilities primarily reflected higher liabilities for remaining coverage as at the end of 1H 2026, following the renewal cycle of major insurance contracts during the first half of the year.
Page 3 of 20
Condensed Interim Consolidated Statement of Cash Flows Period ended 30 June 2026 6 months ended 30 June 2026 S$'000
6 months ended 30 June 2025 S$'000
29,287
32,461
Amortisation of intangible assets Depreciation of property, plant and equipment
900 21,085
1,347 20,723
Equity-settled share-based payment transactions Finance costs
1,421 1,113
1,613 2,179
Finance income
(2,117)
(4,435)
– (2)
(68) (4)
14 9,865
121 11,450
61,566
65,387
Insurance and reinsurance contracts
31,392
15,317
Inventories Trade and other payables
581 (16,028)
(513) (12,882)
Trade and other receivables Cash generated from operations Tax paid
(758) 76,753 (12,201)
550 67,859 (11,259)
Net cash from operating activities
64,552
56,600
2,196 (3,037)
4,426 (2,845)
Cash flows from operating activities Profit for the period Adjustments for :
Gain on lease derecognition and modification Gain on disposal of property, plant and equipment, net Property, plant and equipment written off Tax expense Changes in working capital :
Cash flows from investing activities Interest received Purchase of property, plant and equipment Acquisition of intangible assets
(175)
(1,710)
(1,016)
(129)
Dividends paid to owners of the Company Acquisition of own shares
(55,206) –
(46,273) (7,523)
Proceeds from issue of shares under share option scheme Proceeds from bank loans Repayment of bank loans Principal repayment of lease liabilities Interest paid Lease interest paid
24 – (51,104) (5,220) (623) (554)
416 1,289 (3,951) (6,216) (1,593) (538)
Net cash used in financing activities
(112,683)
(64,389)
Net decrease in cash and cash equivalents Cash and cash equivalents at 1 January
(49,147)
(7,918)
Effect of exchange rate fluctuations on cash held
310,791 654
343,671 (1,570)
Cash and cash equivalents at 30 June
262,298
334,183
Net cash used in investing activities Cash flows from financing activities
Explanatory Notes to the Condensed Interim Consolidated Statement of Cash Flows The Group’s cash and cash equivalents decreased by S$48.5 million from S$310.8 million as at 31 December 2025 to S$262.3 million as at 30 June 2026, attributed by cash outflows for dividends, and repayment of bank loans despite increase in net cash generated from operating activities from S$56.6 million to S$64.6 million.
Page 4 of 20
Condensed Interim Statements of Changes in Equity Period ended 30 June 2026
Equity Translation compensation Revaluation reserve reserve reserve S$’000 S$’000 S$’000
Reserve for own shares S$’000
Noncontrolling interests S$’000
Group
Share capital S$’000
At 1 January 2026
440,099
(25,256)
42,572
16,367
(1,438)
(48,121)
634,257
1,058,480
(2,517)
1,055,963
Total comprehensive income for the period Profit for the period
–
–
–
–
–
–
29,020
29,020
267
29,287
Other comprehensive income Foreign currency translation differences - foreign operations Total other comprehensive income for the period Total comprehensive income for the period
– – –
8,844 8,844 8,844
– – –
– – –
– – –
– – –
– – 29,020
8,844 8,844 37,864
32 32 299
8,876 8,876 38,163
–
–
–
–
(8)
32
–
24
–
24
– – –
– – –
1,421 – 1,421
– – –
– – (8)
– – 32
– (55,206) (55,206)
1,421 (55,206) (53,761)
– – –
1,421 (55,206) (53,761)
440,099
(16,412)
43,993
16,367
(1,446)
(48,089)
608,071
1,042,583
(2,218)
1,040,365
Transactions with owners, recognised directly in equity Contributions by and distributions to owners Exercise of share options under Raffles Medical Group Employees’ Share Option Schemes Value of employee services received for issue of share options and share awards Final dividend paid of 3.0 cents per ordinary share - Cash Total contributions by and distributions to owners At 30 June 2026
Page 5 of 20
Other reserve S$’000
Total attributable to owners Accumulated of the profits Company S$’000 S$’000
Total equity S$’000
Condensed Interim Statements of Changes in Equity (cont’d) Period ended 30 June 2026
Equity Translation compensation Revaluation reserve reserve reserve S$’000 S$’000 S$’000
Reserve for own shares S$’000
Other reserve S$’000
Total attributable to owners Accumulated of the profits Company S$’000 S$’000
Noncontrolling interests S$’000
Group
Share capital S$’000
At 1 January 2025
440,099
(21,012)
40,521
16,367
(5,590)
(30,579)
609,960
1,049,766
15,213
1,064,979
Total comprehensive income for the period Profit for the period
–
–
–
–
–
–
32,108
32,108
353
32,461
Other comprehensive income Foreign currency translation differences - foreign operations Total other comprehensive income for the period Total comprehensive income for the period
– – –
(11,141) (11,141) (11,141)
– – –
– – –
– – –
– – –
– – 32,108
(11,141) (11,141) 20,967
52 52 405
(11,089) (11,089) 21,372
Total equity S$’000
Transactions with owners, recognised directly in equity Contributions by and distributions to owners Exercise of share options under Raffles Medical Group Employees’ Share Option Schemes Acquisition of own shares Value of employee services received for issue of share options and share awards Final dividend paid of 2.5 cents per ordinary share - Cash Total contributions by and distributions to owners
– –
– –
– –
– –
(159) –
575 (7,523)
– –
416 (7,523)
– –
416 (7,523)
– – –
– – –
1,613 – 1,613
– – –
– – (159)
– – (6,948)
– (46,273) (46,273)
1,613 (46,273) (51,767)
– – –
1,613 (46,273) (51,767)
Changes in ownership interests in subsidiaries Present value of the exercise price of written put options Total changes in ownership interests in subsidiaries Total transactions with owners
– – –
– – –
– – 1,613
– – –
182 182 23
– – (6,948)
– – (46,273)
182 182 (51,585)
– – –
182 182 (51,585)
440,099
(32,153)
42,134
16,367
(5,567)
(37,527)
595,795
1,019,148
15,618
1,034,766
At 30 June 2025
Page 6 of 20
Condensed Interim Statements of Changes in Equity (cont’d) Period ended 30 June 2026
Company
Share capital S$'000
At 1 January 2026
440,099
Equity compensation reserve S$’000
Other reserve S$’000
Reserve for own shares S$’000
Accumulated profits S$'000
42,572
(321)
(48,121)
674,942
Total S$'000 1,109,171
Total comprehensive income for the period Profit for the period
–
–
–
–
6,911
6,911
Total comprehensive income for the period
–
–
–
–
6,911
6,911
–
–
(8)
32
–
24
–
1,421
–
–
–
1,421
–
–
–
–
(55,206)
(55,206)
–
1,421
(8)
32
(55,206)
(53,761)
At 30 June 2026
440,099
43,993
(329)
(48,089)
626,647
1,062,321
At 1 January 2025
440,099
40,521
(39)
(30,579)
634,992
1,084,994
Transactions with owners, recognised directly in equity Contributions by and distributions to owners Exercise of share options under Raffles Medical Group Employees’ Share Option Schemes Value of employee services received for issue of share options and share awards Final dividend paid of 3.0 cents per ordinary share - Cash Total contributions by and distributions to owners
Total comprehensive income for the period Profit for the period
–
–
–
–
15,505
15,505
Total comprehensive income for the period
–
–
–
–
15,505
15,505
–
–
–
(7,523)
–
(7,523)
–
–
(159)
575
–
416
–
1,613
–
–
–
1,613
–
–
–
–
(46,273)
(46,273)
–
1,613
(159)
(6,948)
(46,273)
(51,767)
440,099
42,134
(198)
(37,527)
604,224
1,048,732
Transactions with owners, recognised directly in equity Contributions by and distributions to owners Acquisition of own shares Exercise of share options under Raffles Medical Group Employees’ Share Option Schemes Value of employee services received for issue of share options and share awards Final dividend paid of 2.5 cents per ordinary share - Cash Total contributions by and distributions to owners At 30 June 2025
Page 7 of 20
Notes to the Condensed Interim Financial Statements 1
Corporate information Raffles Medical Group Ltd (the Company) is a company incorporated in Singapore. The address of the Company’s registered office is 585 North Bridge Road, Raffles Hospital #11-00, Singapore 188770. These condensed interim financial statements as at and for the six months ended 30 June 2026 comprise the Company and its subsidiaries (together referred to as the Group). The principal activities of the Company are those relating to the operation of medical clinics, other general medical services and investment holdings. The Group and the Company are the sole proprietor of the following: Family Doctors RafflesCare Raffles Airport Medical Centre Raffles Corporate Wellness Raffles Dental Surgery Raffles Healthcare Consultancy Raffles Healthcare Institute Raffles Health Screeners Raffles Longevity Raffles Medical Management Raffles Medihelp Raffles Optica Raffles Pharmacare Raffles Pharmacy Raffles Solitaire Raffles Solitaire International Raffles Specialist Centre Raffles Wellness The Group and the Company are partners of the following: Raffles International Medical Assistance LLP All transactions of these sole proprietorships and partnerships are reflected in the condensed interim financial statements of the Company. The immediate and ultimate holding company during the financial period is Raffles Medical Holdings Pte Ltd, which is incorporated in Singapore.
2
Basis of preparation The condensed interim financial statements for the six months ended 30 June 2026 have been prepared in accordance with SFRS(I) 1-34 Interim Financial Reporting issued by the Accounting Standards Council Singapore. The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with SFRS(I)s, except for the adoption of new and amended standards as set out in Note 2.1. The condensed interim financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group’s financial position and performance of the Group since the last annual financial statements for the year ended 31 December 2025. The condensed interim financial statements are presented in Singapore dollar which is the Company’s functional currency. Page 8 of 20
Basis of preparation (cont’d)
2.1 New and amended standards adopted by the Group Amendments to the Singapore Financial Reporting Standards (International) (SFRS(I)s) have become applicable in the current reporting period. The adoption of these amendments did not have a material impact on the Group's condensed interim financial statements. 2.2 Use of estimates and judgements In preparing the condensed interim financial statements, management has made judgements, estimates and assumptions about the future, including climate-related risks and opportunities that affect the Group’s application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates. The significant judgements made by management in applying the Group’s accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the year ended 31 December 2025. Estimates and underlying assumptions are reviewed on an ongoing basis and are consistent with the Group’s risk management and climate-related commitments where appropriate. Revisions to accounting estimates are recognised prospectively. Information about critical judgements in applying accounting policies that have the most significant effect on the amounts recognised in the condensed financial statements is insurance and reinsurance contract: estimation of fulfilment cash flows. Fulfilment cash flows Although the insurance contract liabilities are estimated based on management’s best knowledge and judgement of current facts, the actual outcome may differ from the estimates. The areas involving a higher degree of judgement or complexity, or areas whereby judgement, assumptions and estimates have been involved in estimating the fulfilment cash flows comprise: estimates of future cash flows; an adjustment to reflect the time value of money and the financial risks related to future cash flows, to the extent that the financial risks are not included in the estimates of future cash flows; and a risk adjustment for non-financial risk. Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next financial year are included in the following notes: recoverable amounts of property, plant and equipment impairment test of goodwill: key assumptions underlying recoverable amounts (Note 10) determination of fair value of investment properties on the basis of significant unobservable inputs (Note 12) measurement of insurance and reinsurance contracts and recognition of loss component on onerous contracts
Page 9 of 20
Basis of preparation (cont’d)
2.2 Use of estimates and judgements (cont’d) Measurement of fair values A number of the Group’s accounting policies and disclosures require the measurement of fair values, for both financial and non-financial assets, and financial and non-financial liabilities. If third party information, such as property valuation report, is used to measure fair values, the Group assesses the evidence obtained from the third parties to support the conclusion that these valuations meet the requirements of SFRS(I), including the level in the fair value hierarchy in which the valuations should be classified. Significant valuation issues are reported to the Audit & Risk Committee. 3
Seasonal operations The Group’s businesses are not affected significantly by seasonal or cyclical factors during the financial period.
4
Segment and revenue information The Group has 4 reportable segments, as described below, which are the Group’s strategic business units. The strategic business units offer different products and services, and are managed separately because they require different technology and marketing strategies. For each of the strategic business units, the Group’s Executive Chairman reviews internal management reports regularly. The following summary describes the operations in each of the Group’s reportable segments: Healthcare services : The operations of medical clinics and other general medical services; trading in pharmaceutical and nutraceutical products and diagnostic equipment, and provision of management, consultancy and third-party administration services. Hospital services
:
The provision of specialised medical services and operation of hospital and business of medical laboratory and imaging centre.
Investment holdings :
Investment holding and those relating to investment properties.
Insurance services :
The provision of insurance products.
Performance is measured based on segment profit before tax, as included in the internal management reports that are reviewed by the Group’s Executive Chairman. Segment profit is used to measure performance as management believes that such information is most relevant in evaluating the results of certain segments relative to other entities operating within these businesses. Inter-segment pricing is determined on mutually agreed terms. Segment results, assets and liabilities include items directly attributable to a segment as well as those that can be allocated on a reasonable basis. Unallocated items mainly comprise current tax and deferred tax liabilities and assets. Segment capital expenditure is the total cost incurred during the period to acquire segment assets that are expected to be used for more than one period.
Page 10 of 20
4.1 Reportable segments Healthcare services Hospital services 6 months 6 months 6 months 6 months ended 30 ended 30 ended 30 ended 30 June 2026 June 2025 June 2026 June 2025 S$’000 S$’000 S$’000 S$’000
Insurance services 6 months 6 months ended 30 ended 30 June 2026 June 2025 S$’000 S$’000
Investment holdings 6 months 6 months ended 30 ended 30 June 2026 June 2025 S$’000 S$’000
Total 6 months 6 months ended 30 ended 30 June 2026 June 2025 S$’000 S$’000
Revenue and expenses 119,468
142,246
170,174
174,008
88,513
94,888
22,351
22,245
400,506
433,387
Inter-segment revenue
7,383
6,811
18,926
27,035
2,154
2,279
18,853
18,815
47,316
54,940
Finance costs
(603)
(575)
(1)
(474)
(22)
(41)
(487)
(1,089)
(1,113)
(2,179)
Depreciation and amortisation
(8,633)
(8,407)
(4,703)
(5,108)
(512)
(666)
(136)
(139)
(13,984)
(14,320)
Reportable segment profit before tax
15,592
24,931
19,704
17,745
(1,113)
(3,115)
12,779
11,545
46,962
51,106
(61)
(140)
(1,171)
(873)
–
–
–
–
(1,232)
(1,013)
1,385,168 1,282,881
243,685
255,568
155,578
164,720
1,154,368
1,066,370
2,938,799
2,769,539
Revenue
Other material non-cash items:
- Impairment losses on trade receivable Reportable segment assets Capital expenditure Reportable segment liabilities
3,863
10,257
995
2,447
108
158
5
50
4,971
12,912
613,333
342,735
172,064
177,646
114,836
134,112
1,087,793
847,256
1,988,026
1,501,749
Page 11 of 20
4.1 Reportable segments (cont’d) Reconciliations of reportable segment revenues, profit or loss, assets and liabilities and other material items 6 months 6 months ended 30 ended 30 June 2026 June 2025 S$’000 S$’000 Revenues Total revenue for reportable segments 400,506 433,387 Elimination of inter-segment revenue (47,316) (54,940) Consolidated revenue 353,190 378,447 Profit or loss before tax Total profit for reportable segments Elimination of inter-segment profits / Consolidation adjustment Adjustment for depreciation of property, plant and equipment and amortisation of intangible assets Consolidated profit before tax
46,962 191
51,106 555
(8,001) 39,152
(7,750) 43,911
Assets Total assets for reportable segments Elimination of inter-segment assets Unallocated amounts-current tax and deferred tax assets Consolidated total assets
2,938,799 (1,558,066) 1,979 1,382,712
2,769,539 (1,282,259) 2,750 1,490,030
Liabilities Total liabilities for reportable segments Elimination of inter-segment liabilities Unallocated amounts-current tax and deferred tax liabilities Consolidated total liabilities
1,988,026 (1,674,904) 29,225 342,347
1,501,749 (1,079,429) 32,944 455,264
Reportable segment totals S$’000
Adjustments S$’000
Consolidated totals S$’000
30 June 2026 Depreciation and amortisation
13,984
8,001
21,985
30 June 2025 Depreciation and amortisation
14,320
7,750
22,070
Other material items
The Group’s properties at Raffles Holland V, Raffles Hospital, Raffles Specialist Centre, Raffles Hospital Chongqing and Raffles Hospital Shanghai are owned by its subsidiaries and classified as investment properties in the subsidiaries’ standalone financial statements. For the preparation of the consolidated interim financial statements, a portion of these properties are reclassified from investment properties to property, plant and equipment as these properties are used in the supply of medical services by the Group. Accordingly, the carrying values of these properties are depreciated over their useful lives in the condensed consolidated financial statements of the Group.
Page 12 of 20
4.1 Reportable segments (cont’d) The amount of S$8,001,000 (30 June 2025: S$7,750,000) relates to the depreciation of these properties for the year ended 30 June 2026. Geographical information The Group operations are primarily in Singapore, Greater China, Vietnam, Cambodia and Japan. In presenting information on the basis of geographical segments, segment revenue is based on the geographical location of customers and segment assets are based on the geographical location of the assets. Group 6 months 6 months ended 30 ended 30 June 2026 June 2025 S$’000 S$’000 Revenue Singapore Greater China Rest of Asia Consolidated revenue
309,816 34,405 8,969 353,190
339,992 29,876 8,579 378,447
Non-current assets Singapore Greater China Rest of Asia Consolidated non-current assets*
663,013 307,159 12,122 982,294
670,009 301,137 12,586 983,732
Non-current assets exclude financial instruments and deferred tax assets.
4.2 Disaggregation of Revenue Group 6 months 6 months ended 30 ended 30 June 2026 June 2025 S$’000 S$’000 263,484 4,074 85,632 353,190
Revenue from contracts with customers Rental income Insurance revenue
Page 13 of 20
282,902 3,725 91,820 378,447
5
Financial assets and financial liabilities As at 30 June 2026 and 31 December 2025, the carrying amounts of the Group's and the Company's financial assets and financial liabilities that are not measured at fair value are reasonable approximations of their fair values.
6
Profit before tax Profit before tax has been arrived after charging/(crediting): Group 6 months 6 months ended 30 ended 30 June 2026 June 2025 S$’000 S$’000 Contributions to defined contribution plans Foreign exchange (gain)/loss Gain on disposal of property, plant and equipment, net Interest expense:
- bank loans
- non-controlling interest
- lease liabilities Interest income Wage credit and other grants Property, plant and equipment written-off Recovery of bad debts Value of employee services received for issue of share options and share awards, included in staff costs Write-off for stock obsolescence
7
11,539 (1,615) (2)
11,426 1,732 (4)
559 – 554 (2,117) (401) 14 (557)
944 697 538 (4,435) (539) 121 (646)
1,421 179
1,613 17
During the period, interest expense of $22,000 (2025: $41,000) was included in ‘insurance service expenses’ in the statement of profit or loss.
Taxation The Group calculates the period income tax expense using the tax rate that would be applicable to the expected total annual earnings. The major components of income tax expense in the condensed interim consolidated statement of profit or loss are: Group 6 months 6 months ended 30 ended 30 June 2026 June 2025 S$’000 S$’000 Current income tax expense Current withholding tax expense Deferred income tax expense relating to origination and reversal of temporary differences
Adjustment for prior years Current income tax expense – Adjustment for prior years Deferred tax expense – Adjustment for prior years
Page 14 of 20
9,518 456
11,606 570
112 10,086
(429) 11,747
(543) 322 9,865
(297) – 11,450
8
Dividends Group 6 months 6 months ended 30 ended 30 June 2026 June 2025 S$’000 S$’000 Dividends paid: Final dividend in respect of the previous financial year, approved and paid during the interim period, of 3.0 cents per share (6 months ended 30 June 2025: 2.5 cents per share)
9
55,206
46,273
Net asset value Group 30 June 31 December 2026 2025 S$ S$ Net asset value per ordinary share [C]
56.66 cents
Company 30 June 31 December 2026 2025 S$ S$
57.52 cents 57.73 cents
60.28 cents
[C] The calculation of net asset value per ordinary share was based on 1,840,190,875 shares as at 30 June 2026 (31 December 2025: 1,840,160,875).
10
Intangible assets and goodwill Software under Customer Membership rights development Software Goodwill relationship S$’000 S$’000 S$’000 S$’000 S$’000
Total S$’000
Group Cost At 1 January 2025 Additions Write-off Reclassification Effects of movement in exchange rate At 31 December 2025 Additions Reclassification Effects of movement in exchange rate At 30 June 2026
23,709 – – – (511) 23,198 – – 757 23,955
4,139 – – – (71) 4,068 – – 52 4,120
114 – – – – 114 – – – 114
1,344 348 – (1,521) – 171 52 (135) – 88
18,286 1,811 (3,568) 1,521 (87) 17,963 123 135 158 18,379
47,592 2,159 (3,568) – (669) 45,514 175 – 967 46,656
Accumulated amortisation and impairment losses At 1 January 2025 Amortisation Write-off Impairment loss Effects of movement in exchange rate At 31 December 2025 Amortisation Effects of movement in exchange rate At 30 June 2026
15,499 – – 316 (366) 15,449 – 472 15,921
3,848 71 – – (66) 3,853 35 49 3,937
87 – – – – 87 – – 87
– – – – – – – – –
12,674 2,351 (2,777) – (46) 12,202 865 105 13,172
32,108 2,422 (2,777) 316 (478) 31,591 900 626 33,117
Carrying amounts At 1 January 2025 At 31 December 2025 At 30 June 2026
8,210 7,749 8,034
291 215 183
27 27 27
1,344 171 88
5,612 5,761 5,207
15,484 13,923 13,539
Page 15 of 20
10
Intangible assets and goodwill (cont’d) Impairment testing Goodwill that has an indefinite useful life is not subject to amortisation and is tested for impairment annually, or more frequently if events or changes in circumstances indicate that it might be impaired. No impairment indicators were identified as at 30 June 2026 based on the CGU’s business performance. The Group performed its annual impairment test in December 2025. The key assumptions used to determine the recoverable amount for the CGU were disclosed in the annual consolidated financial statements for the year ended 31 December 2025.
11
Property, plant and equipment During the six months ended 30 June 2026, the Group acquired property, plant and equipment amounting to S$4,796,000 (30 June 2025: S$11,201,000) and disposed of assets amounting to S$12,000 (30 June 2025: S$17,000).
12
Investment properties Group 2026 S$’000 Balance as at 1 January and 30 June
2025 S$’000
233,600
246,100
Valuation of investment properties The Group’s policy is for investment property to be measured at fair value for which the Group completes property valuations at least annually by independent registered valuers at the end of the year. The Group did not engage an independent valuer to determine the fair value of the properties as at 30 June 2026. However, the Management had taken into considerations those underlying factors that would have impacts to the fair value of the investment properties since the last valuations completed in December 2025; including any tenant changes, assessing market rentals, etc. There are no major factors that could significantly affect the fair value of the investment properties as at 30 June 2026.
13
Loans and borrowings Group 30 June 31 December 2026 2025 S$’000 S$’000 Amount repayable within one year or on demand Unsecured bank loans
–
Page 16 of 20
49,704
Company 30 June 31 December 2026 2025 S$’000 S$’000
–
11,204
14
Share capital 30 June 2026 No. of shares ’000 S$’000
31 December 2025 No. of shares ’000 S$’000
Company Fully paid ordinary shares, with no par value: At 1 January / 30 June / 31 December
1,884,544
440,099
1,884,544
440,099
The total number of issued shares excluding treasury shares as at 30 June 2026 was 1,840,190,875 (31 December 2025: 1,840,160,875). (i) Exercise of share options and share awards During the first half ended 30 June 2026, the Company utilised 30,000 treasury shares to fulfil the exercise of options, at exercise price of S$0.81 per share, under the Raffles Medical Group Share Option Scheme. As at 30 June 2026, there were 69,257,000 (30 June 2025: 69,572,000) options outstanding in relation to ordinary shares of the Company. As at 30 June 2026, the number of shares comprised in contingent awards granted under the Raffles Medical Group (2020) Performance Share Plan which has not been released was 2,033,100 (30 June 2025: 2,063,950). (ii) Treasury shares The Company holds 44,354,050 treasury shares as at 30 June 2026 (30 June 2025: 33,594,000). Treasury shares held by the Company as at 30 June 2026 represent 2.41% (30 June 2025: 1.81%) of the total number of issued shares (excluding treasury shares). Number of treasury shares Balance as at 1 January 2026 Use of treasury shares Balance as at 30 June 2026
44,384,050 (30,000) 44,354,050
(iii) Subsidiary holdings There is no subsidiary holdings as at 30 June 2026 (30 June 2025: Nil). There were no sales, transfers, cancellation and/or use of subsidiary holdings as at 30 June 2026 (30 June 2025: Nil). 15
Subsequent events There are no known subsequent events which led to adjustments to this set of interim financial statements.
Page 17 of 20
Other Information Required by Listing Rule Appendix 7.2 1
Whether the figures have been audited or reviewed and in accordance with which auditing standard or practice. The condensed interim financial statements of Raffles Medical Group Ltd (the Company) and its subsidiaries (the Group), which comprise the condensed interim consolidated statement of financial position of the Group and the condensed interim statement of financial position of the Company as at 30 June 2026, the condensed interim consolidated statement of profit or loss, condensed interim consolidated statement of comprehensive income, condensed interim consolidated statements of changes in equity and condensed interim consolidated statement of cash flows of the Group for the six-month period then ended, and notes to the condensed interim financial statements have not been audited or reviewed.
2
A review of the performance of the group, to the extent necessary for a reasonable understanding of the group’s business. It must include a discussion of the following:(a) any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and (b) any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on. The Group recorded a 6.7% lower revenue of S$353.2 million for the first half of 2026, as compared to S$378.4 million in the corresponding period last year. Profit after tax and minority interests (PATMI) stood at S$29.0 million, 9.6% lower than 1H 2025. The Hospital Services division remained a key contributor to the Group’s performance, recording revenue of S$170.2 million. Profit increased by 11.0% to S$19.7 million from S$17.7 million in 1H 2025. This was driven by improved operational efficiency and cost management in both Singapore and China hospitals. Consequently, the Hospital Services division profit margin improved from 10.2% in 1H 2025 to 11.6% in 1H 2026. The Healthcare Services division registered a revenue of S$119.5 million in 1H 2026, a decrease of 16.0% from 1H 2025, mainly due to lower occupancy of transitional care facilities (TCF). Correspondingly, Healthcare Services profit decreased to S$15.6 million from S$24.9 million 1H 2025. For China market, revenue increased 13.0% from CNY163.6 (S$29.9) million to CNY184.8 (S$34.4) million in 1H 2026. The RafflesHospital brand continues to receive greater recognition among patients in China, further enhancing its reputation as a trusted provider of quality healthcare. Cost optimisation initiatives implemented in prior periods have also contributed to improved financial performance. RafflesHealthInsurance (RHI) registered revenue of S$88.5 million in 1H 2026, compared with S$94.9 million in the corresponding period last year. RHI’s operating loss narrowed by 64.3% to S$1.1 million from S$3.1 million in 1H 2025, driven by better claims experience, prudent claims adjudication and effective cost management. The Group generated operating cash flow of S$64.6 million in 1H 2026, up from S$56.6 million in 1H 2025. During 1H 2026, following the Company’s Annual General Meeting in April 2026, the Group distributed cash dividends totaling S$55.2 million and fully repaid bank loans amounting to S$51.1 million. The Group’s financial position remains strong, with cash and cash equivalents amounting to S$262.3 million as of 30 June 2026.
3
Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results. The current financial period’s results are in line with the Directors’ expectations as disclosed in the Group’s FY2025 results announcement.
Page 18 of 20
4
A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months. The global economic outlook remains uncertain amid ongoing geopolitical tensions, evolving trade disputes and volatility in financial markets. While these factors may affect business confidence, the demand for quality healthcare services is expected to remain resilient. The Group remains focused on delivering integrated healthcare and insurance solutions that address the evolving needs of individuals and corporate clients. By leveraging its comprehensive healthcare ecosystem, the Group is well positioned to provide accessible, coordinated and high-quality care while generating sustainable long-term value for its stakeholders. The Group is also committed to strengthening its regional healthcare network by broadening its range of clinical services, enhancing specialist capabilities and expanding access to quality healthcare across the Asian cities in which it operates. Innovation and digital transformation remain key strategic priorities. The Group will continue to evaluate and adopt appropriate technologies, including artificial intelligence (AI), to improve operational efficiency, enhance service excellence and support the delivery of safe, high-quality healthcare services. As the Group marks its 50th Anniversary in 2026, it remain guided by its core values of Compassion, Commitment, Excellence, Teamwork and Value (CCETV). Building on five decades of service to the communities in which it operates, the Group will continue to innovate, strengthen its capabilities and enhance patient care in support of its mission to deliver trusted healthcare. While the operating environment remains challenging, the Directors are optimistic that, barring unforeseen circumstances, the Group will remain profitable for the financial year ending 31 December 2026.
5
Dividend (a) Current Financial Period Reported on Any dividend declared for the current financial period reported on? No Interim Dividend is declared. (b) Corresponding Period of the Immediately Preceding Financial Year Any dividend declared for the corresponding period of the immediately preceding financial year? No (c) Date payable Not applicable. (d) Record date Not applicable.
6
If no dividend has been declared/recommended, a statement to that effect. During the FY2020 results’ announcement, the Board announced its intent to consolidate its interim and final dividends with effect from FY2021 into an annual core dividend. In view of the foregoing, the Directors will not be declaring any interim dividend.
Page 19 of 20
7
If the group has obtained a general mandate from shareholders for Interested Person Transactions (IPTs), the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect. The Company did not obtain a general mandate from shareholders for IPTs.
8
Confirmation pursuant to Rule 720 (1) of the Listing Manual The Company confirms that it has procured undertakings from all its Directors and executive officers (in the format set out in Appendix 7.7) under Rule 720 (1) of the Listing Manual.
9
Disclosures of incorporation of Entities, Acquisition and Realisation of Shares pursuant to Rule 706(A) of the Listing Manual There was no further incorporation of entities, acquisition and realisation of shares by the Group for the period 1 January 2026 to 30 June 2026 to be disclosed under Rule 706(A) of the Listing Manual except for those previously announced in the FY2025 results announcement in February 2026.
10
Confirmation by the Board pursuant to Rule 705 (5) of the Listing Manual On behalf of the Board of Directors of the Company, we, the undersigned, hereby confirm to the best of our knowledge that nothing has come to the attention of the Board of Directors of the Company which may render the condensed interim financial statements for the six-month period ended 30 June 2026 to be false or misleading in any material aspect.
On behalf of the Board of Directors
Dr Loo Choon Yong Chairman
Mr Lew Yoong Keong Allen Director
BY ORDER OF THE BOARD
Yap Chew Fern Company Secretary 27 July 2026
Page 20 of 20
Result Announcement for 1H 2026 (unaudited figures S$’m) 1H 2026 (S$’m)
1H 2025 (S$’m)
% change
Revenue
353.2
378.4
(6.7)
EBITDA
60.1
63.7
(5.6)
Operating Profit
38.1
41.6
(8.4)
Profit After Tax
29.3
32.5
(9.8)
PATMI
29.0
32.1
(9.6)
1H 2026 (cents)
1H 2025 (cents)
% change
Diluted Earnings per Share (cts)
1.57
1.73
(9.2)
Net Asset Value per Share (cts)
56.66
57.52*
(1.5)
.* As at 31 December 2025
Highlights of 1H 2026 Performance
Group’s Revenue recorded a revenue of S$353.2 million
Group Profit after Tax stood at S$29.3 million
Healthy cash position of S$262.3 million
1
MEDIA RELEASE
RafflesMedicalGroup Reports S$29.0 million PATMI in 1H2026 as Hospital Services Profit Grows 11% Singapore, 27 July 2026 – RafflesMedicalGroup (RMG or the Group) reported Profit After Tax and Minority Interests (PATMI) of S$29.0 million for the first half of 2026, supported by improved profitability in its Hospital Services Division and continued improvement at RafflesHealthinsurance (RHI). Group revenue for 1H2026 was S$353.2 million, compared to S$378.4 million in the corresponding period last year. The Hospital Services Division remained a key contributor to the Group’s performance, recording revenue of S$170.2 million. Profit increased 11.0% to S$19.7 million from S$17.7 million in 1H2025, driven by improved operational efficiency and cost management across the Group’s hospitals in Singapore and China. Consequently, the Division’s profit margin improved from 10.2% in 1H2025 to 11.6% in 1H2026. The Healthcare Services Division recorded revenue of S$119.5 million, 16.0% lower than in 1H2025, mainly due to lower occupancy at transitional care facilities. Correspondingly, profit was S$15.6 million, compared with S$24.9 million in 1H2025. RafflesChinaHealthcare recorded encouraging progress, with revenue increasing 13.0% from CNY163.6 million (S$29.9 million) in 1H2025 to CNY184.8 million (S$34.4 million) in 1H2026. The RafflesHospital brand continued to gain recognition among patients in China, further strengthening its reputation as a trusted provider of quality healthcare. Costoptimisation initiatives implemented in prior periods also contributed to the improved financial performance. RHI recorded revenue of S$88.5 million in 1H2026, compared with S$94.9 million in the corresponding period last year. RHI continued to move closer to breakeven, with its operating loss narrowing 64.3% to S$1.1 million from S$3.1 million in 1H2025, driven by better claims experience, prudent claims adjudication and effective cost management. The Group generated operating cash flows of S$64.6 million in 1H2026, up from S$56.6 million in 1H2025. During the period, the Group distributed S$55.2 million in dividends and repaid S$51.1 million in bank loans.
2
The Group’s financial position remained strong, with S$262.3 million in cash and cash equivalents as at 30 June 2026, providing flexibility to support existing operations and pursue disciplined growth opportunities.
Business Updates
Navigating an Uncertain Operating Environment The global economic outlook remains uncertain amid ongoing geopolitical tensions, evolving trade disputes and volatility in financial markets. While these factors may affect business confidence, demand for quality healthcare services is expected to remain resilient.
Delivering Integrated Healthcare and Insurance Solutions The Group remains focused on delivering integrated healthcare and insurance solutions that address the evolving needs of individuals and corporate clients. By leveraging its comprehensive healthcare ecosystem, RMG is well positioned to provide accessible, coordinated and high-quality care while generating sustainable long-term value for its stakeholders.
Strengthening the Group’s Regional Healthcare Network RMG remains committed to strengthening its regional healthcare network by broadening its range of clinical services, enhancing specialist capabilities and expanding access to quality healthcare across the Asian cities in which it operates. The Group will continue to deepen its capabilities in its existing markets while maintaining a disciplined approach to growth. It will also evaluate opportunities that complement its integrated healthcare model and support sustainable regional development.
Advancing Innovation and Digital Transformation Innovation and digital transformation remain key strategic priorities. The Group will continue to evaluate and adopt appropriate technologies, including artificial intelligence, to improve operational efficiency, enhance service excellence and support the delivery of safe, high-quality healthcare services. 3
Celebrating 50 Years of Care RMG crossed the milestone of 50 million patient visits on 23 July 2026, a significant achievement in the Group’s 50th anniversary year. The figure reflects cumulative patient visits across the Group’s integrated healthcare network over the past five decades and the trust placed in RMG by generations of patients and their families. Since its founding in 1976, the Group has remained guided by its core values of Compassion, Commitment, Excellence, Teamwork and Value (CCETV) and its vision to be the Trusted Partner for Health. As it enters its next chapter, RMG will continue to innovate, strengthen its capabilities, and enhance patient care while upholding its pledge: “To Our Patients, Our Best.”
Based on current conditions and barring unforeseen circumstances, the Board expects the Group to remain profitable in FY2026. “Fifty years ago, RafflesMedicalGroup began with two clinics and a simple purpose: to care for our patients and give them our best. Reaching 50 million patient visits in our 50th anniversary year is a meaningful reflection of the trust that generations of patients and their families have placed in us, and the dedication of our people. As we look towards Raffles 100, we will build on this legacy, deepen our capabilities across Asia and continue caring for generations
to
come,”
said
Dr
Loo
Choon
Yong,
Executive
Chairman,
RafflesMedicalGroup. For media queries, please contact: Stara Tan Deputy Manager, Communications Raffles Medical Group Email: [email protected] Mobile: 9694 6901
4
About Us About Raffles Medical Group Founded in 1976, RafflesMedicalGroup (RMG or the Group) is one of the leading integrated private healthcare providers in the region, providing a continuum of services from primary and tertiary care to health insurance for people across Asia. A proudly Singaporean brand, RMG is listed on the mainboard of the Singapore stock exchange (SGX: BSL) and operates in 12 cities in five countries in Asia. This network includes four hospitals and over 100 multi-disciplinary clinics, offering services such as health screening, specialist care, diagnostic radiology, dental and traditional Chinese medicine. Together with about 2,900 employees, RMG brings 50 years of trusted healthcare expertise and care to more than 2.8 million patients across our network as their trusted partner for health. For more information, please visit rafflesmedicalgroup.com. About Raffles Medical RafflesMedical is the primary care network of RafflesMedicalGroup operating over 55 practices and clinics in Singapore providing family medicine, health screening and dental services. RafflesMedical also has Japanese clinics and/or clinics offering Japanese services in Singapore, Beijing, Shanghai, Osaka, Fukuoka, and Ho Chi Minh City, servicing its Japanese patients with family medicine and dental services. In Singapore, RafflesMedical represents one of the largest networks of primary care clinics and services over 7,000 corporate clients, supporting the healthcare needs of businesses and employees. Through RafflesMedicalInternational, the Raffles brand of quality and affordable care is available to patients in 12 cities, including Singapore, Greater China, Japan as well as Cambodia and Vietnam. About Raffles Hospital RafflesHospital is the flagship private tertiary hospital offering of the Group in Singapore that currently operates a growing network of tertiary hospitals in Singapore and China, including RafflesHospitalChongqing, RafflesHospitalShanghai, RafflesHospitalBeijing and American International Hospital (AIH) in Ho Chi Minh City, Vietnam, which the Group commenced managing in January 2024. In Singapore, RafflesHospital offers a comprehensive range of medical and dental specialties as well as diagnostic services. RafflesHospital is the only private tertiary hospital certified by the Ministry of Health to meet the stringent standards of acute trauma care. Since 2015, RafflesHospital has been the first and only private healthcare provider in Singapore to collaborate with the Ministry of Health under the Acute and Critical Care Scheme to serve the community. Under the collaboration, RafflesHospital’s Raffles24 Acute & Critical Care provides care to patients sent in by the Singapore Civil Defence Force ambulances. The Hospital also operates more than 30 specialist centres and specialist satellite clinics, covering over 30 disciplines. Subscribing to the Group Practice model of healthcare, over 1,500 physicians, nurses and allied healthcare professionals bring the Raffles brand of quality, peer-reviewed healthcare to patients in the region. About Raffles China Healthcare RafflesChinaHealthcare is the operating division of the RafflesMedicalGroup in China. The Group’s presence in China began in 1995 with the opening of RafflesMedicalGroup’s first overseas clinic in Hong Kong. Since then, RafflesChinaHealthcare has grown its presence and provides primary and tertiary care through its clinics and hospitals in five cities – Beijing, Shanghai, Chongqing, Nanjing, and Hong Kong SAR. RafflesChinaHealthcare’s network of tertiary hospitals includes RafflesHospitalChongqing, Singapore’s first private tertiary hospital in China, and RafflesHospitalShanghai, which opened in July 2021, as well as the RafflesHospitalBeijing, bringing the Raffles brand of quality, peer-reviewed healthcare to more patients in China. About Raffles Health Insurance RafflesHealthinsurance (RHI) is the health insurance division of RafflesMedicalGroup, providing healthcare insurance to corporates and individuals in Singapore. Backed by the expertise of a trusted medical group with 50 years of experience, RafflesHealthinsurance seeks to provide healthcare financing solutions that cater to the needs of all its policy owners and members. Incorporated in 2004, RafflesHealthinsurance is a wholly-owned subsidiary of the RafflesMedicalGroup and is an Integrated Shield Plan provider appointed by the Ministry of Health in Singapore. RafflesHealthinsurance, through its partnership with Bupa Global, also offers a wider range of international private health plans, which are co-insured by RHI and Bupa, to cater to the needs of individuals and corporate clients of the international business community in Singapore.
5
1
Result Announcement for 1H 2026 (unaudited figures S$’m)
1H 2026
1H 2025 % (S$’m) (S$’m)
change Revenue 353.2 378.4 (6.7) EBITDA 60.1 63.7 (5.6) Operating Profit 38.1
41.6 (8.4) Profit After Tax 29.3
32.5 (9.8) PATMI 29.0
32.1 (9.6) 1H 2026 1H 2025 % (cents) (cents)
change
Diluted Earnings per Share (cts) 1.57 1.73 (9.2) Net Asset Value per Share (cts) 56.66 57.52* (1.5) .* As at 31 December 2025
Highlights of 1H 2026 Performance
Group’s Revenue recorded a revenue of S$353.2 million
Group Profit after Tax stood at S$29.3 million
Healthy cash position of S$262.3 million
2
MEDIA RELEASE
RafflesMedicalGroup Reports S$29.0 million PATMI in 1H2026 as
Hospital Services Profit Grows 11%
Singapore, 27 July 2026 – RafflesMedicalGroup (RMG or the Group) reported Profit After
Tax and Minority Interests (PATMI) of S$29.0 million for the first half of 2026, supported by
improved profitability in its Hospital Services Division and continued improvement at
RafflesHealthinsurance (RHI).
Group revenue for 1H2026 was S$353.2 million, compared to S$378.4 million in the
corresponding period last year.
The Hospital Services Division remained a key contributor to the Group’s performance,
recording revenue of S$170.2 million. Profit increased 11.0% to S$19.7 million from S$17.7
million in 1H2025, driven by improved operational efficiency and cost management across
the Group’s hospitals in Singapore and China. Consequently, the Division’s profit margin
improved from 10.2% in 1H2025 to 11.6% in 1H2026.
The Healthcare Services Division recorded revenue of S$119.5 million, 16.0% lower than in
1H2025, mainly due to lower occupancy at transitional care facilities. Correspondingly, profit
was S$15.6 million, compared with S$24.9 million in 1H2025.
RafflesChinaHealthcare recorded encouraging progress, with revenue increasing 13.0%
from CNY163.6 million (S$29.9 million) in 1H2025 to CNY184.8 million (S$34.4 million) in
1H2026. The
RafflesHospital brand continued to gain recognition among patients in China,
further strengthening its reputation as a trusted provider of quality healthcare. Cost-
optimisation initiatives implemented in prior periods also contributed to the improved financial
performance.
RHI recorded revenue of S$88.5 million in 1H2026, compared with S$94.9 million in the
corresponding period last year. RHI continued to move closer to breakeven, with its operating
loss narrowing 64.3% to S$1.1 million from S$3.1 million in 1H2025, driven by better claims
experience, prudent claims adjudication and effective cost management.
The Group generated operating cash flows of S$64.6 million in 1H2026, up from S$56.6
million in 1H2025. During the period, the Group distributed S$55.2 million in dividends and
repaid S$51.1 million in bank loans.
3
The Group’s financial position remained strong, with S$262.3 million in cash and cash equivalents as at 30 June 2026, providing flexibility to support existing operations and pursue disciplined growth opportunities.
Business Updates
Navigating an Uncertain Operating Environment
The global economic outlook remains uncertain amid ongoing geopolitical tensions,
evolving trade disputes and volatility in financial markets. While these factors may
affect business confidence, demand for quality healthcare services is expected to
remain resilient.
Delivering Integrated Healthcare and Insurance Solutions
The Group remains focused on delivering integrated healthcare and insurance
solutions that address the evolving needs of individuals and corporate clients.
By leveraging its comprehensive healthcare ecosystem, RMG is well positioned to
provide accessible, coordinated and high-quality care while generating sustainable
long-term value for its stakeholders.
Strengthening the Group’s Regional Healthcare Network
RMG remains committed to strengthening its regional healthcare network by
broadening its range of clinical services, enhancing specialist capabilities and
expanding access to quality healthcare across the Asian cities in which it operates.
The Group will continue to deepen its capabilities in its existing markets while
maintaining a disciplined approach to growth. It will also evaluate opportunities that
complement its integrated healthcare model and support sustainable regional
development.
Advancing Innovation and Digital Transformation
Innovation and digital transformation remain key strategic priorities. The Group will
continue to evaluate and adopt appropriate technologies, including artificial
intelligence, to improve operational efficiency, enhance service excellence and
support the delivery of safe, high-quality healthcare services.
4
Celebrating 50 Years of Care
RMG crossed the milestone of 50 million patient visits on 23 July 2026, a significant
achievement in the Group’s 50
th
anniversary year. The figure reflects cumulative
patient visits across the Group’s integrated healthcare network over the past five
decades and the trust placed in RMG by generations of patients and their families.
Since its founding in 1976, the Group has remained guided by its core values of
Compassion, Commitment, Excellence, Teamwork and Value (CCETV) and its vision
to be the Trusted Partner for Health. As it enters its next chapter, RMG will continue
to innovate, strengthen its capabilities, and enhance patient care while upholding its
pledge: “To Our Patients, Our Best.”
Based on current conditions and barring unforeseen circumstances, the Board expects the
Group to remain profitable in FY2026.
“Fifty years ago,
RafflesMedicalGroup began with two clinics and a simple purpose: to care
for our patients and give them our best. Reaching 50 million patient visits in our 50
th
anniversary year is a meaningful reflection of the trust that generations of patients and their families have placed in us, and the dedication of our people. As we look towards Raffles 100, we will build on this legacy, deepen our capabilities across Asia and continue caring for generations to come,” said Dr Loo Choon Yong, Executive Chairman, RafflesMedicalGroup. For media queries, please contact: Stara Tan Deputy Manager, Communications Raffles Medical Group Email: [email protected] Mobile: 9694 6901
5
About Us
About Raffles Medical Group Founded in 1976, RafflesMedicalGroup (RMG or the Group) is one of the leading integrated private healthcare providers in the region, providing a continuum of services from primary and tertiary care to health insurance for people across Asia. A proudly Singaporean brand, RMG is listed on the mainboard of the Singapore stock exchange (SGX: BSL) and operates in 12 cities in five countries in Asia. This network includes four hospitals and over 100 multi-disciplinary clinics, offering services such as health screening, specialist care, diagnostic radiology, dental and traditional Chinese medicine. Together with about 2,900 employees, RMG brings 50 years of trusted healthcare expertise and care to more than 2.8 million patients across our network as their trusted partner for health. For more information, please visit rafflesmedicalgroup.com.
About Raffles Medical RafflesMedical is the primary care network of RafflesMedicalGroup operating over 55 practices and clinics in Singapore providing family medicine, health screening and dental services. RafflesMedical also has Japanese clinics and/or clinics offering Japanese services in Singapore, Beijing, Shanghai, Osaka, Fukuoka, and Ho Chi Minh City, servicing its Japanese patients with family medicine and dental services. In Singapore, RafflesMedical represents one of the largest networks of primary care clinics and services over 7,000 corporate clients, supporting the healthcare needs of businesses and employees. Through RafflesMedicalInternational, the Raffles brand of quality and affordable care is available to patients in 12 cities, including Singapore, Greater China, Japan as well as Cambodia and Vietnam.
About Raffles Hospital RafflesHospital is the flagship private tertiary hospital offering of the Group in Singapore that currently operates a growing network of tertiary hospitals in Singapore and China, including RafflesHospitalChongqing, RafflesHospitalShanghai, RafflesHospitalBeijing and American International Hospital (AIH) in Ho Chi Minh City, Vietnam, which the Group commenced managing in January 2024. In Singapore, RafflesHospital offers a comprehensive range of medical and dental specialties as well as diagnostic services. RafflesHospital is the only private tertiary hospital certified by the Ministry of Health to meet the stringent standards of acute trauma care. Since 2015, RafflesHospital has been the first and only private healthcare provider in Singapore to collaborate with the Ministry of Health under the Acute and Critical Care Scheme to serve the community. Under the collaboration, RafflesHospital’s Raffles24 Acute & Critical Care provides care to patients sent in by the Singapore Civil Defence Force ambulances. The Hospital also operates more than 30 specialist centres and specialist satellite clinics, covering over 30 disciplines. Subscribing to the Group Practice model of healthcare, over 1,500 physicians, nurses and allied healthcare professionals bring the Raffles brand of quality, peer-reviewed healthcare to patients in the region.
About Raffles China Healthcare RafflesChinaHealthcare is the operating division of the RafflesMedicalGroup in China. The Group’s presence in China began in 1995 with the opening of RafflesMedicalGroup’s first overseas clinic in Hong Kong. Since then, RafflesChinaHealthcare has grown its presence and provides primary and tertiary care through its clinics and hospitals in five cities – Beijing, Shanghai, Chongqing, Nanjing, and Hong Kong SAR. RafflesChinaHealthcare’s network of tertiary hospitals includes RafflesHospitalChongqing, Singapore’s first private tertiary hospital in China, and RafflesHospitalShanghai, which opened in July 2021, as well as the RafflesHospitalBeijing, bringing the Raffles brand of quality, peer-reviewed healthcare to more patients in China.
About Raffles Health Insurance RafflesHealthinsurance (RHI) is the health insurance division of RafflesMedicalGroup, providing healthcare insurance to corporates and individuals in Singapore. Backed by the expertise of a trusted medical group with 50 years of experience, RafflesHealthinsurance seeks to provide healthcare financing solutions that cater to the needs of all its policy owners and members. Incorporated in 2004, RafflesHealthinsurance is a wholly-owned subsidiary of the RafflesMedicalGroup and is an Integrated Shield Plan provider appointed by the Ministry of Health in Singapore. RafflesHealthinsurance, through its partnership with Bupa Global, also offers a wider range of international private health plans, which are co-insured by RHI and Bupa, to cater to the needs of individuals and corporate clients of the international business community in Singapore.
1
MEDIA RELEASE – FOR IMMEDIATE RELEASE
RafflesMedicalGroup Surpasses 50 Million Patient Visits, Marking 50 Years of Care Singapore, 23 July 2026 – RafflesMedicalGroup (RMG or the Group) has surpassed 50 million patient visits, a significant milestone in the Group's 50th anniversary year. The figure reflects cumulative patient visits across the Group's integrated healthcare network
Raffles Medical Group Ltd and its Subsidiaries Registration Number : 198901967K
Condensed Interim Financial Statements For the six months ended 30 June 2026
Table of contents
A. Condensed Interim Consolidated Statement of Profit or Loss and Other Comprehensive Income 1 B. Condensed Interim Statements of Financial Position 3 C. Condensed Interim Consolidated Statement of Cash Flows 4 D. Condensed Interim Statements of Changes in Equity 5 E. Notes to the Condensed Interim Financial Statements 8 F. Other Information Required by Listing Rule Appendix 7.2 18
Page 1 of 20
Condensed Interim Consolidated Statement of Profit or Loss and Other Comprehensive Income Period ended 30 June 2026
Condensed Interim Consolidated Statement of Profit or Loss
Note
6 months ended 30 June 2026 S$’000 6 months ended 30 June 2025 S$’000 Change
%
Revenue 353,190 378,447 (6.7) Other operating income 5,703 729 nm Inventories and consumables used (31,271) (30,321) 3.1 Purchased and contracted services (19,748) (16,779) 17.7 Insurance service expenses (75,864) (81,918) (7.4) Net expenses from reinsurance contracts (3,221) (5,854) (45.0) Staff costs (147,274) (157,464) (6.5) Depreciation of property, plant and equipment (20,890) (20,564) 1.6 Amortisation of intangible assets (614) (867) (29.2) Operating lease expenses (827) (822) 0.6 Impairment loss on trade receivables (1,232) (1,013) 21.6 Other operating expenses (19,826) (21,960) (9.7) Profit from operating activities 38,126 41,614 (8.4) Finance income 2,117 4,435 (52.3) Finance costs (1,091) (2,138) (49.0) Profit before tax 639,152 43,911 (10.8) Tax expense 7(9,865) (11,450) (13.8) Profit for the period
29,287 32,461 (9.8)
Profit attributable to:
Owners of the Company
29,020 32,108 (9.6) Non-controlling interests
267 353
(24.4)
Profit for the period 29,287 32,461 (9.8)
Note:
(i) nm denotes not meaningful.
Page 2 of 20
Condensed Interim Consolidated Statement of Profit or Loss and Other Comprehensive Income Period ended 30 June 2026 (cont’d) Condensed Interim Consolidated Statement of Other Comprehensive Income
6 months ended 30 June 2026 S$’000 6 months ended 30 June 2025 S$’000 Change %
Profit for the period
29,287 32,461
(9.8)
Other comprehensive income
Item that is or may be reclassified subsequently to profit or loss:
Foreign currency translation differences - foreign operations
8,876
(11,089)nm
Total comprehensive income for the period 38,163 21,37278.6
Total comprehensive income attributable to:
Owners of the Company 37,864 20,96780.6
Non-controlling interests 299 405(26.2)
Total comprehensive income for the period
38,163 21,37278.6
Earnings per share
Basic earnings per share (cents) [Note k] 1.581.73(8.7)
Diluted earnings per share (cents) [Note l]
1.571.73
(9.2)
Note:
(i) nm denotes not meaningful.
Explanatory Notes to the Condensed Interim Consolidated Statement of Profit or Loss and Other Comprehensive Income
(a) The Group’s revenue in 1H 2026 decreased by 6.7% mainly due to lower occupancy of transitional care facilities in the Healthcare Services segment and lower insurance revenue. The decline was partially offset by continued growth in the Group’s China operations.
(b) Other operating income increased mainly due to foreign exchange gain and non-recurring income recognised during 1H 2026.
(c) Purchased and contracted services increased mainly due to higher purchases of medical clinical services to support business operations.
(d) The decrease in insurance service expenses in 1H 2026 was mainly attributable to improved claims experience and lower insurance revenue.
(e) Net expenses from reinsurance contracts decreased mainly due to lower reinsurance premiums ceded, partially offset by lower claim recoveries from reinsurers.
(f) The decrease in staff costs in 1H 2026 was mainly due to manpower optimisation to support business operations.
(g) The decrease in other operating expenses was mainly attributable to an unfavourable foreign exchange loss recognised in 1H 2025, compared with a favourable foreign exchange gain recognised under other operating income in 1H 2026.
(h) The decrease in finance income in 1H 2026 was mainly due to lower interest income from bank fixed deposits, resulting from lower prevailing interest rates compared to 1H 2025.
(i) The decrease in finance costs in 1H 2026 was primarily attributable to lower interest expenses, as the Group has fully repaid its loans.
(j) Lower tax expense was attributable to a lower current tax provision in 1H 2026.
(k) The calculation of earnings per ordinary share was based on weighted average number of shares 1,840,169,991 (First Half 2025: 1,853,767,122) in issue during the period.
(l) The calculation of earnings per ordinary share (on a fully diluted basis) was based on weighted average number of shares 1,843,775,141 (First Half 2025: 1,856,899,196) in issue during the period.
Page 3 of 20
Condensed Interim Statements of Financial Position
As at 30 June 2026
Group Company
30 June 2026 31 December 2025 30 June 2026 31 December 2025 Note S$’000 S$’000 S$’000 S$’000
Non-current assets
Property, plant and equipment 11 735,155 741,397 12,227 12,433
Intangible assets and goodwill 10 13,539 13,923 19 68
Investment properties 12 233,600 233,600 – –
Subsidiaries – – 1,006,709 1,001,146
Deferred tax assets 1,979 2,197 – –
Trade and other receivables 3,000 3,017 17,010 16,976
987,273 994,134 1,035,965 1,030,623
Current assets
Inventories 10,681 11,262 2,295 2,494
Trade and other receivables 96,420 95,984 71,638 94,526
Reinsurance contract assets 26,040 17,768 – –
Cash and cash equivalents 262,298 310,791 57,454 86,366
395,439 435,805 131,387 183,386
Total assets 1,382,712 1,429,939 1,167,352 1,214,009
Equity attributable to owners of
the Company
Share capital 14 440,099 440,099 440,099 440,099
Reserves 602,484 618,381 622,222 669,072
1,042,583 1,058,480 1,062,321 1,109,171
Non-controlling interests (2,218) (2,517) – –
Total equity 1,040,365 1,055,963 1,062,321 1,109,171
Non-current liabilities
Trade and other payables 6,626 5,105 – –
Lease liabilities 22,356 27,430 2,386 1,987
Deferred tax liabilities 8,073 7,859 152 9
37,055 40,394 2,538 1,996
Current liabilities
Loans and borrowings 13 – 49,704 – 11,204
Current tax liabilities 21,152 24,347 4,730 6,924
Trade and other payables 168,037 184,630 97,146 84,194
Lease liabilities 11,824 10,286 617 520
Insurance contract liabilities 104,279 64,615 – –
305,292 333,582 102,493 102,842
Total liabilities 342,347 373,976 105,031 104,838
Total equity and liabilities 1,382,712 1,429,939 1,167,352 1,214,009
Explanatory Notes to the Condensed Interim Statements of Financial Position
(a) The increase in Reinsurance contract assets was primarily driven by higher remaining coverage balances resulting from reinsurance premiums ceded on renewed contracts during 1H 2026, in line with the renewal cycle of the underlying insurance policies.
(b) Trade and other payables decreased due to the settlement of accrued operating expenses and payment to suppliers during 1H 2026.
(c) The increase in Insurance contract liabilities primarily reflected higher liabilities for remaining coverage as at the end of 1H 2026, following the renewal cycle of major insurance contracts during the first half of the year.
Page 4 of 20
Condensed Interim Consolidated Statement of Cash Flows Period ended 30 June 2026
6 months
ended 30
June 2026
6 months
ended 30
June 2025
Cash flows from operating activities S$'000 S$'000
Profit for the period 29,287 32,461
Adjustments for :
Amortisation of intangible assets 900 1,347
Depreciation of property, plant and equipment 21,085 20,723
Equity-settled share-based payment transactions 1,421 1,613
Finance costs 1,113 2,179
Finance income (2,117) (4,435)
Gain on lease derecognition and modification
–
(68)
Gain on disposal of property, plant and equipment, net (2) (4)
Property, plant and equipment written off 14 121
Tax expense 9,865 11,450
61,566 65,387
Changes in working capital :
Insurance and reinsurance contracts 31,392 15,317
Inventories 581 (513)
Trade and other payables (16,028) (12,882)
Trade and other receivables (758) 550
Cash generated from operations
76,753
67,859 Tax paid (12,201)
(11,259) Net cash from operating activities 64,552 56,600
Cash flows from investing activities
Interest received 2,196 4,426
Purchase of property, plant and equipment
(3,037)
(2,845) Acquisition of intangible assets (175) (1,710) Net cash used in investing activities (1,016) (129)
Cash flows from financing activities
Dividends paid to owners of the Company (55,206) (46,273)
Acquisition of own shares – (7,523)
Proceeds from issue of shares under share option scheme 24 416
Proceeds from bank loans – 1,289
Repayment of bank loans (51,104) (3,951)
Principal repayment of lease liabilities (5,220) (6,216)
Interest paid
(623)
(1,593) Lease interest paid (554) (538) Net cash used in financing activities (112,683) (64,389)
Net decrease in cash and cash equivalents (49,147)
(7,918) Cash and cash equivalents at 1 January 310,791
343,671 Effect of exchange rate fluctuations on cash held 654
(1,570) Cash and cash equivalents at 30 June 262,298
334,183
Explanatory Notes to the Condensed Interim Consolidated Statement of Cash Flows
The Group’s cash and cash equivalents decreased by S$48.5 million from S$310.8 million as at 31 December 2025 to S$262.3 million as at 30 June 2026, attributed by cash outflows for dividends, and repayment of bank loans despite increase in net cash generated from operating activities from S$56.6 million to S$64.6 million.
Page 5 of 20
Condensed Interim Statements of Changes in Equity Period ended 30 June 2026
Share
capital
Translation
reserve
Equity
compensation
reserve
Revaluation
reserve
Other
reserve
Reserve
for own
shares
Accumulated
profits
Total
attributable
to owners
of the Company Non- controlling interests Total equity Group S$’000 S$’000
S$’000
S$’000 S$’000 S$’000 S$’000
S$’000
S$’000
S$’000
At 1 January 2026 440,099
(25,256)
42,572 16,367
(1,438) (48,121) 634,257
1,058,480
(2,517)
1,055,963
Total comprehensive income for the period
Profit for the period –
–
– –
–
– 29,020
29,020
267
29,287
Other comprehensive income
Foreign currency translation differences - foreign operations
–
8,844
–
–
–
–
–
8,844
32
8,876
Total other comprehensive income for the period –
8,844
–
–
–
–
–
8,844
32
8,876
Total comprehensive income for the period –
8,844
–
–
–
–
29,020
37,864
299
38,163
Transactions with owners, recognised directly in eq uity
Contributions by and distributions to owners
Exercise of share options under Raffles Medical Gro up Employees’ Share Option Schemes –
–
– –
(8) 32 –
24
–
24
Value of employee services received for issue of sh are options and share awards
–
–
1,421
–
–
–
–
1,421
–
1,421
Final dividend paid of 3.0 cents per ordinary share
- Cash –
–
–
–
–
– (55,206)
(55,206)
–
(55,206)
Total contributions by and distributions to owners –
–
1,421 –
(8) 32 (55,206)
(53,761)
–
(53,761)
At 30 June 2026 440,099
(16,412)
43,993 16,367
(1,446) (48,089) 608,071
1,042,583
(2,218)
1,040,365
Page 6 of 20
Condensed Interim Statements of Changes in Equity (
cont’d)
Period ended 30 June 2026
Share
capital
Translation
reserve
Equity
compensation
reserve
Revaluation
reserve
Other
reserve
Reserve
for own
shares
Accumulated
profits
Total
attributable
to owners
of the Company Non- controlling interests Total equity Group S$’000 S$’000
S$’000
S$’000 S$’000 S$’000 S$’000
S$’000
S$’000
S$’000
At 1 January 2025 440,099
(21,012)
40,521 16,367
(5,590) (30,579) 609,960
1,049,766
15,213
1,064,979
Total comprehensive income for the period
Profit for the period –
–
– –
–
– 32,108
32,108
353
32,461
Other comprehensive income
Foreign currency translation differences - foreign operations
–
(11,141)
–
–
–
–
–
(11,141)
52
(11,089)
Total other comprehensive income for the period –
(11,141)
–
–
–
–
–
(11,141)
52
(11,089)
Total comprehensive income for the period –
(11,141)
–
–
–
–
32,108
20,967
405
21,372
Transactions with owners, recognised directly in eq uity
Contributions by and distributions to owners
Exercise of share options under Raffles Medical Gro up Employees’ Share Option Schemes –
–
– –
(159) 575 –
416
–
416
Acquisition of own shares –
–
– –
–
(7,523) –
(7,523)
–
(7,523)
Value of employee services received for issue of sh are options and share awards
–
–
1,613
–
–
–
–
1,613
–
1,613
Final dividend paid of 2.5 cents per ordinary share
- Cash –
–
–
–
–
– (46,273)
(46,273)
–
(46,273)
Total contributions by and distributions to owners –
–
1,613 –
(159) (6,948) (46,273)
(51,767)
–
(51,767)
Changes in ownership interests in subsidiaries
Present value of the exercise price of written put
options
–
–
–
–
182
– –
182
–
182
Total changes in ownership interests in subsidiarie s –
–
–
–
182
– –
182
–
182
Total transactions with owners –
–
1,613 –
23
(6,948) (46,273)
(51,585)
–
(51,585)
At 30 June 2025 440,099
(32,153)
42,134 16,367
(5,567) (37,527) 595,795
1,019,148
15,618
1,034,766
Page 7 of 20
Condensed Interim Statements of Changes in Equity (cont’d) Period ended 30 June 2026
Share capital Equity compensation reserve Other reserve Reserve for own shares Accumulated profits Total Company S$'000 S$’000 S$’000 S$’000 S$'000 S$'000
At 1 January 2026 440,099 42,572 (321) (48,121) 674,942 1,109,171
Total comprehensive income for the period
Profit for the period – – – – 6,911 6,911
Total comprehensive income for the period – – – – 6,911 6,911
Transactions with owners, recognised
directly in equity
Contributions by and distributions to owners
Exercise of share options under Raffles Medical
Group Employees’ Share Option Schemes
– – (8) 32 – 24 Value of employee services received for issue of share options and share awards – 1,421 – – – 1,421 Final dividend paid of 3.0 cents per ordinary share - Cash – – – – (55,206) (55,206) Total contributions by and distributions to owners – 1,421 (8) 32 (55,206) (53,761)
At 30 June 2026 440,099 43,993 (329) (48,089) 626,647 1,062,321
At 1 January 2025 440,099 40,521 (39) (30,579) 634,992 1,084,994
Total comprehensive income for the period
Profit for the period – – – – 15,505 15,505
Total comprehensive income for the period – – – – 15,505 15,505
Transactions with owners, recognised
directly in equity
Contributions by and distributions to owners
Acquisition of own shares – – – (7,523) – (7,523)
Exercise of share options under Raffles Medical
Group Employees’ Share Option Schemes
– – (159) 575 – 416 Value of employee services received for issue of share options and share awards – 1,613 – – – 1,613 Final dividend paid of 2.5 cents per ordinary share - Cash – – – – (46,273) (46,273) Total contributions by and distributions to owners – 1,613 (159) (6,948) (46,273) (51,767)
At 30 June 2025 440,099 42,134 (198) (37,527) 604,224 1,048,732
Page 8 of 20
Notes to the Condensed Interim Financial Statements
1 Corporate information
Raffles Medical Group Ltd (the Company) is a company incorporated in Singapore. The address of the Company’s registered office is 585 North Bridge Road, Raffles Hospital #11-00, Singapore 188770.
These condensed interim financial statements as at and for the six months ended 30 June 2026 comprise the Company and its subsidiaries (together referred to as the Group).
The principal activities of the Company are those relating to the operation of medical clinics, other general medical services and investment holdings.
The Group and the Company are the sole proprietor of the following:
Family Doctors
RafflesCare
Raffles Airport Medical Centre
Raffles Corporate Wellness
Raffles Dental Surgery
Raffles Healthcare Consultancy
Raffles Healthcare Institute
Raffles Health Screeners
Raffles Longevity
Raffles Medical Management
Raffles Medihelp
Raffles Optica
Raffles Pharmacare
Raffles Pharmacy
Raffles Solitaire
Raffles Solitaire International
Raffles Specialist Centre
Raffles Wellness
The Group and the Company are partners of the following:
Raffles International Medical Assistance LLP
All transactions of these sole proprietorships and partnerships are reflected in the condensed interim financial statements of the Company.
The immediate and ultimate holding company during the financial period is Raffles Medical Holdings Pte Ltd, which is incorporated in Singapore.
2 Basis of preparation
The condensed interim financial statements for the six months ended 30 June 2026 have been prepared in
accordance with SFRS(I) 1-34 Interim Financial Reporting issued by the Accounting Standards Council Singapore. The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with SFRS(I)s, except for the adoption of new and amended standards as set out in Note 2.1.
The condensed interim financial statements do not include all the information required for a complete set of
financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group’s financial position and performance of the Group since the last annual financial statements for the year ended 31 December 2025.
The condensed interim financial statements are presented in Singapore dollar which is the Company’s functional currency.
Page 9 of 20
- Basis of preparation (cont’d)
2.1 New and amended standards adopted by the Group
Amendments to the Singapore Financial Reporting Standards (International) (SFRS(I)s) have become applicable in the current reporting period. The adoption of these amendments did not have a material impact on the Group's condensed interim financial statements.
2.2 Use of estimates and judgements
In preparing the condensed interim financial statements, management has made judgements, estimates and assumptions about the future, including climate-related risks and opportunities that affect the Group’s application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.
The significant judgements made by management in applying the Group’s accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the year ended 31 December 2025.
Estimates and underlying assumptions are reviewed on an ongoing basis and are consistent with the Group’s risk management and climate-related commitments where appropriate. Revisions to accounting estimates are recognised prospectively.
Information about critical judgements in applying accounting policies that have the most significant effect on the amounts recognised in the condensed financial statements is insurance and reinsurance contract: estimation of fulfilment cash flows.
Fulfilment cash flows
Although the insurance contract liabilities are estimated based on management’s best knowledge and judgement of current facts, the actual outcome may differ from the estimates.
The areas involving a higher degree of judgement or complexity, or areas whereby judgement, assumptions and estimates have been involved in estimating the fulfilment cash flows comprise:
estimates of future cash flows; an adjustment to reflect the time value of money and the financial risks related to future cash flows, to the extent that the financial risks are not included in the estimates of future cash flows; and a risk adjustment for non-financial risk.
Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next financial year are included in the following notes:
recoverable amounts of property, plant and equipment impairment test of goodwill: key assumptions underlying recoverable amounts (Note 10) determination of fair value of investment properties on the basis of significant unobservable inputs (Note 12) measurement of insurance and reinsurance contracts and recognition of loss component on onerous contracts
Page 10 of 20
- Basis of preparation (cont’d)
2.2 Use of estimates and judgements (cont’d)
Measurement of fair values
A number of the Group’s accounting policies and disclosures require the measurement of fair values, for both financial and non-financial assets, and financial and non-financial liabilities.
If third party information, such as property valuation report, is used to measure fair values, the Group assesses the evidence obtained from the third parties to support the conclusion that these valuations meet the requirements of SFRS(I), including the level in the fair value hierarchy in which the valuations should be classified. Significant valuation issues are reported to the Audit & Risk Committee.
3 Seasonal operations
The Group’s businesses are not affected significantly by seasonal or cyclical factors during the financial period.
4 Segment and revenue information
The Group has 4 reportable segments, as described below, which are the Group’s strategic business units. The strategic business units offer different products and services, and are managed separately because they require different technology and marketing strategies. For each of the strategic business units, the Group’s Executive Chairman reviews internal management reports regularly. The following summary describes the operations in each of the Group’s reportable segments:
Healthcare services : The operations of medical clinics and other general medical services; trading in pharmaceutical and nutraceutical products and diagnostic equipment, and provision of management, consultancy and third-party administration services.
Hospital services : The provision of specialised medical services and operation of hospital and business of medical laboratory and imaging centre.
Investment holdings : Investment holding and those relating to investment properties.
Insurance services : The provision of insurance products.
Performance is measured based on segment profit before tax, as included in the internal management reports that are reviewed by the Group’s Executive Chairman. Segment profit is used to measure performance as management believes that such information is most relevant in evaluating the results of certain segments relative to other entities operating within these businesses.
Inter-segment pricing is determined on mutually agreed terms.
Segment results, assets and liabilities include items directly attributable to a segment as well as those that can be allocated on a reasonable basis. Unallocated items mainly comprise current tax and deferred tax liabilities and assets.
Segment capital expenditure is the total cost incurred during the period to acquire segment assets that are expected to be used for more than one period.
Page 11 of 20
4.1 Reportable segments
Healthcare services Hospital services Insurance ser vices Investment holdings Total
6 months ended 30 June 2026 6 months ended 30 June 2025
6 months ended 30 June 2026 6 months ended 30 June 2025 6 months ended 30 June 2026 6 months ended 30 June 2025 6 months ended 30 June 2026 6 months ended 30 June 2025 6 months ended 30 June 2026 6 months ended 30 June 2025
S$’000 S$’000 S$’000 S$’000 S$’000 S$’000 S$’000 S$ ’000 S$’000 S$’000 Revenue and expenses
Revenue
119,468 142,246 170 ,174 174,008 88,513 94,888 22,351 22,245 40 0 ,506 433,387
Inter
segment revenue
7,383 6,811 18 ,926 27,035 2,154 2,279 18,853 18,815 4 7 ,316 54,940
Finance costs (603) (575) (1) (474) (22) (41) (487) (1,089) (1,113) (2,179)
Depreciation and amortisation
(8,6 33 ) (8,407) (4, 703 ) (5,108) (512) (666) ( 136 ) (139) (13,984) (14,320)
Reportable segment profit before tax
15,592 24,931 19,704 17,745 (1,113) (3,115) 12,779 11,545 46,962 51,106
Other material non-cash items: - Impairment losses on trade receivable (61) (140) (1,171) (873) – – – – (1,232) (1,013)
Reportable segment assets
1,385,168 1,282,881 243,685 255,568 155,578 164,720 1,154,368 1,066,370 2,938,799 2,769,539 Capital expenditure 3,863 10,257 995 2,447 108 158 5 50 4,971 12,912 Reportable segment liabilities 613,333 342,735 172,06 4 177,646 114,836 134,112 1,087,793 847,256 1,988,026 1,501,749
Page 12 of 20
4.1 Reportable segments (cont’d)
Reconciliations of reportable segment revenues, profit or loss, assets and liabilities and other material items
6 months
ended 30
June 2026
6 months
ended 30
June 2025
S$’000 S$’000
Revenues
Total revenue for reportable segments 400,506 433,387 Elimination of inter-segment revenue (47,316) (54,940) Consolidated revenue 353,190 378,447
Profit or loss before tax
Total profit for reportable segments 46,962 51,106
Elimination of inter-segment profits / Consolidation adjustment 191 555
Adjustment for depreciation of property, plant and equipment and
amortisation of intangible assets (8,001) (7,750)
Consolidated profit before tax 39,152 43,911
Assets
Total assets for reportable segments 2,938,799 2,769,539
Elimination of inter-segment assets (1,558,066) (1,282,259)
Unallocated amounts-current tax and deferred tax assets 1,979 2,750
Consolidated total assets 1,382,712 1,490,030
Liabilities
Total liabilities for reportable segments 1,988,026 1,501,749
Elimination of inter-segment liabilities (1,674,904) (1,079,429)
Unallocated amounts-current tax and deferred tax liabilities 29,225 32,944
Consolidated total liabilities 342,347 455,264
Other material items
Reportable
segment
totals
Adjustments
Consolidated
totals
S$’000 S$’000 S$’000
30 June 2026
Depreciation and amortisation 13,984 8,001 21,985
30 June 2025
Depreciation and amortisation 14,320 7,750 22,070
The Group’s properties at Raffles Holland V, Raffles Hospital, Raffles Specialist Centre, Raffles Hospital Chongqing and Raffles Hospital Shanghai are owned by its subsidiaries and classified as investment properties in the subsidiaries’ standalone financial statements.
For the preparation of the consolidated interim financial statements, a portion of these properties are reclassified from investment properties to property, plant and equipment as these properties are used in the supply of medical services by the Group. Accordingly, the carrying values of these properties are depreciated over their useful lives in the condensed consolidated financial statements of the Group.
Page 13 of 20
4.1 Reportable segments (cont’d)
The amount of S$8,001,000 (30 June 2025: S$7,750,000) relates to the depreciation of these properties for the year ended 30 June 2026.
Geographical information
The Group operations are primarily in Singapore, Greater China, Vietnam, Cambodia and Japan.
In presenting information on the basis of geographical segments, segment revenue is based on the geographical location of customers and segment assets are based on the geographical location of the assets.
Group
6 months
ended 30
June 2026
6 months
ended 30
June 2025
S$’000 S$’000
Revenue
Singapore 309,816 339,992
Greater China 34,405 29,876
Rest of Asia 8,969 8,579
Consolidated revenue 353,190 378,447
Non-current assets
Singapore 663,013 670,009
Greater China 307,159 301,137
Rest of Asia 12,122 12,586
Consolidated non-current assets* 982,294 983,732
- Non-current assets exclude financial instruments and deferred tax assets.
4.2 Disaggregation of Revenue
Group
6 months
ended 30
June 2026
6 months
ended 30
June 2025
S$’000 S$’000
Revenue from contracts with customers
263,484 282,902
Rental income
4,074 3,725
Insurance revenue
85,632 91,820
353,190 378,447
Page 14 of 20
5 Financial assets and financial liabilities
As at 30 June 2026 and 31 December 2025, the carrying amounts of the Group's and the Company's financial assets and financial liabilities that are not measured at fair value are reasonable approximations of their fair values.
6 Profit before tax
Profit before tax has been arrived after charging/(crediting):
Group
6 months
ended 30
June 2026
6 months
ended 30
June 2025
S$’000 S$’000
Contributions to defined contribution plans 11,539 11,426 Foreign exchange (gain)/loss (1,615) 1,732 Gain on disposal of property, plant and equipment, net (2) (4) Interest expense:
- bank loans 559 944
- non-controlling interest – 697
- lease liabilities 554 538 Interest income (2,117) (4,435) Wage credit and other grants (401) (539) Property, plant and equipment written-off 14 121 Recovery of bad debts (557) (646) Value of employee services received for issue of share options and share awards, included in staff costs 1,421 1,613 Write-off for stock obsolescence 179 17
- During the period, interest expense of $22,000 (2025: $41,000) was included in ‘insurance service expenses’ in the statement of profit or loss.
7 Taxation
The Group calculates the period income tax expense using the tax rate that would be applicable to the expected total annual earnings. The major components of income tax expense in the condensed interim consolidated statement of profit or loss are:
Group
6 months
ended 30
June 2026
6 months
ended 30
June 2025
S$’000 S$’000
Current income tax expense 9,518 11,606
Current withholding tax expense 456 570
Deferred income tax expense relating to
origination and reversal of temporary differences 112 (429)
10,086 11,747
Adjustment for prior years
Current income tax expense – Adjustment for prior years (543) (297)
Deferred tax expense – Adjustment for prior years 322 –
9,865 11,450
Page 15 of 20
8 Dividends
Group
6 months
ended 30
June 2026
6 months
ended 30
June 2025
S$’000 S$’000
Dividends paid:
Final dividend in respect of the previous financial year,
approved and paid during the interim period, of 3.0
cents per share (6 months ended 30 June 2025: 2.5
cents per share) 55,206 46,273
9 Net asset value Group Company
30 June
2026
31 December
2025
30 June
2026
31 December
2025
S$ S$ S$ S$
Net asset value per ordinary share [C] 56.66 cents 57.52 cents 57.73 cents 60.28 cents
[C] The calculation of net asset value per ordinary share was based on 1,840,190,875 shares as at 30 June 2026 (31 December 2025: 1,840,160,875).
10 Intangible assets and goodwill
Goodwill
Customer
relationship
Membership
rights
Software
under
development
Software Total
S$’000 S$’000 S$’000 S$’000 S$’000 S$’000
Group
Cost
At 1 January 2025 23,7094,139114 1,34418,28647,592
Additions ––– 3481,8112,159
Write-off ––– –(3,568)(3,568)
Reclassification ––– (1,521)1,521–
Effects of movement in exchange rate (511)(71)– –(87)(669)
At 31 December 2025 23,1984,068114 17117,96345,514
Additions ––– 52123175
Reclassification –––
(135)135–
Effects of movement in exchange rate 75752– –158967
At 30 June 2026 23,9554,120114 8818,37946,656
Accumulated amortisation and impairment losses
At 1 January 2025 15,4993,848 87–12,67432,108 Amortisation –71 ––2,3512,422 Write-off –– –– (2,777)(2,777) Impairment loss 316– –––316 Effects of movement in exchange rate (366)(66) ––(46)(478) At 31 December 2025 15,4493,853 87–12,20231,591 Amortisation –35 ––865900 Effects of movement in exchange rate 47249 ––105626 At 30 June 2026 15,9213,937 87–13,17233,117
Carrying amounts
At 1 January 2025 8,210291 271,3445,61215,484 At 31 December 2025 7,749215 271715,76113,923 At 30 June 2026 8,034183 27885,20713,539
Page 16 of 20
10 Intangible assets and goodwill (cont’d)
Impairment testing
Goodwill that has an indefinite useful life is not subject to amortisation and is tested for impairment annually, or more frequently if events or changes in circumstances indicate that it might be impaired. No impairment indicators were identified as at 30 June 2026 based on the CGU’s business performance.
The Group performed its annual impairment test in December 2025. The key assumptions used to determine the recoverable amount for the CGU were disclosed in the annual consolidated financial statements for the year ended 31 December 2025.
11 Property, plant and equipment
During the six months ended 30 June 2026, the Group acquired property, plant and equipment amounting to S$4,796,000 (30 June 2025: S$11,201,000) and disposed of assets amounting to S$12,000 (30 June 2025: S$17,000).
12 Investment properties
Group 2026 2025 S$’000 S$’000
Balance as at 1 January and 30 June
233,600
246,100
Valuation of investment properties The Group’s policy is for investment property to be measured at fair value for which the Group completes property valuations at least annually by independent registered valuers at the end of the year. The Group did not engage an independent valuer to determine the fair value of the properties as at 30 June 2026. However, the Management had taken into considerations those underlying factors that would have impacts to the fair value of the investment properties since the last valuations completed in December 2025; including any tenant changes, assessing market rentals, etc. There are no major factors that could significantly affect the fair value of the investment properties as at 30 June 2026.
13 Loans and borrowings
Group Company
30 June
2026
31 December
2025
30 June
2026
31 December
2025
S$’000 S$’000 S$’000 S$’000
Amount repayable within one year or on
demand
Unsecured bank loans – 49,704 – 11,204
Page 17 of 20
14 Share capital
30 June 2026 31 December 2025
No. of shares No. of shares
’000 S$’000 ’000 S$’000
Company
Fully paid ordinary shares, with no par value:
At 1 January / 30 June / 31 December 1,884,544 440,099 1,884,544 440,099
The total number of issued shares excluding treasury shares as at 30 June 2026 was 1,840,190,875 (31 December 2025: 1,840,160,875).
(i) Exercise of share options and share awards
During the first half ended 30 June 2026, the Company utilised 30,000 treasury shares to fulfil the exercise of options, at exercise price of S$0.81 per share, under the Raffles Medical Group Share Option Scheme.
As at 30 June 2026, there were 69,257,000 (30 June 2025: 69,572,000) options outstanding in relation to ordinary shares of the Company.
As at 30 June 2026, the number of shares comprised in contingent awards granted under the Raffles Medical Group (2020) Performance Share Plan which has not been released was 2,033,100 (30 June 2025: 2,063,950).
(ii) Treasury shares
The Company holds 44,354,050 treasury shares as at 30 June 2026 (30 June 2025: 33,594,000).
Treasury shares held by the Company as at 30 June 2026 represent 2.41% (30 June 2025: 1.81%) of the total number of issued shares (excluding treasury shares).
(iii) Subsidiary holdings
There is no subsidiary holdings as at 30 June 2026 (30 June 2025: Nil).
There were no sales, transfers, cancellation and/or use of subsidiary holdings as at 30 June 2026
(30 June 2025: Nil).
15 Subsequent events
There are no known subsequent events which led to adjustments to this set of interim financial statements.
Number of treasury shares Balance as at 1 January 2026 44,384,050 Use of treasury shares (30,000) Balance as at 30 June 2026 44,354,050
Page 18 of 20
Other Information Required by Listing Rule Appendix 7.2
1 Whether the figures have been audited or reviewed and in accordance with which auditing standard or practice.
The condensed interim financial statements of Raffles Medical Group Ltd (the Company) and its subsidiaries (the Group), which comprise the condensed interim consolidated statement of financial position of the Group and the condensed interim statement of financial position of the Company as at 30 June 2026, the condensed interim consolidated statement of profit or loss, condensed interim consolidated statement of comprehensive income, condensed interim consolidated statements of changes in equity and condensed interim consolidated statement of cash flows of the Group for the six-month period then ended, and notes to the condensed interim financial statements have not been audited or reviewed.
2 A review of the performance of the group, to the extent necessary for a reasonable understanding of the group’s business. It must include a discussion of the following:-
(a) any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and (b) any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on.
The Group recorded a 6.7% lower revenue of S$353.2 million for the first half of 2026, as compared to S$378.4 million in the corresponding period last year. Profit after tax and minority interests (PATMI) stood at S$29.0 million, 9.6% lower than 1H 2025.
The Hospital Services division remained a key contributor to the Group’s performance, recording revenue of S$170.2 million. Profit increased by 11.0% to S$19.7 million from S$17.7 million in 1H 2025. This was driven by improved operational efficiency and cost management in both Singapore and China hospitals. Consequently, the Hospital Services division profit margin improved from 10.2% in 1H 2025 to 11.6% in 1H 2026. The Healthcare Services division registered a revenue of S$119.5 million in 1H 2026, a decrease of 16.0% from 1H 2025, mainly due to lower occupancy of transitional care facilities (TCF). Correspondingly, Healthcare Services profit decreased to S$15.6 million from S$24.9 million 1H 2025.
For China market, revenue increased 13.0% from CNY163.6 (S$29.9) million to CNY184.8 (S$34.4) million in 1H 2026. The RafflesHospital brand continues to receive greater recognition among patients in China, further enhancing its reputation as a trusted provider of quality healthcare. Cost optimisation initiatives implemented in prior periods have also contributed to improved financial performance.
RafflesHealthInsurance (RHI) registered revenue of S$88.5 million in 1H 2026, compared with S$94.9 million in the corresponding period last year. RHI’s operating loss narrowed by 64.3% to S$1.1 million from S$3.1 million in 1H 2025, driven by better claims experience, prudent claims adjudication and effective cost management.
The Group generated operating cash flow of S$64.6 million in 1H 2026, up from S$56.6 million in 1H 2025. During 1H 2026, following the Company’s Annual General Meeting in April 2026, the Group distributed cash dividends totaling S$55.2 million and fully repaid bank loans amounting to S$51.1 million.
The Group’s financial position remains strong, with cash and cash equivalents amounting to S$262.3 million as of 30 June 2026.
3 Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.
The current financial period’s results are in line with the Directors’ expectations as disclosed in the Group’s FY2025 results announcement.
Page 19 of 20
4 A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.
The global economic outlook remains uncertain amid ongoing geopolitical tensions, evolving trade disputes and volatility in financial markets. While these factors may affect business confidence, the demand for quality healthcare services is expected to remain resilient.
The Group remains focused on delivering integrated healthcare and insurance solutions that address the evolving needs of individuals and corporate clients. By leveraging its comprehensive healthcare ecosystem, the Group is well positioned to provide accessible, coordinated and high-quality care while generating sustainable long-term value for its stakeholders.
The Group is also committed to strengthening its regional healthcare network by broadening its range of clinical services, enhancing specialist capabilities and expanding access to quality healthcare across the Asian cities in which it operates.
Innovation and digital transformation remain key strategic priorities. The Group will continue to evaluate and adopt appropriate technologies, including artificial intelligence (AI), to improve operational efficiency, enhance service excellence and support the delivery of safe, high-quality healthcare services.
As the Group marks its 50 th Anniversary in 2026, it remain guided by its core values of Compassion, Commitment, Excellence, Teamwork and Value (CCETV). Building on five decades of service to the communities in which it operates, the Group will continue to innovate, strengthen its capabilities and enhance patient care in support of its mission to deliver trusted healthcare.
While the operating environment remains challenging, the Directors are optimistic that, barring unforeseen circumstances, the Group will remain profitable for the financial year ending 31 December 2026.
5 Dividend
(a) Current Financial Period Reported on
Any dividend declared for the current financial period reported on? No Interim Dividend is declared.
(b) Corresponding Period of the Immediately Preceding Financial Year
Any dividend declared for the corresponding period of the immediately preceding financial year? No
(c) Date payable
Not applicable.
(d) Record date
Not applicable.
6 If no dividend has been declared/recommended, a statement to that effect.
During the FY2020 results’ announcement, the Board announced its intent to consolidate its interim and final dividends with effect from FY2021 into an annual core dividend. In view of the foregoing, the Directors will not be declaring any interim dividend.
Page 20 of 20
7 If the group has obtained a general mandate from shareholders for Interested Person Transactions (IPTs), the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect.
The Company did not obtain a general mandate from shareholders for IPTs.
8 Confirmation pursuant to Rule 720 (1) of the Listing Manual
The Company confirms that it has procured undertakings from all its Directors and executive officers (in the format set out in Appendix 7.7) under Rule 720 (1) of the Listing Manual.
9 Disclosures of incorporation of Entities, Acquisition and Realisation of Shares pursuant to Rule 706(A) of the Listing Manual
There was no further incorporation of entities, acquisition and realisation of shares by the Group for the period 1 January 2026 to 30 June 2026 to be disclosed under Rule 706(A) of the Listing Manual except for those previously announced in the FY2025 results announcement in February 2026.
10 Confirmation by the Board pursuant to Rule 705 (5) of the Listing Manual BY ORDER OF THE BOARD
Yap Chew Fern Company Secretary 27 July 2026
On behalf of the Board of Directors of the Company, we, the undersigned, hereby confirm to the best of our knowledge that nothing has come to the attention of the Board of Directors of the Company which may render the condensed interim financial statements for the six-month period ended 30 June 2026 to be false or misleading in any material aspect.
On behalf of the Board of Directors
Dr Loo Choon Yong Mr Lew Yoong Keong Allen Chairman Director
1
Result Announcement For the Second-Half and Full Year 2025
Audited
2H2025
2H2024 Change
2025
2024 Change (S$’m) (S$’m) % (S$’m) (S$’m) % Revenue 386.9 385.9 0.3 765.3 751.6 1.8 EBITDA 71.3 64.4 10.7 135.0 125.7 7.4 Operating Profit 48.7 41.2 18.3 90.4 82.5 9.5 Profit After Tax 38.6 31.4 23.1 71.1 62.3 14.1 PATMI 38.5 31.6 21.7 70.6 62.2 13.4 2025 (cents)
2024 (cents)
Change %
Diluted Earnings per Share 3.81 3.34 14.1
Net Assets Value per Share 57.52 56.50 1.8
Key Highlights
Revenue grew 1.8% to S$765.3 million PATMI for 2H 2025 and FY2025 improved 21.7% and 13.4% respectively Diluted earnings per share increased 14.1% to 3.81 cents Continued healthy cash position of S$310.8 million Proposed final dividend of 3.0 cents per share, at 84% payout ratio on sustainable Group PATMI
2
MEDIA RELEASE
RafflesMedicalGroup Delivers
22% PATMI Growth to $38.5 million in 2H2025
Singapore, 23 February 2026 – RafflesMedicalGroup (RMG or the Group) delivered strong growth in the second half of 2025, with Profit After Tax and Minority Interests (PATMI) rising 22% to S$38.5 million for 2H2025, compared to S$31.6 million in 2H2024.
For FY2025, PATMI increased 13.4% to S$70.6 million, driven by improved performance from the Hospital Services and Insurance businesses, as well as fair value gains on investment properties. Group revenue for FY2025 rose 1.8% year-on-year to S$765.3 million, underpinned by higher patient volumes, improved average bill sizes and operational efficiencies.
The strong results reflect disciplined operational execution across the Group’s businesses and continued momentum in China.
The Hospital Services Division delivered strong growth, with revenue increasing 3.5% year-on-year to S$357.8 million and profit rising 15.3% to S$41.1 million. Performance was supported by steady patient volumes, higher bill sizes, and operational efficiencies across both Singapore and China.
The Healthcare Services Division generated revenue of S$285.9 million, with profitability remaining broadly stable. Together, these results demonstrate the Group’s ability to translate operational improvements into sustained earnings growth, particularly in the second half of the year.
The RafflesHospital brand continued to gain recognition among patients in China, reinforcing its position as a trusted provider of quality healthcare. RafflesChinaHealthcare contributed positively to the Group’s performance, with revenue increasing 2.3% to CNY359.4 million (S$65.4 million) in FY2025, from CNY351.3 million (S$65.3 million) in FY2024.
Earlier cost efficiency initiatives have improved bottomline, while strategic partnerships with Shanghai’s Renji Hospital and Chongqing’s First Affiliated Hospital continue to strengthen the integration of our international standards with local expertise to provide high quality patient care. These initiatives position RafflesChinaHealthcare for sustainable growth and a growing contribution to the Group’s overall results.
3
RafflesHealthinsurance (RHI) recorded revenue growth of 4.1%, increasing from S$178.0 million in FY2024 to S$185.2 million in FY2025, driven by contract repricing and new contracts. Disciplined claims management and prudent expense control underpinned improved profitability, reflecting a 50.6% improvement compared to FY2024, despite a higher-cost insurance environment.
The Group generated operating cash flows of S$101.3 million in FY2025. Its balance sheet remained strong, with S$310.8 million in cash and cash equivalents as at 31 December 2025, providing flexibility to support strategic growth initiatives while continuing to return value to shareholders.
During FY2025, the Group undertook share buybacks and acquisitions of minority interests, reinforcing its financial position while balancing growth investments with shareholder returns. For FY2025, the Board has proposed a final core dividend of 3.0 cents per share, representing approximately 84% of sustainable Group PATMI.
Business Updates
Positioned for Demographic Shifts in Singapore and China Singapore and China both face demographic challenges of ageing populations and declining birth rates. The Group operates in both geographies and we will respond to these trends and grow services that are in demand.
Commitment to Caring Across Generations and Regional Expansion The Group is celebrating its 50 th anniversary of caring this year. We resolve to continue serving our patients, corporate clients with the same compassion, commitment, excellence, through our teamwork of physicians, nurses and healthcare managers, adding value to the lives of our patients.
We will expand and grow our depth and breadth of services in the 14 cities of Asia where we operate now. We are continually exploring and evaluating earnings-accretive businesses and assets in the Asia Pacific.
The RafflesHealthyLongevityCentre, scheduled to open in Q1 2026, is a physician-led, multidisciplinary service focused on helping individuals achieve healthier, longer lives. Through advanced diagnostics and evidence-based therapies, the Centre will provide personalised and preventive care tailored to each individual’s health profile.
4
Technology Adoption and Innovative Care Delivery Globally, technological and social changes are gathering momentum. We will monitor these changes closely. We intend to be early adopters of appropriate AI applications in healthcare, both to improve efficiencies as well as to transform care and service delivery.
Proactive Response to Regulatory Changes In Singapore, rising insurance premiums and private healthcare costs have prompted the Ministry of Health to introduce a higher co-payment cap to a minimum of S$6,000. RHI will launch a new rider, that complies with the new regulations. The change is not expected to have a significant impact to RHI’s financials, demonstrating the Group’s ability to adapt efficiently to regulatory developments.
Delivering Integrated Healthcare Solutions Amidst evolving patient needs and rising healthcare costs, RMG is well-positioned as an integrated healthcare provider, delivering end-to-end healthcare and insurance solutions to individuals and corporates.
Based on the current conditions and barring unforeseen circumstances, the Board is optimistic that the Group will remain profitable in FY2026.
“This year, we celebrate 50 years of RafflesMedicalGroup, a milestone that, together with our strong performance in 2025, is a testament to the strength of our foundations, the trust earned through generations of patient care, and our pledge to give our patients our very best. We are ready to enter our next phase of growth, anchored in our strengths and our commitment to excellence and value creation,” said Dr Loo Choon Yong, Executive Chairman, RafflesMedicalGroup.
For media queries, please contact Joanna Lee (Ms) Senior Manager, Corporate Communications Raffles Medical Group Email: [email protected]
5
About Us
About Raffles Medical Group Founded in 1976, RafflesMedicalGroup (RMG or the Group) is one of the leading integrated private healthcare providers in the region, providing a continuum of services from primary and tertiary care to health insurance for people across Asia. A proudly Singaporean brand, RMG is listed on the mainboard of the Singapore stock exchange (SGX: BSL) and operates in 14 cities in five countries in Asia. This network includes four hospitals and over 100 multi-disciplinary clinics, offering services such as health screening, specialist care, diagnostic radiology, dental and traditional Chinese medicine. Together with about 2,900 employees, RMG brings 50 years of trusted healthcare expertise and care to more than 2.8 million patients across our network as their trusted partner for health. For more information, please visit rafflesmedicalgroup.com.
About Raffles Medical RafflesMedical is the primary care network of RafflesMedicalGroup operating over 55 practices and clinics in Singapore providing family medicine, health screening and dental services. RafflesMedical also has Japanese clinics and/or clinics offering Japanese services in Singapore, Beijing Tianjin, Shanghai, Osaka, Fukuoka, and Ho Chi Minh City, servicing its Japanese patients with family medicine and dental services. In Singapore, RafflesMedical represents one of the largest networks of primary care clinics and services over 7,000 corporate clients, supporting the healthcare needs of businesses and employees. Through RafflesMedicalInternational, the Raffles brand of quality and affordable care is available to patients in 14 cities, including Singapore, Greater China, Japan as well as Cambodia and Vietnam.
About Raffles Hospital RafflesHospital is the flagship private tertiary hospital offering of the Group in Singapore that currently operates a growing network of tertiary hospitals in Singapore and China, including RafflesHospitalChongqing, RafflesHospitalShanghai, RafflesHospitalBeijing and American International Hospital (AIH) in Ho Chi Minh City, Vietnam, which the Group commenced managing in January 2024. In Singapore, RafflesHospital offers a comprehensive range of medical and dental specialties as well as diagnostic services. RafflesHospital is the only private tertiary hospital in Singapore to be recognised by the Ministry of Health as Trauma Centre and is authorised to accept emergency cases from public ambulances under the Emergency Care Collaboration Scheme. The Hospital also operates more than 30 specialist centres and specialist satellite clinics, covering over 30 disciplines. Subscribing to the Group Practice model of healthcare, over 1,500 physicians, nurses and allied healthcare professionals bring the Raffles brand of quality, peer-reviewed healthcare to patients in the region.
About Raffles China Healthcare RafflesChinaHealthcare is the operating division of the RafflesMedicalGroup in China, its presence in China first started in 1995 with the opening of RafflesMedicalGroup’s first overseas clinic in Hong Kong. Since then, RafflesChinaHealthcare has grown its presence and provides primary and tertiary care through its clinics and hospitals in seven cities – Beijing, Shanghai, Chongqing, Tianjin, Nanjing, Dalian and Hong Kong SAR. RafflesChinaHealthcare’s network of tertiary hospitals includes RafflesHospitalChongqing, Singapore’s first private tertiary hospital in China, and RafflesHospitalShanghai, which opened in July 2021, as well as the RafflesHospitalBeijing, bringing the Raffles brand of quality, peer-reviewed healthcare to more patients in China.
About Raffles Health Insurance RafflesHealthinsurance (RHI) is the health insurance division of RafflesMedicalGroup, providing healthcare insurance to corporates and individuals in Singapore. Backed by the expertise of a trusted medical group with 50 years of experience, RafflesHealthinsurance seeks to provide healthcare financing solutions that cater to the needs of all its policy owners and members. Incorporated in 2004, RafflesHealthinsurance is a wholly-owned subsidiary of the RafflesMedicalGroup and is an Integrated Shield Plan provider appointed by the Ministry of Health in Singapore. RafflesHealthinsurance, through its partnership with Bupa Global, also offers a wider range of international private health plans, which are co-insured by RHI and Bupa, to cater to the needs of individuals and corporate clients of the international business community in Singapore.
Raffles Medical Group Ltd and its Subsidiaries Registration Number : 198901967K
Condensed Financial Statements
For the six months and full year ended
31 December 2025
Table of contents
A. Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income 1 B. Condensed Statements of Financial Position 3 C. Condensed Consolidated Statement of Cash Flows 4 D. Condensed Statements of Changes in Equity 5 E. Notes to the Condensed Consolidated Financial Statements 8 F. Other Information Required by Listing Rule Appendix 7.2 23
Page 1 of 27
Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income Condensed Consolidated
6 months
ended 31
December
2025
6 months
ended 31
December
2024
Change
%
12 months
ended 31
December
2025
12 months
ended 31
December
2024
Change
%
Statement of Profit or Loss
Note S$’000
S$’000 S$’000 S$’000
Revenue 386,852 385,874 0.3 765,299 751,564 1.8 Other operating income 4,836 294 nm 5,565 2,512 nm Inventories and consumables used (33,272) (31,469) 5.7 (63,593)(61,180) 3.9 Purchased and contracted services (20,733) (19,974) 3.8 (37,512)(37,340) 0.5 Insurance service expenses (71,763) (84,305) (14.9) (153,681) (162,903) (5.7) Net expenses from reinsurance contracts (7,379)(276) nm (13,233)(4,003) nm Staff costs (159,692) (160,535) (0.5) (317,156) (314,873) 0.7 Depreciation of property, plant and equipment (21,250) (21,834) (2.7) (41,814)(40,329) 3.7 Amortisation of intangible assets (706)(766) (7.8) (1,573)(1,545) 1.8 Operating lease expenses (823)(656) 25.5 (1,645)(1,566) 5.0 Impairment loss on trade receivables (2,184)(953)nm (3,197)(1,262)nm Impairment loss on intangible assets and goodwill (316) (2,601) (87.9) (316)(2,601) (87.9) Other operating expenses (24,828) (21,584) 15.0 (46,788)(43,980) 6.4 Profit from operating activities 48,742 41,215 18.3 90,356 82,494 9.5 Finance income 2,898 4,951 (41.5) 7,333 10,247 (28.4) Finance costs (1,957)(2,616) (25.2) (4,095)(5,779) (29.1) Profit before tax 6 49,68343,550 14.1 93,594 86,962 7.6 Tax expense 7 (11,073) (12,197) (9.2) (22,523)(24,680) (8.7) Profit for the period/year 38,61031,353 23.1 71,07162,282 14.1
Profit attributable to:
Owners of the Company (PATMI) 38,46231,600 21.7 70,57062,243 13.4
Non-controlling interests 148(247) nm 50139 nm
Profit for the period/year 38,61031,353 23.1 71,07162,282 14.1
Note: (i) nm denotes not meaningful
Page 2 of 27
Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income (cont’d)
Condensed Consolidated Statement 6 months ended 31 December 2025 6 months ended 31 December
2024 Change
%
12 months
ended 31
December
2025
12 months
ended 31
December
2024
Change
%
of Other Comprehensive Income S$’000 S$’000 S$’000 S$’000
Profit for the period/year 38,610 31,353 23.1
71,071 62,282 14.1
Other comprehensive income
Item that is or may be reclassified
subsequently to profit or loss:
Foreign currency translation differences - foreign operations 6,808 763 nm (4,281) 1,328 nm Total comprehensive income for the period/year 45,418 32,116 41.4 66,790 63,610 5.0
Total comprehensive income attributable to:
Owners of the Company 45,359 32,390 40.0 66,326 63,570 4.3 Non-controlling interests 59 (274) nm 464 40 nm Total comprehensive income for the period/year 45,418 32,116
41.4
66,790
63,610 5.0
Earnings per share
Basic earnings per share (cents) [Note i] 2.08 1.70 22.4 3.81 3.35 13.7
Diluted earnings per share (cents) [Note j]
2.08 1.70 22.4 3.81 3.34
14.1
Note:
(i) nm denotes not meaningful.
Explanatory Notes to the Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income
(a) Higher other operating income in 2H2025 and FY2025 was mainly due to a fair value gain of S$4.7 million on investment properties, partially offset by lower government grants received.
(b) The decrease in insurance service expenses for 2H2025 and FY2025 was mainly due to improved claims experience, despite insurance revenue increasing by 4.5% in FY2025.
(c) Net expenses from reinsurance contracts increased mainly because improved claims experience led to lower claim recoveries for 2H2025 and FY2025.
(d) The increase in impairment loss on trade receivables was mainly due to higher provisions made for long outstanding receivables for 2H2025 and FY2025.
(e) The increase in other operating expenses in 2H 2025 and FY2025 was mainly due to higher professional fees, adverse foreign exchange variances and intangible assets written off.
(f) The decrease in finance income was due to lower interest rates on bank fixed deposits in 2H2025 and FY2025.
(g) The decrease in finance costs was due to lower interest expenses on bank loans and amounts due to non-controlling interests in FY2025.
(h) Lower tax expense was due to a reduction in unrecognised tax losses and the higher reversal of prior years tax overprovision in FY2025.
(i) The calculation of earnings per ordinary share for the second half and full year ended 31 December 2025 were based on the weighted average number of shares 1,846,533,921 (2H 2024: 1,857,847,353) and 1,850,129,015 (FY2024: 1,857,487,887) in issue during the period.
(j) The calculation of earnings per ordinary share (on a fully diluted basis) for the second half and full year ended 31 December 2025 were based on weighted average number of shares 1,850,920,041 (2H 2024: 1,860,518,110) and 1,854,054,300 (FY2024: 1,860,824,148) in issue during the period.
Page 3 of 27
Condensed Statements of Financial Position
As at 31 December 2025
Group Company
31 December
2025
31 December
2024
31 December
2025
31 December
2024
Note S$’000 S$’000 S$’000 S$’000
Non-current assets
Property, plant and equipment 11 741,397 748,248 12,433 13,777
Intangible assets and goodwill 10 13,923 15,484 68 286
Investment properties 12 233,600 246,100 – –
Subsidiaries – – 1,001,146 929,546
Deferred tax assets 2,197 2,089 – 141
Trade and other receivables 3,017 2,553 16,976 15,684
994,134 1,014,474 1,030,623 959,434
Current assets
Inventories 11,262 10,762 2,494 2,184
Trade and other receivables 95,984 101,586 94,526 71,574
Reinsurance contract assets 17,768 19,008 – –
Cash and cash equivalents 310,791 343,671 86,366 145,658
435,805 475,027 183,386 219,416
Total assets 1,429,939 1,489,501 1,214,009 1,178,850
Equity attributable to owners
of the Company
Share capital 14 440,099 440,099 440,099 440,099
Reserves 618,381 609,667 669,072 644,895
1,058,480 1,049,766 1,109,171 1,084,994
Non-controlling interests (2,517) 15,213 – –
Total equity 1,055,963 1,064,979 1,109,171 1,084,994
Non-current liabilities
Loans and borrowings 13 – 49,116 – 10,000
Trade and other payables 5,105 4,205 – 940
Lease liabilities 27,430 22,655 1,987 810
Deferred tax liabilities 7,859 7,902 9 –
40,394 83,878 1,996 11,750
Current liabilities
Loans and borrowings 13 49,704 6,866 11,204 1,265
Current tax liabilities 24,347 24,775 6,924 7,620
Trade and other payables 184,630 218,483 84,194 72,706
Lease liabilities 10,286 9,531 520 515
Other financial liabilities – 2,788 – –
Insurance contract liabilities 64,615 78,201 – –
333,582 340,644 102,842 82,106
Total liabilities 373,976 424,522 104,838 93,856
Total equity and liabilities 1,429,939 1,489,501 1,214,009 1,178,850
Explanatory Notes to the Condensed Statements of Financial Position
(a) Current trade and other receivables for the Group decreased mainly due to improved debt collection and higher allowance for doubtful trade receivables.
(b) The decrease in trade and other payables for the Group was mainly due to repayment of a loan to a minority shareholder.
(c) The decrease in insurance contract liabilities for the Group were aligned with improved claim experience in FY2025.
Page 4 of 27
Condensed Consolidated Statement of Cash Flows
Group
6 months
ended
31 December
2025
S$'000
6 months
ended
31 December
2024
S$'000
12 months
ended
31 December
2025
S$'000
12 months
ended
31 December
2024
S$'000
Cash flows from operating activities
Profit for the period/year
38,610 31,353 71,071 62,282
Adjustments for :
Amortisation of intangible assets
1,075 1,204 2,422 2,406
Changes in fair value of investment properties
(4,700) – (4,700) –
Depreciation of property, plant and equipment
21,414 21,992
42,137 40,682
Equity-settled share-based payment transactions
1,453 1,641 3,066 3,465
Finance costs
1,991 2,595 4,170 5,870
Finance income
(2,898) (4,951) (7,333) (10,247)
(Gain)/Loss on disposal of property, plant and equipment, net
1 1,921 (3) 1,922
Gain on lease derecognition
(56) (779) (124) (816)
Impairment loss on intangible assets and goodwill
316
2,601 316 2,601
Intangible asset written off
791 – 791 46
Property, plant and equipment written off
956 184 1,077 446
Tax expense
11,073 12,197
22,523 24,680
70,026 69,958 135,413 133,337 Changes in working capital:
Insurance and reinsurance contracts (27,663) (10,590) (12,346) (5,254) Inventories 13 744 (500) 1,703 Trade and other payables 9,053 4,674 (3,829) (1,543) Trade and other receivables 4,332 (798) 4,882 (16,151) Cash generated from operations 55,761 63,988 123,620 112,092 Tax paid (11,030) (12,301) (22,289) (25,838) Net cash from operating activities 44,731 51,687 101,331 86,254
Cash flows from investing activities
Acquisition of intangible assets (449) (500) (2,159) (1,639) Interest received 3,089 4,821 7,515 9,951 Proceeds from disposal of property, plant and equipment 6 2 6 1,085 Purchase of property, plant and equipment (5,022) (7,591) (7,867) (19,270) Net cash used in investing activities (2,376) (3,268) (2,505) (9,873)
Cash flows from financing activities
Acquisition of own shares (12,394) – (19,917) – Acquisition of non-controlling interest (16,594) – (16,594) (1,564) Dividends paid to owners of the Company – – (46,273) (44,576) Interest paid (1,270) (1,848) (2,863) (3,756) Lease interest paid (651) (606) (1,189) (1,277) Payment of lease liabilities (5,226) (4,150) (11,442) (9,882) Proceeds from bank loans (85) 13,524 1,204 67,673 Proceeds from issue of shares under share option scheme 708 29 1,124 280 Repayment of bank loans (1,562) (28,095) (5,513) (81,504) Repayment of loan to minority shareholder (29,383) (48) (29,383) (1,597) Net cash used in financing activities (66,457) (21,194) (130,846) (76,203)
Net (decrease)/increase in cash and cash equivalents (24,102) 27,225 (32,020) 178 Cash and cash equivalents at 1 July / 1 January 334,183 316,263 343,671 342,543 Effect of exchange rate fluctuations on cash held 710 183 (860) 950 Cash and cash equivalents at 31 December 310,791 343,671 310,791 343,671
Explanatory Notes to the Condensed Consolidated Statement of Cash Flows
The Group’s cash and cash equivalents decreased by S$32.9 million in FY2025, attributed by cash outflows for dividends, share buybacks, acquisition of non-controlling interests, and repayment of a loan to a minority shareholder despite net cash generated from operating activities of S$101.3 million.
Page 5 of 27
Condensed Statements of Changes in Equity
Share
capital
Translation
reserve
Equity
compensation
reserve
Revaluation
reserve
Other
reserve
Reserve
for own
shares
Accumulated
profits
Total
attributable
to owners
of the Company Non- controlling interests Total equity Group S$’000 S$’000
S$’000
S$’000 S$’000 S$’000 S$’000
S$’000
S$’000
S$’000
At 1 January 2025 440,099
(21,012)
40,521 16,367
(5,590) (30,579) 609,960
1,049,766
15,213
1,064,979
Total comprehensive income for the year
Profit for the year –
–
– –
–
– 70,570
70,570
501
71,071
Other comprehensive income
Foreign currency translation differences - foreign operations
–
(4,244)
–
–
–
–
–
(4,244)
(37)
(4,281)
Total other comprehensive income for the year –
(4,244)
–
–
–
–
–
(4,244)
(37)
(4,281)
Total comprehensive income for the year –
(4,244)
–
–
–
–
70,570
66,326
464
66,790
Transactions with owners, recognised directly in eq uity
Contributions by and distributions to owners
Own shares reissued pursuant to Raffles Medical Gro up Performance Share Plan
–
–
(1,015)
–
181
834
–
–
–
–
Value of employee services received for issue of sh are options and share awards
–
–
3,066
–
–
–
–
3,066
–
3,066
Exercise of share options under Raffles Medical Gro up Employees’ Share Option Schemes –
–
– –
(417) 1,541
–
1,124
–
1,124
Acquisition of own shares –
–
– –
–
(19,917)
–
(19,917)
–
(19,917)
Final dividend paid of 2.5 cents per ordinary share
- Cash –
–
–
–
–
–
(46,273)
(46,273)
–
(46,273)
Total contributions by and distributions to owners –
–
2,051 –
(236) (17,542) (46,273)
(62,000)
–
(62,000)
Changes in ownership interests in subsidiaries
Acquisition of non-controlling interests without a change in control –
–
– –
1,600
– –
1,600
(18,194)
(16,594)
Derecognition of written put option –
–
– –
2,788
– –
2,788
–
2,788
Total changes in ownership interests in subsidiarie s –
–
– –
4,388
– –
4,388
(18,194)
(13,806)
Total transactions with owners –
–
2,051 –
4,152
(17,542) (46,273)
(57,612)
(18,194)
(75,806)
Balance at 31 December 2025 440,099
(25,256)
42,572 16,367
(1,438) (48,121) 634,257
1,058,480
(2,517)
1,055,963
Page 6 of 27
Condensed Statements of Changes in Equity (cont’d)
Share
capital
Translation
reserve
Equity
compensation
reserve
Revaluation
reserve
Other
reserve
Reserve
for own
shares
Accumulated
profits
Total
attributable
to owners
of the Company Non- controlling interests Total equity Group S$’000 S$’000
S$’000
S$’000 S$’000 S$’000 S$’000
S$’000
S$’000
S$’000
At 1 January 2024 439,819
(22,339)
38,172 16,367
(5,091) (31,483) 592,293
1,027,738
16,114
1,043,852
Total comprehensive income for the year
Profit for the year –
–
– –
–
– 62,243
62,243
39
62,282
Other comprehensive income
Foreign currency translation differences - foreign operations
–
1,327
– –
–
– –
1,327
1
1,328
Total other comprehensive income for the year –
1,327
– –
–
– –
1,327
1
1,328
Total comprehensive income for the year –
1,327
– –
–
– 62,243
63,570
40
63,610
Transactions with owners, recognised directly in eq uity
Contributions by and distributions to owners
Issue of shares upon the exercise of options under Raffles Medical Group Employees’ Share Option Schemes
280
–
–
–
–
–
–
280
–
280
Own shares reissued pursuant to Raffles Medical Gro up Performance Share Plan
–
–
(1,116)
–
212
904
–
–
–
–
Value of employee services received for issue of sh are options and share awards
–
–
3,465
–
–
–
–
3,465
–
3,465
Final dividend paid of 2.4 cents per ordinary share
- Cash –
–
– –
–
– (44,576)
(44,576)
–
(44,576)
Total contributions by and distributions to owners 280
–
2,349 –
212 904 (44,576)
(40,831)
–
(40,831)
Changes in ownership interests in subsidiaries
Acquisition of non-controlling interests without a change in control
–
–
–
–
(623)
–
–
(623)
(941)
(1,564)
Present value of the exercise price of written put
options
–
–
– –
(88) – –
(88)
–
(88)
Total changes in ownership interests in subsidiarie s –
–
– –
(711) – –
(711)
(941)
(1,652)
Total transactions with owners 280
–
2,349 –
(499) 904 (44,576)
(41,542)
(941)
(42,483)
Balance at 31 December 2024 440,099
(21,012)
40,521 16,367
(5,590) (30,579)
609,960
1,049,766
15,213
1,064,979
Page 7 of 27
Condensed Statements of Changes in Equity (cont’d)
Share capital Equity compensation reserve Other reserve Reserve for own shares Accumulated profits Total Company S$'000 S$’000 S$’000 S$’000 S$'000 S$'000
At 1 January 2025 440,099 40,521 (39) (30,579) 634,992 1,084,994
Total comprehensive income for the year
Profit for the year – – – – 86,223 86,223
Total comprehensive income for the year – – – – 86,223 86,223
Transactions with owners, recognised directly
in equity
Contributions by and distributions to owners
Own shares reissued pursuant to Raffles Medical
Group Performance Share Plan
– (1,015) 135 834 – (46)
Value of employee services received for issue of
share options and share awards
– 3,066 – – – 3,066
Exercise of share options – – (417) 1,541 – 1,124
Acquisition of own shares – – – (19,917) – (19,917)
Final dividend paid of 2.5 cents per ordinary share
- Cash – – – – (46,273) (46,273) Total contributions by and distributions to owners – 2,051 (282) (17,542) (46,273) (62,046)
At 31 December 2025 440,099 42,572 (321) (48,121) 674,942 1,109,171
At 1 January 2024 439,819 38,172 (142) (31,483) 587,276 1,033,642
Total comprehensive income for the year
Profit for the year – – – – 92,292 92,292
Total comprehensive income for the year – – – – 92,292 92,292
Transactions with owners, recognised directly
in equity
Contributions by and distributions to owners
Issue of shares upon the exercise of options
under Raffles Medical Group Employees’ Share
Option Schemes
280 – – – – 280
Own shares reissued pursuant to Raffles Medical
Group Performance Share Plan
– (1,116) 103 904 – (109)
Value of employee services received for issue of
share options and share awards
– 3,465 – – – 3,465
Final dividend paid of 2.4 cents per ordinary share
- Cash – – – – (44,576) (44,576) Total contributions by and distributions to owners 280 2,349 103 904 (44,576) (40,940)
At 31 December 2024 440,099 40,521 (39) (30,579) 634,992 1,084,994
Page 8 of 27
Notes to the Condensed Consolidated Financial Statements
1 Corporate information
Raffles Medical Group Ltd (the Company) is a company incorporated in Singapore. The address of the Company’s registered office is 585 North Bridge Road, Raffles Hospital #11-00, Singapore 188770.
These condensed financial statements as at and for the six months and full year ended 31 December 2025 comprise the Company and its subsidiaries (together referred to as the Group).
The principal activities of the Company are those relating to the operation of medical clinics, other general medical services and investment holdings.
The Group and the Company are the sole proprietor of the following:
Family Doctors
RafflesCare
Raffles Airport Medical Centre
Raffles Corporate Wellness
Raffles Dental Surgery
Raffles Healthcare Consultancy
Raffles Healthcare Institute
Raffles Health Screeners
Raffles Longevity
Raffles Medical Management
Raffles Medihelp
Raffles Optica
Raffles Pharmacare
Raffles Pharmacy
Raffles Solitaire
Raffles Solitaire International
Raffles Specialist Centre
Raffles Wellness
The Group and the Company are partners of the following:
Raffles International Medical Assistance LLP
All transactions of these sole proprietorships and partnerships are reflected in the condensed financial statements of the Company.
The immediate and ultimate holding company during the financial year is Raffles Medical Holdings Pte Ltd, which is incorporated in Singapore.
2 Basis of preparation
The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with SFRS(I)s, except for the adoption of new and amended standards as set out in Note 2.1.
The condensed financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group’s financial position and performance of the Group since the last interim financial statements for the period ended 30 June 2025.
The condensed financial statements are presented in Singapore dollar, which is the Company’s functional currency. All financial information presented in Singapore dollars have been rounded to the nearest thousand, unless otherwise stated.
Page 9 of 27
- Basis of preparation (cont’d)
2.1 New standards and amendments
The Group has applied SFRS(I) 1-21 Lack of Exchangeability for the first time for the annual period beginning on 1 January 2025. The application of the amendment to accounting standards does not have a material effect on the financial statements.
2.2 Use of estimates and judgements
In preparing the condensed financial statements, management has made judgements, estimates and assumptions about the future, including climate-related risks and opportunities that affect the Group’s application of accounting policies and the reported amounts of assets, liabilities, income and expense. Actual results may differ from these estimates.
The significant judgements made by management in applying the Group’s accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the year ended 31 December 2024.
Estimates and underlying assumptions are reviewed on an ongoing basis and are consistent with the Group’s risk management and climate-related commitments where appropriate. Revisions to accounting estimates are recognised prospectively.
Information about critical judgements in applying accounting policies that have the most significant effect on the amounts recognised in the condensed financial statements is insurance and reinsurance contract: estimation of fulfilment cash flows.
Fulfilment cash flows
Although the insurance contract liabilities are estimated based on management’s best knowledge and judgement of current facts, the actual outcome may differ from the estimates.
The areas involving a higher degree of judgement or complexity, or areas whereby judgement, assumptions and estimates have been involved in estimating the fulfilment cash flows comprise:
estimates of future cash flows; an adjustment to reflect the time value of money and the financial risks related to future cash flows, to the extent that the financial risk are not included in the estimates of future cash flows; and a risk adjustment for non-financial risk.
Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next financial year are included in the following notes:
recoverable amounts of property, plant and equipment
impairment test of goodwill: key assumptions underlying recoverable amounts (Note 10)
determination of fair value of investment properties on the basis of significant unobservable inputs
(Note 12)
measurement of insurance and reinsurance contracts
and recognition of loss component on onerous
contracts
Page 10 of 27
- Basis of preparation (cont’d)
2.2 Use of estimates and judgements (cont’d)
Measurement of fair values
A number of the Group’s accounting policies and disclosures require the measurement of fair values, for both financial and non-financial assets, and financial and non-financial liabilities.
If third party information, such as property valuation report, is used to measure fair values, the Group assesses the evidence obtained from the third parties to support the conclusion that these valuations meet the requirements of SFRS(I)s, including the level in the fair value hierarchy in which the valuations should be classified. Significant valuation issues are reported to the Audit & Risk Committee.
3 Seasonal operations
The Group’s businesses are not affected significantly by seasonal or cyclical factors during the financial periods.
4 Segment and revenue information
The Group has 4 reportable segments, as described below, which are the Group’s strategic business units. The strategic business units offer different products and services, and are managed separately because they require different technology and marketing strategies. For each of the strategic business units, the Group’s Executive Chairman reviews internal management reports regularly. The following summary describes the operations in each of the Group’s reportable segments:
Healthcare services : The operations of medical clinics and other general medical services; trading in pharmaceutical and nutraceutical products and diagnostic equipment, and provision of management, consultancy and third-party administration services.
Hospital services : The provision of specialised medical services and operation of hospital and business of medical laboratory and imaging centre.
Investment holdings : Investment holding and those relating to investment properties.
Insurance services : The provision of insurance products.
Performance is measured based on segment profit before tax, as included in the internal management reports that are reviewed by the Group’s Executive Chairman. Segment profit is used to measure performance as management believes that such information is most relevant in evaluating the results of certain segments relative to other entities operating within these businesses.
Inter-segment pricing is determined on mutually agreed terms.
Segment results, assets and liabilities include items directly attributable to a segment as well as those that can be allocated on a reasonable basis. Unallocated items mainly comprise current tax and deferred tax liabilities and assets.
Segment capital expenditure is the total cost incurred during the period to acquire segment assets that are expected to be used for more than one period.
Page 11 of 27
4.1 Reportable segments
Healthcare services Hospital services Insurance services Investment holdings Total
31
December
2025
31
December
2024
31
December
2025
31
December
2024
31
December
2025
31
December
2024
31
December
2025
31
December
2024
31
December
2025
31
December
2024
S$’000 S$’000 S$’000 S$’000 S$’000 S$’000 S$’000 S$ ’000 S$’000 S$’000 Revenue and expenses
Revenue 285,898 295,050 357,823 345,652 185,230 177,985 44,314 44,894 873,265 863,581
Inter
segment revenue
14,408 12,824 51,826 57,187 4,232 4,273 37,500 37,733 107,966 112,017
Finance expenses (1,277) (2,038) (3) (987) (75) (91) (2,815) (2,754) (4,170) (5,870) Depreciation and amortisation (17,446) (16,072) (10,147) (9,888) (1,224) (1,253) (270) (244) (29,087) (27,457)
Reportable segment profit/(loss) before tax 42,489 45,123 41,132 35,683 (3,116) (6,305) 27,162 23,734 107,667 98,235
Other material non-cash items: - Impairment loss on intangible assets and goodwill (316) (2,601) – – – – – – (316) (2,601)
- Impairment gain/(loss) on trade receivable (824) (322) (2,338) (940) (35) – – – (3,197) (1,262)
Reportable segment assets
1,501,364 1,195,708 294,554 256,305 118,338 125,833 1,300,204 936,215 3,214,460 2,514,061 Capital expenditure 23,860 20,044 4,096 6,893 1,710 1,087 85 135 29,751 28,159 Reportable segment liabilities 489,836 189,884 240,21 8 212,744 76,495 92,128 1,103,585 711,424 1,910,134 1,206,180
Page 12 of 27
4.1 Reportable segments (cont’d)
Reconciliations of reportable segment revenues, profit or loss, assets and liabilities and other material items
31
December
2025
31
December
2024
S$’000 S$’000
Revenues
Total revenue for reportable segments 873,265 863,581 Elimination of inter-segment revenue (107,966) (112,017) Consolidated revenue 765,299 751,564
Profit or loss before tax
Total profit before tax for reportable segments 107,667 98,235
Elimination of inter-segment profits / Consolidation adjustment 1,399 4,358
Adjustment for depreciation of property, plant and equipment (15,472) (15,631)
Consolidated profit before tax 93,594 86,962
Assets
Total assets for reportable segments 3,214,460 2,514,061
Elimination of inter-segment assets (1,786,718) (1,026,649)
Unallocated amounts-current tax and deferred tax assets 2,197 2,089
Consolidated total assets 1,429,939 1,489,501
Liabilities
Total liabilities for reportable segments 1,910,134 1,206,180
Elimination of inter-segment liabilities (1,568,364)
(814,335)
Unallocated amounts-current tax and deferred tax liabilities 32,206 32,677
Consolidated total liabilities 373,976 424,522
Other material items
Reportable
segment
totals Adjustments
Consolidated
totals
S$’000 S$’000 S$’000
31 December 2025
Depreciation and amortisation 29,087 15,472 44,559
31 December 2024
Depreciation and amortisation
27,457 15,631 43,088
The Group’s properties at Raffles Holland V, Raffles Hospital, Raffles Specialist Centre, Raffles Hospital Chongqing and Raffles Hospital Shanghai are owned by its subsidiaries and classified as investment properties in the subsidiaries’ standalone financial statements.
For the preparation of the consolidated financial statements, a portion of these properties are reclassified from investment properties to property, plant and equipment as these properties are used in the supply of medical services by the Group. Accordingly, the carrying values of these properties are depreciated over their useful lives in the condensed consolidated financial statements of the Group.
Page 13 of 27
4.1 Reportable segments (cont’d)
The amount of S$15,472,000 (2024: S$15,631,000) relates to the depreciation of these properties for the year ended 31 December 2025.
Geographical information
The Group operations are primarily in Singapore, Greater China, Vietnam, Cambodia and Japan.
In presenting information on the basis of geographical segments, segment revenue is based on the geographical location of customers and segment assets are based on the geographical location of the assets.
Group
31
December
2025
31
December
2024
S$’000 S$’000
Revenue
Singapore 680,795 669,145
Greater China 65,357 65,302
Rest of Asia 19,147 17,117
Consolidated revenue 765,299 751,564
Non-current assets
Singapore 671,501 677,195
Greater China 304,010 322,945
Rest of Asia 13,409 9,692
Consolidated non-current assets* 988,920 1,009,832
- Non-current assets exclude financial instruments and deferred tax assets.
4.2 Disaggregation of Revenue
Group
31
December
2025
31
December
2024
S$’000 S$’000
Revenue from contracts with customers
578,501 572,906
Rental income
7,678 7,323
Insurance revenue
179,120 171,335
765,299 751,564
Page 14 of 27
5 Financial assets and financial liabilities
Set out below is an overview of the financial asset
s and financial liabilities of the Group as at 31 D
ecember 2025
and 31 December 2024:
Carrying amount
Fair value
At amortised cost
Other financial liabilities
Total
Level 1
Level 2
Level 3
Total
Group
S$’000
S$’000
S$’000
S$’000
S$’000
S$’000
S$’000
31 December 202 5
Financial assets not measured at fair value
Trade and other receivables
96,277
–
96,277
Cash and cash equivalents 310,791
–
310,791
407,068
–
407,068
Financial liabilities not measured at fair value
Loans and borrowings –
(49,704)
(49,704)
– (49,704)
– (49,704)
Trade and other payables* –
(186,749)
(186,749)
–
(236,453)
(236,453)
31 December 2024
Financial assets not measured at fair value
Trade and other receivables
100,749
–
100,749
Cash and cash equivalents 343,671
–
343,671
444,420
–
444,420
Financial liabilities not measured at fair value
Loans and borrowings –
(55,982)
(55,982)
– (55,982)
– (55,982)
Trade and other payables* –
(216,232)
(216,232)
Other financial liabilities –
(2,788)
(2,788)
– – (2,788)
(2,788)
–
(275,002)
(275,002)
Excludes prepayments * Excludes deferred income and other long-term empl
oyee benefits
Page 15 of 27
5 Financial assets and financial liabilities (cont’ d)
Carrying amount
Fair value
At amortised cost
Other financial liabilities
Total
Level 1
Level 2
Level 3
Total
Company
S $’000
S $’000
S $’000
S $’000
S $’000
S $’000
S $’000
3 1
December
202 5
Financial assets not measured at fair value
Trade and other receivables
109,965
–
109,965
Cash and cash equivalents 86,366
–
86,366
196,331
–
196,331
Financial liabilities not measured at fair value
Loans and borrowings –
(11,204)
(11,204)
– (11,204)
– (11,204)
Trade and other payables* –
(83,742)
(83,742)
–
(94,946)
(94,946)
31 December 202 4
Financial assets not measured at fair value
Trade and other receivables
85,617
–
85,617
Cash and cash equivalents 145,658
–
145,658
231,275
–
231,275
Financial liabilities not measured at fair value
Loans and borrowings –
(11,265)
(11,265)
– (11,265)
– (11,265)
Trade and other payables* –
(70,962)
(70,962)
–
(82,227)
(82,227)
Excludes prepayments * Excludes deferred income and other long-term empl
oyee benefits
Page 16 of 27
6 Profit before tax
Profit before tax has been arrived after charging/(crediting):
Group
6 months
ended 31
December
2025
6 months
ended 31
December
2024
12 months
ended 31
December
2025
12 months
ended 31
December
2024
S$’000 S$’000 S$’000 S$’000
Changes in fair value in investment properties (4,700)–(4,700)– Contributions to defined contribution plans 10,685 11,542 22,111 21,282 Foreign exchange loss/(gain) 59 (47)1,791 308 (Gain)/Loss on disposal of property, plant and equipment, net 1 1,921 (3)1,922 Impairment loss on intangible assets and goodwill 316 2,601 3162,601 Interest expense:
- bank loans 852 1,220 1,7962,824
- non-controlling interest 481 713 1,178 1,438
- lease liabilities 651 606 1,189 1,277
- others 7 56 7331 Interest income (2,898) (4,951)(7,333) (10,247) Property, plant and equipment written off 956 184 1,077 446 Recovery of bad debts (205) (160)(851) (376) Value of employee services received for issue of share options and share awards, included in staff costs 1,4531,6413,066 3,465 Write-off for stock obsolescence 24589262 254
Page 17 of 27
7 Taxation
The Group calculates the period income tax expense using the tax rate that would be applicable to the expected total annual earnings. The major components of income tax expense in the condensed consolidated statement of profit or loss are:
Group
6 months
ended 31
December
2025
6 months
ended 31
December
2024
12 months
ended 31
December
2025
12 months
ended 31
December
2024
S$’000 S$’000 S$’000 S$’000
Current income tax expense 10,7519,943 22,357 23,112 Current withholding tax expense 4056299751,219 Deferred income tax expense relating to origination and reversal of temporary differences 2422,150 (187)626
11,39812,72223,14524,957
Adjustment for prior years Current income tax expense – Adjustment for prior years (366)(171)(663)67 Deferred tax expense – Adjustment for prior years 41 (354)41(344)
(325)(525)(622)(277)
Tax expense 11,07312,19722,52324,680
8 Dividends
Group
6 months
ended 31
December
2025
6 months
ended 31
December
2024
12 months
ended 31
December
2025
12 months
ended 31
December
2024
S$’000 S$’000 S$’000 S$’000
Dividends paid:
Final dividend in respect of the previous
financial year of 2.5 (2024: 2.4) cents per
share
– – 46,273 44,576
9 Net assets value
Group Company
31 December 2025 31 December 2024 31 December 2025 31 December 2024 S$ S$ S$ S$
Net asset value per ordinary share [C] 57.52 cents56.50 cents60.28 cents58.39 cents
[C] The calculation of net asset value per ordinary share was based on 1,840,160,875 shares as at 31 December 2025 (31 December 2024: 1,858,137,925).
Page 18 of 27
10 Intangible assets and goodwill Goodwill Customer relationship Membership rights Software under development
Software Total
S$’000 S$’000 S$’000 S$’000 S$’000 S$’000
Group
Cost
At 1 January 2024 23,5744,125 13964017,38845,866
Additions –– –7049351,639
Write-off –– (25)–(54)(79)
Effects of movement in exchange rate 13514 ––17166
At 31 December 2024 23,7094,139 1141,34418,28647,592
Additions –– –3481,8112,159
Write-off –– –– (3,568)(3,568)
Reclassification –– –(1,521)1,521–
Effects of movement in exchange rate (511)(71) ––(87)(669)
At 31 December 2025 23,1984,068 11417117,96345,514
Accumulated amortisation and impairment losses
At 1 January 2024
12,8153,762 111–10,33527,023
Amortisation*
–72 ––2,3342,406
Write-off –– (25)–(8)(33)
Impairment loss
2,600– 1––2,601
Effects of movement in exchange rate
8414 ––13111
At 31 December 2024
15,4993,848 87–12,67432,108
Amortisation* –71 ––2,3512,422
Write-off –– ––(2,777)(2,777)
Impairment loss 316– –––316
Effects of movement in exchange rate (366)(66) ––(46)(478)
At 31 December 2025 15,4493,853 87–12,20231,591
Carrying amounts
At 1 January 2024 10,759363 286407,05318,843 At 31 December 2024 8,210291 271,3445,61215,484 At 31 December 2025 7,749215 271715,76113,923
- During the year, amortisation charge of $849,000 (2024: $861,000) was included in ‘insurance service expenses’ in the consolidated statement of profit or loss.
For the purposes of impairment testing, goodwill has been allocated to the Group’s cash generating units (CGUs) (operating divisions) as follows:
Group Group 2025 2024 China clinics S$’000 S$’000
North region 3,875 3,938 East region 3,874 3,937
Cambodia clinic – 335 7,749 8,210
The recoverable amount of CGUs were based on its value in use, determined by discounting the pre-tax future cash flows to be generated from the continuing use of the CGUs.
Page 19 of 27
10 Intangible assets and goodwill (cont’d)
The recoverable amounts of CGUs were based on its value in use, determined by discounting the pre-tax future cash flows to be generated from the continuing use of the CGUs.
Key assumptions used in the estimation of value in use were as follows:
Group Group
2025 2024
% %
China clinics
North region
Discount rate 12.1 12.6 Terminal growth rate 2.0 2.0 Revenue growth rate for next five years 4.0 2.2 – 2.5
East region
Discount rate 13.2 14.8
Terminal growth rate 2.0 2.0
Revenue growth rate for next five years 4.0 1.7 – 2.0
Cambodia
Discount rate 18.2 20.0
Terminal growth rate 3.0 3.0
Revenue growth rate for next five years 0.5 2.1
The discount rate was a pre-tax measure based on the rate of 10-year government bonds issued by the government in the relevant market and in the same currency as the cash flows, adjusted for a risk premium to reflect both the increased risk of investing in equities generally and the systematic risk of the specific CGU.
Five years of cash flows were included in the discounted cash flow model. A long-term growth rate into perpetuity has been determined as the nominal GDP rates for the countries in which the CGUs operate.
Revenue growth was projected based on expectation of future outcomes, taking into account the average growth levels experienced over the past five years and the estimated growth for the next five years.
11 Property, plant and equipment
During the year ended 31 December 2025, the Group acquired property, plant and equipment (PPE) amounting to S$27,592,000 (31 December 2024: S$26,520,000), transferred S$17,200,000 (31 December 2024: S$ Nil), from investment property which were re-designated as premises occupied by the owner to PPE and disposed of assets amounting to S$104,000 (31 December 2024: S$5,325,000).
During the six months ended 31 December 2025, the Group acquired PPE amounting to S$16,391,000 (31 December 2024: S$10,396,000), transferred S$17,200,000 (31 December 2024: S$ Nil), from investment property which were re-designated as premises occupied by the owner to PPE and disposed of assets amounting to S$87,000 (31 December 2024: S$3,967,000) .
Page 20 of 27
12 Investment properties
Group 2025 2024 S$’000 S$’000
Balance as at 1 January
246,100 246,100
Reclassification to property, plant and equipment
(17,200) –
Changes in fair value
4,700 –
Balance as at 31 December
233,600
246,100
Valuation technique and significant unobservable inputs
The Group’s policy is for investment property to be measured at fair value for which the Group completes property valuations at least annually by independent registered valuers at the end of the year. Investment properties that are measured at fair value are stated at fair value as at 31 December 2025 based on valuation performed by independent professional valuer, Colliers International Consultancy & Valuation (Singapore) Pte Ltd, having appropriate recognised professional qualifications and recent experience in the location and category of property being valued.
The fair value measurement for investment properties of $233,600,000 (2024: $246,100,000) has been categorised as a Level 3 fair value based on the inputs to the valuation technique used.
The following table shows the Group’s valuation technique used in measuring the fair value of investment properties, as well as the significant unobservable inputs used.
Valuation technique
Significant unobservable
inputs
Inter-relationship between
key unobservable inputs and fair
value measurement
Capitalisation approach
Capitalisation rates 3.50% to 5.30%
(2024: 3.50% to 5.50%)
The estimated fair value varies inversely against the capitalisation rates.
Capitalisation and
discounted cash flow
approach
Capitalisation rate 4.00%
(2024: 4.00%)
Discount rates 7.00%
(2024: 7.00%)
Terminal yield rates 4.25%
(2024: 4.25%)
The estimated fair value varies inversely against the capitalisation rates, terminal yield rates and discount rates.
13 Loans and borrowings
Group Company 2025202420252024 S$’000S$’000S$’000S$’000 Amount repayable after one year
Unsecured bank loans –49,116 – 10,000
Amount repayable within one year or on demand
Unsecured bank loans 49,7046,866 11,204 1,265
Total loans and borrowings 49,70455,982 11,204 11,265
Page 21 of 27
14 Share capital
2025 2024
No. of shares No. of shares
’000 S$’000 ’000 S$’000
Company
Fully paid ordinary shares, with no par value:
At 1 January 1,884,544 440,099 1,884,198 439,819
Issue of shares under share option scheme –
– 346 280
At 31 December 1,884,544 440,099 1,884,544 440,099
The total number of issued shares excluding treasury shares at 31 December 2025 was 1,840,160,875 (31 December 2024: 1,858,137,925).
(i) Exercise of share options and share awards
During the year, the Company utilised 2,142,850 treasury shares pursuant to the Raffles Medical Group Performance Share Plan.
On 8 September 2025, options to subscribe for 10,250,000 ordinary shares at an exercise price of S$1.01 were granted to 144 eligible participants pursuant to the Raffles Medical Group (2020) Share Option Scheme.
On 8 September 2025, 900,000 share awards were granted to 309 eligible participants pursuant to Raffles Medical Group (2020) Performance Share Plan.
As at 31 December 2025, there were 78,707,000 (31 December 2024: 82,421,000) options outstanding in relation to ordinary shares of the Company.
As at 31 December 2025, the number of shares comprised in contingent awards granted under the Raffles Medical Group (2020) Performance Share Plan which has not been released was 2,109,850 (31 December 2024: 2,136,050).
(ii) Treasury shares
The Company holds 44,384,050 treasury shares as at 31 December 2025 (31 December 2024: 26,407,000).
Treasury shares held by the Company as at 31 December 2025 represent 2.41% (31 December 2024: 1.42%) of the total number of issued shares (excluding treasury shares).
Number of treasury shares Balance as at 1 January 2025 26,407,000 Acquisition of treasury shares 20,119,900 Use of treasury shares (2,142,850) Balance as at 31 December 2025 44,384,050
Page 22 of 27
14 Share capital (cont’d)
(iii) Subsidiary holdings
There is no subsidiary holdings as at 31 December 2025 (31 December 2024: Nil).
There were no sales, transfers, cancellation and/or use of subsidiary holdings as at 31 December 2025
(31 December 2024: Nil).
.
Page 23 of 27
Other Information Required by Listing Rule Appendix 7.2
1 Whether the figures have been audited or reviewed and in accordance with which auditing standard or practice.
The financial statements of Raffles Medical Group Ltd (the Company) and its subsidiaries (the Group), which comprise the consolidated statement of financial position of the Group and the statement of financial position of the Company as at 31 December 2025, the consolidated statement of profit or loss, consolidated statement of comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows of the Group for the year then ended, and notes to the financial statements have been audited in accordance with Singapore Standards on Auditing. A copy of the Independent Auditors’ report is attached.
The condensed consolidated statement of profit or loss and other comprehensive income and condensed consolidated statement of cash flows for the six-month period ended 31 December 2025 and certain explanatory notes have not been audited or reviewed.
2 A review of the performance of the group, to the extent necessary for a reasonable understanding of the group’s business. It must include a discussion of the following:-
(a) any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and (b) any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on.
The Group reported a revenue of S$765.3 million for the financial year (FY) ended 31 December 2025, a 1.8% increase as compared to FY2024. Profit after tax and minority interests (PATMI) for the year stood at S$70.6 million, a 13.4% increase over FY2024. The increase in PATMI was attributable to improvement in performance from the hospital services and insurance businesses and fair value gain on investment properties in FY2025. The PATMI for the second half (2H) of 2025 improved by 21.7% to S$38.5 million compared to S$31.6 million in 2H2024.
The Hospital Services division remained a key contributor, with revenue growing 3.5% to S$357.8 million and profit increasing 15.3% to S$41.1 million, supported by steady patient volumes, higher bill size and operational efficiencies in both Singapore and China. The Healthcare Services division also recorded revenue of S$285.9 million, with profitability remaining broadly stable. The 3% decrease in revenue is due to reduced consumption of services.
In the China market, revenue increased 2.3% from CNY351.3 (S$65.3) million in FY2024 to CNY359.4 (S$65.4) million in FY2025. The RafflesHospital brand continues to gain wider recognition among patients in China, reinforcing its position as a trusted provider of quality healthcare. Cost saving measures put in place earlier are helping to improve bottomline. Strategic partnerships with Shanghai’s Renji Hospital, Zhongshan Hospital and Chongqing’s First Affiliated Hospital will enable our RafflesChinaHealthcare to better integrate our international standards with local expertise, to provide high quality patient-centred care in China.
RafflesHealthInsurance (RHI), the Group’s Health Insurance Services Division, saw a 4.1% increase in revenue from S$178.0 million in FY2024 to S$185.2 million in FY2025, mainly contributed by contract repricing and new contracts. The healthcare insurance industry is generally facing a higher loss ratio as a result of medical inflation. With vigilant and watchful claims adjudication and thoughtful control of management expenses, RHl's results reflected a 50.6% improvement when compared to FY2024.
On a full year basis, the Group generated S$101.3 million in cash from operating activities. Its balance sheet remains strong, with cash and cash equivalents totaling S$310.8 million as of 31 December 2025. During FY2025, the Group distributed cash dividends of S$46.3 million, acquired S$19.9 million of its own shares, acquired a minority shareholder’s share at S$16.6 million and made repayment of a loan to minority shareholder amounting to S$29.4 million.
For the financial year ended 31 December 2025, the Directors are pleased to recommend a final core dividend of 3.0 cents per share, an increase of 20% year-on-year. This represents 84% of the sustainable Group PATMI for FY2025.
Page 24 of 27
3 Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.
The current financial period’s results are in line with the Directors’ expectations as disclosed in the Group’s 1H2025 results announcement.
4 A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.
Global trade tensions and geopolitical uncertainties remain a challenge to the global economy. Volatility in
financial markets and interest rate uncertainties will affect investor sentiments. The healthcare sector remains
less cyclical because of stable demand for its services.
Singapore and China both face demographic challenges of aging population and falling birth rates. The Group
operates in both of these geographies and we will respond to these trends and grow services that are in
demand.
To address rising insurance premiums and private healthcare costs in Singapore, the Ministry of Health
introduced a higher co-payment cap to a minimum of S$6,000. RHI will introduce a new rider that complies
with the new regulations. The change is not expected to have a significant impact to the financials of RHI.
We will expand and grow our depth and breadth of services in the 14 cities of Asia where we currently operate.
Globally, technological and social changes are gathering momentum. We will monitor these changes closely.
We intend to be early adopters of appropriate AI applications in healthcare, both to improve efficiencies as
well as to transform care and service delivery.
The
RafflesHealthyLongevityCentre, scheduled to open in Q1 2026, is a physician-led, multidisciplinary
service focused on helping individuals achieve healthier, longer lives. Through advanced diagnostics and
evidence-based therapies, the Centre will provide personalised and preventive care tailored to each
individual’s health profile.
Amidst rising healthcare costs and evolving patient needs, the Group, as an integrated healthcare provider,
is well-poised to provide individuals and corporates with end-to-end insurance and healthcare solutions.
This year, the Group celebrates its 50
th
Anniversary of caring. We resolve to continue serving our patients
and corporate clients with the same Compassion, Commitment, Excellence, through our Teamwork of
physicians, nurses and healthcare managers adding Value to the lives of our patients (CCETV, our core
values).
Barring unforeseen circumstances, the Directors are optimistic that the Group will be profitable in the current
financial year 2026.
5 Dividend
a) Current Financial Period Reported on
Any dividend declared for the current financial period reported on? Yes
Name of dividend Proposed Final Dividend Type Ordinary Dividend Amount per Share (in cents) 3.0 cents per ordinary share (one-tier tax) Tax Rate Tax Exempt
Page 25 of 27
5 Dividend (cont’d)
(b) Corresponding Period of the Immediately Preceding Financial Year
Any dividend declared for the corresponding period of the immediately preceding financial year? Yes
Name of dividend Final Dividend Type Ordinary Dividend Amount per Share (in cents) 2.5 cents per ordinary share (one-tier tax) Tax Rate Tax Exempt
(c) Date payable
The Directors are pleased to recommend a final dividend of 3.0 cents per share, amounting approximately to S$55.2 million in respect of the financial year ended 31 December 2025 for approval by the shareholders at the next Annual General Meeting to be convened on 24 April 2026.
The date of payment of the proposed dividend, if approved at the Annual General Meeting, will be on 22 May 2026.
(d) Books closure date
Notice is hereby given that, subject to shareholders’ approval of the payment of the final dividend (Dividend) at the Annual General Meeting scheduled for 24 April 2026, the Share Transfer Books and the Register of Members of the Company will be closed on 14 May 2026, for determining of shareholders' entitlements to the Dividend.
Registrable transfers received by the Company's Registrar, Boardroom Corporate & Advisory Services Pte Ltd at 1 Harbourfront Avenue, Keppel Bay Tower, #14-07, Singapore 098632, up to the close of business at 5.00 p.m. on 13 May 2026 (Record Date) will be registered for the Dividend. In respect of ordinary shares in securities accounts with The Central Depository (Pte) Limited (CDP), entitlements to the Dividend will be computed based on the shareholding position after settlement of all trades on Record Date. The Dividend will be paid by the Company to CDP which will, in turn, distribute the Dividend to holders of the securities accounts.
(e) Scrip Dividend Scheme
The Scrip Dividend Scheme will not be applicable to the final dividend this year.
6 If no dividend has been declared/recommended, a statement to that effect.
Not applicable.
7 If the group has obtained a general mandate from shareholders for Interested Parties Transactions (IPTs), the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect.
The Company did not obtain a general mandate from shareholders for IPTs.
8 Confirmation pursuant to Rule 720 (1) of the Listing Manual
The Company confirms that it has procured undertakings from all its Directors and executive officers (in the format set out in Appendix 7.7) under Rule 720 (1) of the Listing Manual.
Page 26 of 27
9 In the review of performance, the factors leading to any material changes in contributions to turnover and earnings by the business or geographical segments.
Please refer to Item 2.
10 A breakdown of sales.
Group 2025 S$’000 2024 S$’000 Change % (a) Revenue reported for first half year 378,447 365,690 3.5 (b) Operating profit after tax before deducting non- controlling interests reported for first half year 32,461 30,929 5.0 (c) Revenue reported for second half year 386,852 385,874 0.3 (d) Operating profit after tax before deducting non- controlling interests reported for second half year 38,610 31,353 23.1
11 Disclosures of incorporation of Entities, Acquisition and Realisation of Shares pursuant to Rule 706(A) of the Listing Manual
On 30 October 2025, Shanghai Capital Pte Ltd (SHC), a subsidiary of the Company, completed the acquisition of the remaining 30% which it does not already hold, in the equity interest of Shanghai Qihua Hospital Co. Ltd., China (SQH), for a total cash consideration of S$16.6 million. SHC in turn holds a 100% equity interest of SQH. The net asset of the acquired shares is S$18.2 million at the acquisition date. The consideration was arrived at following arm’s length negotiations on a “willing buyer-willing seller” basis, taking into account, amongst others, the performance of SQH in the recent years, and its existing assets and operations. The consideration was fully satisfied in cash from the Company’s internal resources. With the completion of this acquisition, SQH became a wholly owned subsidiary of SHC.
In January 2026, Raffles HuKan (Chongqing) Internet Hospital Co., Ltd. (RHIH), was incorporated in China as an indirect wholly owned subsidiary of the Company, with a registered share capital of CNY10 million (S$1.8 million). The principal activity of RHIH is the provision of online and offline medical services.
Page 27 of 27
12 Disclosure of person occupying a managerial position in the issuer or any of its principal subsidiaries who is a relative of a director or chief executive officer or substantial shareholder of the issuer pursuant to Rule 704(13). If there are no such persons, the issuer must make an appropriate negative statement.
BY ORDER OF THE BOARD Kimmy Goh Company Secretary 23 February 2026
Name Age Family relationship with any director and/or substantial shareholder Current position and duties, and the year the position was held Details of changes in duties and position held, if any, during the year
Dr Loo
Choon Yong
76
Father of Dr Sarah Lu Qinghui and Dr Lu Liangjian David
Executive Chairman of Raffles Medical Group (RMG) Ltd since 1997, having overall executive responsibility for the business direction, strategies and management of the RMG group of companies.
Nil
Dr Sarah Lu Qinghui
44
Daughter of Dr Loo Choon Yong and sister of Dr Lu Liangjian David (1) Executive and Non- Independent Director, on 1 June 2020
(2) Consultant Breast Surgeon, Raffles Hospital Pte Ltd, on 1 June 2020
(3) Executive Medical Director, Raffles Hospital Pte Ltd, on 1 February 2025
(4) Managing Director, Singapore Healthcare of RMG on 1 August 2025.
Appointed Executive Medical Director, Raffles Hospital Pte Ltd on 1 February 2025
Appointed Managing Director, Singapore Healthcare of RMG on 1 August 2025 with overall responsibility for all commercial matters of the Division.
Raffles Medical Group Ltd and its Subsidiaries Registration Number : 198901967K
Condensed Financial Statements For the six months and full year ended 31 December 2025
Table of contents A.
Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income
1
B.
Condensed Statements of Financial Position
3
C.
Condensed Consolidated Statement of Cash Flows
4
D.
Condensed Statements of Changes in Equity
5
E.
Notes to the Condensed Consolidated Financial Statements
8
F.
Other Information Required by Listing Rule Appendix 7.2
23
Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income
Condensed Consolidated Statement of Profit or Loss
Note
6 months ended 31 December 2025 S$’000
12 months 12 months 6 months ended 31 ended 31 ended 31 Change Change December December December 2024 2025 2024 % % S$’000 S$’000 S$’000
386,852
385,874
0.3
765,299
751,564
1.8
4,836
294
nm
5,565
2,512
nm
Inventories and consumables used
(33,272)
(31,469)
5.7
(63,593)
(61,180)
3.9
Purchased and contracted services
(20,733)
(19,974)
3.8
(37,512)
(37,340)
0.5
Insurance service expenses
(71,763)
(84,305)
(14.9)
(153,681)
(162,903)
(5.7)
Net expenses from reinsurance contracts
(7,379)
(276)
nm
(13,233)
(4,003)
nm
Staff costs
(159,692)
(160,535)
(0.5)
(317,156)
(314,873)
0.7
Depreciation of property, plant and equipment
(21,250)
(21,834)
(2.7)
(41,814)
(40,329)
3.7
Amortisation of intangible assets
(706)
(766)
(7.8)
(1,573)
(1,545)
1.8
Operating lease expenses
(823)
(656)
25.5
(1,645)
(1,566)
5.0
(2,184)
(953)
nm
(3,197)
(1,262)
nm
(316)
(2,601)
(87.9)
(316)
(2,601)
(87.9)
Other operating expenses
(24,828)
(21,584)
15.0
(46,788)
(43,980)
6.4
Profit from operating activities
48,742
41,215
18.3
90,356
82,494
9.5
Finance income
2,898
4,951
(41.5)
7,333
10,247
(28.4)
Finance costs
(1,957)
(2,616)
(25.2)
(4,095)
(5,779)
(29.1)
Revenue Other operating income
Impairment loss on trade receivables Impairment loss on intangible assets and goodwill
Profit before tax
6
49,683
43,550
14.1
93,594
86,962
7.6
Tax expense
7
(11,073)
(12,197)
(9.2)
(22,523)
(24,680)
(8.7)
38,610
31,353
23.1
71,071
62,282
14.1
38,462
31,600
21.7
70,570
62,243
13.4
Non-controlling interests
148
(247)
nm
501
39
nm
Profit for the period/year
38,610
31,353
23.1
71,071
62,282
14.1
Profit for the period/year Profit attributable to: Owners of the Company (PATMI)
Note: (i) nm denotes not meaningful
Page 1 of 27
Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income (cont’d)
% 23.1
12 months ended 31 December 2025 S$’000 71,071
12 months ended 31 December 2024 S$’000 62,282
763
nm
(4,281)
1,328
nm
45,418
32,116
41.4
66,790
63,610
5.0
45,359
32,390
40.0
66,326
63,570
4.3
59
(274)
nm
464
40
nm
45,418
32,116
41.4
66,790
63,610
5.0
Earnings per share Basic earnings per share (cents) [Note i]
2.08
1.70
22.4
3.81
3.35
13.7
Diluted earnings per share (cents) [Note j]
2.08
1.70
22.4
3.81
3.34
14.1
Condensed Consolidated Statement of Other Comprehensive Income Profit for the period/year Other comprehensive income Item that is or may be reclassified subsequently to profit or loss: Foreign currency translation differences foreign operations Total comprehensive income for the period/year Total comprehensive income attributable to: Owners of the Company Non-controlling interests Total comprehensive income for the period/year
6 months ended 31 December 2025 S$’000 38,610
6 months ended 31 December 2024 S$’000 31,353
6,808
Change
Change
% 14.1
Note:
(i)
nm denotes not meaningful.
Explanatory Notes to the Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income (a)
Higher other operating income in 2H2025 and FY2025 was mainly due to a fair value gain of S$4.7 million on investment properties, partially offset by lower government grants received.
(b)
The decrease in insurance service expenses for 2H2025 and FY2025 was mainly due to improved claims experience, despite insurance revenue increasing by 4.5% in FY2025.
(c)
Net expenses from reinsurance contracts increased mainly because improved claims experience led to lower claim recoveries for 2H2025 and FY2025.
(d)
The increase in impairment loss on trade receivables was mainly due to higher provisions made for long outstanding receivables for 2H2025 and FY2025.
(e)
The increase in other operating expenses in 2H 2025 and FY2025 was mainly due to higher professional fees, adverse foreign exchange variances and intangible assets written off.
(f)
The decrease in finance income was due to lower interest rates on bank fixed deposits in 2H2025 and FY2025.
(g)
The decrease in finance costs was due to lower interest expenses on bank loans and amounts due to non-controlling interests in FY2025.
(h)
Lower tax expense was due to a reduction in unrecognised tax losses and the higher reversal of prior years tax overprovision in FY2025.
(i)
The calculation of earnings per ordinary share for the second half and full year ended 31 December 2025 were based on the weighted average number of shares 1,846,533,921 (2H 2024: 1,857,847,353) and 1,850,129,015 (FY2024: 1,857,487,887) in issue during the period.
(j)
The calculation of earnings per ordinary share (on a fully diluted basis) for the second half and full year ended 31 December 2025 were based on weighted average number of shares 1,850,920,041 (2H 2024: 1,860,518,110) and 1,854,054,300 (FY2024: 1,860,824,148) in issue during the period. Page 2 of 27
Condensed Statements of Financial Position As at 31 December 2025
Note Non-current assets Property, plant and equipment Intangible assets and goodwill Investment properties Subsidiaries Deferred tax assets Trade and other receivables
11 10 12
748,248 15,484 246,100 – 2,089 2,553 1,014,474
12,433 68 – 1,001,146 – 16,976 1,030,623
13,777 286 – 929,546 141 15,684 959,434
11,262 95,984 17,768 310,791 435,805 1,429,939
10,762 101,586 19,008 343,671 475,027 1,489,501
2,494 94,526 – 86,366 183,386 1,214,009
2,184 71,574 – 145,658 219,416 1,178,850
14
440,099 618,381 1,058,480 (2,517) 1,055,963
440,099 609,667 1,049,766 15,213 1,064,979
440,099 669,072 1,109,171 – 1,109,171
440,099 644,895 1,084,994 – 1,084,994
13
– 5,105 27,430 7,859 40,394
49,116 4,205 22,655 7,902 83,878
– – 1,987 9 1,996
10,000 940 810 – 11,750
13
49,704 24,347 184,630 10,286 – 64,615 333,582 373,976 1,429,939
6,866 24,775 218,483 9,531 2,788 78,201 340,644 424,522 1,489,501
11,204 6,924 84,194 520 – – 102,842 104,838 1,214,009
1,265 7,620 72,706 515 – – 82,106 93,856 1,178,850
Total assets
Non-controlling interests Total equity Non-current liabilities Loans and borrowings Trade and other payables Lease liabilities Deferred tax liabilities Current liabilities Loans and borrowings Current tax liabilities Trade and other payables Lease liabilities Other financial liabilities Insurance contract liabilities Total liabilities Total equity and liabilities
Company 31 December 31 December 2025 2024 S$’000 S$’000
741,397 13,923 233,600 – 2,197 3,017 994,134
Current assets Inventories Trade and other receivables Reinsurance contract assets Cash and cash equivalents
Equity attributable to owners of the Company Share capital Reserves
Group 31 December 31 December 2025 2024 S$’000 S$’000
Explanatory Notes to the Condensed Statements of Financial Position (a) Current trade and other receivables for the Group decreased mainly due to improved debt collection and higher allowance for doubtful trade receivables. (b) The decrease in trade and other payables for the Group was mainly due to repayment of a loan to a minority shareholder. (c) The decrease in insurance contract liabilities for the Group were aligned with improved claim experience in FY2025.
Page 3 of 27
Condensed Consolidated Statement of Cash Flows 6 months ended 31 December 2025 S$'000
Group 6 months 12 months ended ended 31 December 31 December 2024 2025 S$'000 S$'000
12 months ended 31 December 2024 S$'000
Cash flows from operating activities 38,610
31,353
71,071
62,282
1,075 (4,700) 21,414 1,453 1,991 (2,898) 1 (56) 316 791 956 11,073 70,026
1,204 – 21,992 1,641 2,595 (4,951) 1,921 (779) 2,601 – 184 12,197 69,958
2,422 (4,700) 42,137 3,066 4,170 (7,333) (3) (124) 316 791 1,077 22,523 135,413
2,406 – 40,682 3,465 5,870 (10,247) 1,922 (816) 2,601 46 446 24,680 133,337
Changes in working capital: Insurance and reinsurance contracts Inventories Trade and other payables Trade and other receivables Cash generated from operations Tax paid Net cash from operating activities
(27,663) 13 9,053 4,332 55,761 (11,030) 44,731
(10,590) 744 4,674 (798) 63,988 (12,301) 51,687
(12,346) (500) (3,829) 4,882 123,620 (22,289) 101,331
(5,254) 1,703 (1,543) (16,151) 112,092 (25,838) 86,254
Cash flows from investing activities Acquisition of intangible assets Interest received Proceeds from disposal of property, plant and equipment Purchase of property, plant and equipment Net cash used in investing activities
(449) 3,089 6 (5,022) (2,376)
(500) 4,821 2 (7,591) (3,268)
(2,159) 7,515 6 (7,867) (2,505)
(1,639) 9,951 1,085 (19,270) (9,873)
Cash flows from financing activities Acquisition of own shares Acquisition of non-controlling interest Dividends paid to owners of the Company Interest paid Lease interest paid Payment of lease liabilities Proceeds from bank loans Proceeds from issue of shares under share option scheme Repayment of bank loans Repayment of loan to minority shareholder Net cash used in financing activities
(12,394) (16,594) – (1,270) (651) (5,226) (85) 708 (1,562) (29,383) (66,457)
– – – (1,848) (606) (4,150) 13,524 29 (28,095) (48) (21,194)
(19,917) (16,594) (46,273) (2,863) (1,189) (11,442) 1,204 1,124 (5,513) (29,383) (130,846)
– (1,564) (44,576) (3,756) (1,277) (9,882) 67,673 280 (81,504) (1,597) (76,203)
Net (decrease)/increase in cash and cash equivalents Cash and cash equivalents at 1 July / 1 January Effect of exchange rate fluctuations on cash held Cash and cash equivalents at 31 December
(24,102) 334,183 710 310,791
27,225 316,263 183 343,671
(32,020) 343,671 (860) 310,791
178 342,543 950 343,671
Profit for the period/year Adjustments for : Amortisation of intangible assets Changes in fair value of investment properties Depreciation of property, plant and equipment Equity-settled share-based payment transactions Finance costs Finance income (Gain)/Loss on disposal of property, plant and equipment, net Gain on lease derecognition Impairment loss on intangible assets and goodwill Intangible asset written off Property, plant and equipment written off Tax expense
Explanatory Notes to the Condensed Consolidated Statement of Cash Flows The Group’s cash and cash equivalents decreased by S$32.9 million in FY2025, attributed by cash outflows for dividends, share buybacks, acquisition of non-controlling interests, and repayment of a loan to a minority shareholder despite net cash generated from operating activities of S$101.3 million.
Page 4 of 27
Condensed Statements of Changes in Equity
Equity Translation compensation Revaluation reserve reserve reserve S$’000 S$’000 S$’000
Total attributable to owners Accumulated of the profits Company S$’000 S$’000
Reserve for own shares S$’000
Group At 1 January 2025
440,099
(21,012)
40,521
16,367
(5,590)
(30,579)
609,960
1,049,766
15,213
1,064,979
Total comprehensive income for the year Profit for the year
–
–
–
–
–
–
70,570
70,570
501
71,071
Other comprehensive income Foreign currency translation differences - foreign operations Total other comprehensive income for the year Total comprehensive income for the year
– – –
(4,244) (4,244) (4,244)
– – –
– – –
– – –
– – –
– – 70,570
(4,244) (4,244) 66,326
(37) (37) 464
(4,281) (4,281) 66,790
–
–
(1,015)
–
181
834
–
–
–
–
–
–
3,066
–
–
–
–
3,066
–
3,066
– – – –
– – – –
– – – 2,051
– – – –
(417) – – (236)
1,541 (19,917) – (17,542)
– – (46,273) (46,273)
1,124 (19,917) (46,273) (62,000)
– – – –
1,124 (19,917) (46,273) (62,000)
– – – –
– – – –
– – – 2,051
– – – –
1,600 2,788 4,388 4,152
– – – (17,542)
– – – (46,273)
1,600 2,788 4,388 (57,612)
(18,194) – (18,194) (18,194)
(16,594) 2,788 (13,806) (75,806)
440,099
(25,256)
42,572
16,367
(1,438)
(48,121)
634,257
1,058,480
(2,517)
1,055,963
Transactions with owners, recognised directly in equity Contributions by and distributions to owners Own shares reissued pursuant to Raffles Medical Group Performance Share Plan Value of employee services received for issue of share options and share awards Exercise of share options under Raffles Medical Group Employees’ Share Option Schemes Acquisition of own shares Final dividend paid of 2.5 cents per ordinary share - Cash Total contributions by and distributions to owners Changes in ownership interests in subsidiaries Acquisition of non-controlling interests without a change in control Derecognition of written put option Total changes in ownership interests in subsidiaries Total transactions with owners Balance at 31 December 2025
Page 5 of 27
Other reserve S$’000
Noncontrolling interests S$’000
Share capital S$’000
Total equity S$’000
Condensed Statements of Changes in Equity (cont’d)
Equity Translation compensation Revaluation reserve reserve reserve S$’000 S$’000 S$’000
Reserve for own shares S$’000
Other reserve S$’000
Total attributable to owners Accumulated of the profits Company S$’000 S$’000
Noncontrolling interests S$’000
Group
Share capital S$’000
Total equity S$’000
At 1 January 2024
439,819
(22,339)
38,172
16,367
(5,091)
(31,483)
592,293
1,027,738
16,114
1,043,852
Total comprehensive income for the year Profit for the year
–
–
–
–
–
–
62,243
62,243
39
62,282
Other comprehensive income Foreign currency translation differences - foreign operations Total other comprehensive income for the year Total comprehensive income for the year
– – –
1,327 1,327 1,327
– – –
– – –
– – –
– – –
– – 62,243
1,327 1,327 63,570
1 1 40
1,328 1,328 63,610
280
–
–
–
–
–
–
280
–
280
Transactions with owners, recognised directly in equity Contributions by and distributions to owners Issue of shares upon the exercise of options under Raffles Medical Group Employees’ Share Option Schemes Own shares reissued pursuant to Raffles Medical Group Performance Share Plan Value of employee services received for issue of share options and share awards Final dividend paid of 2.4 cents per ordinary share - Cash Total contributions by and distributions to owners
–
–
(1,116)
–
212
904
–
–
–
–
– – 280
– – –
3,465 – 2,349
– – –
– – 212
– – 904
– (44,576) (44,576)
3,465 (44,576) (40,831)
– – –
3,465 (44,576) (40,831)
Changes in ownership interests in subsidiaries Acquisition of non-controlling interests without a change in control Present value of the exercise price of written put options Total changes in ownership interests in subsidiaries Total transactions with owners
– – – 280
– – – –
– – – 2,349
– – – –
(623) (88) (711) (499)
– – – 904
– – – (44,576)
(623) (88) (711) (41,542)
(941) – (941) (941)
(1,564) (88) (1,652) (42,483)
440,099
(21,012)
40,521
16,367
(5,590)
(30,579)
609,960
1,049,766
15,213
1,064,979
Balance at 31 December 2024
Page 6 of 27
Condensed Statements of Changes in Equity (cont’d)
Share capital
Equity compensation reserve
Other reserve
Reserve for own shares
Accumulated profits
Total
Company
S$'000
S$’000
S$’000
S$’000
S$'000
S$'000
At 1 January 2025
440,099
40,521
(39)
(30,579)
634,992
1,084,994
Total comprehensive income for the year Profit for the year
–
–
–
–
86,223
86,223
Total comprehensive income for the year
–
–
–
–
86,223
86,223
–
(1,015)
135
834
–
(46)
–
3,066
–
–
–
3,066
–
–
(417)
1,541
–
1,124
–
–
–
(19,917)
–
(19,917)
–
–
–
–
(46,273)
(46,273)
–
2,051
(282)
(17,542)
(46,273)
(62,046)
At 31 December 2025
440,099
42,572
(321)
(48,121)
674,942
1,109,171
At 1 January 2024
439,819
38,172
(142)
(31,483)
587,276
1,033,642
Profit for the year
–
–
–
–
92,292
92,292
Total comprehensive income for the year
–
–
–
–
92,292
92,292
Issue of shares upon the exercise of options under Raffles Medical Group Employees’ Share Option Schemes
280
–
–
–
–
280
Own shares reissued pursuant to Raffles Medical Group Performance Share Plan
–
(1,116)
103
904
–
(109)
–
3,465
–
–
–
3,465
–
–
–
–
(44,576)
(44,576)
280
2,349
103
904
(44,576)
(40,940)
440,099
40,521
(39)
(30,579)
634,992
1,084,994
Transactions with owners, recognised directly in equity Contributions by and distributions to owners Own shares reissued pursuant to Raffles Medical Group Performance Share Plan Value of employee services received for issue of share options and share awards Exercise of share options Acquisition of own shares Final dividend paid of 2.5 cents per ordinary share
- Cash Total contributions by and distributions to owners
Total comprehensive income for the year
Transactions with owners, recognised directly in equity Contributions by and distributions to owners
Value of employee services received for issue of share options and share awards Final dividend paid of 2.4 cents per ordinary share
- Cash Total contributions by and distributions to owners At 31 December 2024
Page 7 of 27
Notes to the Condensed Consolidated Financial Statements 1
Corporate information Raffles Medical Group Ltd (the Company) is a company incorporated in Singapore. The address of the Company’s registered office is 585 North Bridge Road, Raffles Hospital #11-00, Singapore 188770. These condensed financial statements as at and for the six months and full year ended 31 December 2025 comprise the Company and its subsidiaries (together referred to as the Group). The principal activities of the Company are those relating to the operation of medical clinics, other general medical services and investment holdings. The Group and the Company are the sole proprietor of the following: Family Doctors RafflesCare Raffles Airport Medical Centre Raffles Corporate Wellness Raffles Dental Surgery Raffles Healthcare Consultancy Raffles Healthcare Institute Raffles Health Screeners Raffles Longevity Raffles Medical Management Raffles Medihelp Raffles Optica Raffles Pharmacare Raffles Pharmacy Raffles Solitaire Raffles Solitaire International Raffles Specialist Centre Raffles Wellness The Group and the Company are partners of the following: Raffles International Medical Assistance LLP All transactions of these sole proprietorships and partnerships are reflected in the condensed financial statements of the Company. The immediate and ultimate holding company during the financial year is Raffles Medical Holdings Pte Ltd, which is incorporated in Singapore.
2
Basis of preparation The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with SFRS(I)s, except for the adoption of new and amended standards as set out in Note 2.1. The condensed financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group’s financial position and performance of the Group since the last interim financial statements for the period ended 30 June 2025. The condensed financial statements are presented in Singapore dollar, which is the Company’s functional currency. All financial information presented in Singapore dollars have been rounded to the nearest thousand, unless otherwise stated.
Page 8 of 27
Basis of preparation (cont’d)
2.1 New standards and amendments The Group has applied SFRS(I) 1-21 Lack of Exchangeability for the first time for the annual period beginning on 1 January 2025. The application of the amendment to accounting standards does not have a material effect on the financial statements. 2.2 Use of estimates and judgements In preparing the condensed financial statements, management has made judgements, estimates and assumptions about the future, including climate-related risks and opportunities that affect the Group’s application of accounting policies and the reported amounts of assets, liabilities, income and expense. Actual results may differ from these estimates. The significant judgements made by management in applying the Group’s accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the year ended 31 December 2024. Estimates and underlying assumptions are reviewed on an ongoing basis and are consistent with the Group’s risk management and climate-related commitments where appropriate. Revisions to accounting estimates are recognised prospectively. Information about critical judgements in applying accounting policies that have the most significant effect on the amounts recognised in the condensed financial statements is insurance and reinsurance contract: estimation of fulfilment cash flows. Fulfilment cash flows Although the insurance contract liabilities are estimated based on management’s best knowledge and judgement of current facts, the actual outcome may differ from the estimates. The areas involving a higher degree of judgement or complexity, or areas whereby judgement, assumptions and estimates have been involved in estimating the fulfilment cash flows comprise: estimates of future cash flows; an adjustment to reflect the time value of money and the financial risks related to future cash flows, to the extent that the financial risk are not included in the estimates of future cash flows; and a risk adjustment for non-financial risk. Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next financial year are included in the following notes:
recoverable amounts of property, plant and equipment impairment test of goodwill: key assumptions underlying recoverable amounts (Note 10) determination of fair value of investment properties on the basis of significant unobservable inputs (Note 12) measurement of insurance and reinsurance contracts and recognition of loss component on onerous contracts
Page 9 of 27
Basis of preparation (cont’d)
2.2 Use of estimates and judgements (cont’d) Measurement of fair values A number of the Group’s accounting policies and disclosures require the measurement of fair values, for both financial and non-financial assets, and financial and non-financial liabilities. If third party information, such as property valuation report, is used to measure fair values, the Group assesses the evidence obtained from the third parties to support the conclusion that these valuations meet the requirements of SFRS(I)s, including the level in the fair value hierarchy in which the valuations should be classified. Significant valuation issues are reported to the Audit & Risk Committee. 3
Seasonal operations The Group’s businesses are not affected significantly by seasonal or cyclical factors during the financial periods.
4
Segment and revenue information The Group has 4 reportable segments, as described below, which are the Group’s strategic business units. The strategic business units offer different products and services, and are managed separately because they require different technology and marketing strategies. For each of the strategic business units, the Group’s Executive Chairman reviews internal management reports regularly. The following summary describes the operations in each of the Group’s reportable segments: Healthcare services : The operations of medical clinics and other general medical services; trading in pharmaceutical and nutraceutical products and diagnostic equipment, and provision of management, consultancy and third-party administration services. Hospital services
: The provision of specialised medical services and operation of hospital and business of medical laboratory and imaging centre.
Investment holdings : Investment holding and those relating to investment properties. Insurance services
: The provision of insurance products.
Performance is measured based on segment profit before tax, as included in the internal management reports that are reviewed by the Group’s Executive Chairman. Segment profit is used to measure performance as management believes that such information is most relevant in evaluating the results of certain segments relative to other entities operating within these businesses. Inter-segment pricing is determined on mutually agreed terms. Segment results, assets and liabilities include items directly attributable to a segment as well as those that can be allocated on a reasonable basis. Unallocated items mainly comprise current tax and deferred tax liabilities and assets. Segment capital expenditure is the total cost incurred during the period to acquire segment assets that are expected to be used for more than one period.
Page 10 of 27
4.1 Reportable segments Healthcare services Hospital services 31 31 31 31 December December December December 2025 2024 2025 2024 S$’000 S$’000 S$’000 S$’000
Insurance services 31 31 December December 2025 2024 S$’000 S$’000
Investment holdings 31 31 December December 2025 2024 S$’000 S$’000
Total 31 31 December December 2024 2025 S$’000 S$’000
Revenue and expenses Revenue
285,898
295,050
357,823
345,652
185,230
177,985
44,314
44,894
873,265
863,581
Inter-segment revenue
14,408
12,824
51,826
57,187
4,232
4,273
37,500
37,733
107,966
112,017
Finance expenses
(1,277)
(2,038)
(3)
(987)
(75)
(91)
(2,815)
(2,754)
(4,170)
(5,870)
Depreciation and amortisation
(17,446)
(16,072)
(10,147)
(9,888)
(1,224)
(1,253)
(270)
(244)
(29,087)
(27,457)
Reportable segment profit/(loss) before tax
42,489
45,123
41,132
35,683
(3,116)
(6,305)
27,162
23,734
107,667
98,235
- Impairment loss on intangible assets and goodwill
(316)
(2,601)
–
–
–
–
–
–
(316)
(2,601)
- Impairment gain/(loss) on trade receivable
(824)
(322)
(2,338)
(940)
(35)
–
–
–
(3,197)
(1,262)
1,501,364 1,195,708
294,554
256,305
118,338
125,833
1,300,204
936,215
3,214,460
2,514,061
Other material non-cash items:
Reportable segment assets Capital expenditure
23,860
20,044
4,096
6,893
1,710
1,087
85
135
29,751
28,159
Reportable segment liabilities
489,836
189,884
240,218
212,744
76,495
92,128
1,103,585
711,424
1,910,134
1,206,180
Page 11 of 27
4.1 Reportable segments (cont’d) Reconciliations of reportable segment revenues, profit or loss, assets and liabilities and other material items 31 31 December December 2025 2024 S$’000 S$’000 Revenues Total revenue for reportable segments 873,265 863,581 Elimination of inter-segment revenue (107,966) (112,017) Consolidated revenue 765,299 751,564 Profit or loss before tax Total profit before tax for reportable segments Elimination of inter-segment profits / Consolidation adjustment Adjustment for depreciation of property, plant and equipment Consolidated profit before tax
107,667 1,399 (15,472) 93,594
98,235 4,358 (15,631) 86,962
Assets Total assets for reportable segments Elimination of inter-segment assets Unallocated amounts-current tax and deferred tax assets Consolidated total assets
3,214,460 (1,786,718) 2,197 1,429,939
2,514,061 (1,026,649) 2,089 1,489,501
Liabilities Total liabilities for reportable segments Elimination of inter-segment liabilities Unallocated amounts-current tax and deferred tax liabilities Consolidated total liabilities
1,910,134 (1,568,364) 32,206 373,976
1,206,180 (814,335) 32,677 424,522
Reportable segment totals S$’000
Adjustments S$’000
Consolidated totals S$’000
31 December 2025 Depreciation and amortisation
29,087
15,472
44,559
31 December 2024 Depreciation and amortisation
27,457
15,631
43,088
Other material items
The Group’s properties at Raffles Holland V, Raffles Hospital, Raffles Specialist Centre, Raffles Hospital Chongqing and Raffles Hospital Shanghai are owned by its subsidiaries and classified as investment properties in the subsidiaries’ standalone financial statements. For the preparation of the consolidated financial statements, a portion of these properties are reclassified from investment properties to property, plant and equipment as these properties are used in the supply of medical services by the Group. Accordingly, the carrying values of these properties are depreciated over their useful lives in the condensed consolidated financial statements of the Group.
Page 12 of 27
4.1 Reportable segments (cont’d) The amount of S$15,472,000 (2024: S$15,631,000) relates to the depreciation of these properties for the year ended 31 December 2025. Geographical information The Group operations are primarily in Singapore, Greater China, Vietnam, Cambodia and Japan. In presenting information on the basis of geographical segments, segment revenue is based on the geographical location of customers and segment assets are based on the geographical location of the assets. Group 31 31 December December 2025 2024 S$’000 S$’000 Revenue Singapore Greater China Rest of Asia Consolidated revenue
680,795 65,357 19,147 765,299
669,145 65,302 17,117 751,564
Non-current assets Singapore Greater China Rest of Asia Consolidated non-current assets*
671,501 304,010 13,409 988,920
677,195 322,945 9,692 1,009,832
Non-current assets exclude financial instruments and deferred tax assets.
4.2 Disaggregation of Revenue Group
Revenue from contracts with customers Rental income Insurance revenue
Page 13 of 27
31 December 2025 S$’000
31 December 2024 S$’000
578,501 7,678 179,120 765,299
572,906 7,323 171,335 751,564
5
Financial assets and financial liabilities Set out below is an overview of the financial assets and financial liabilities of the Group as at 31 December 2025 and 31 December 2024:
Group
At amortised cost S$’000
Carrying amount Other financial liabilities Total S$’000 S$’000
Fair value Level 1 S$’000
Level 2 S$’000
Level 3 S$’000
Total S$’000
31 December 2025 Financial assets not measured at fair value Trade and other receivables # Cash and cash equivalents
96,277 310,791 407,068
– – –
96,277 310,791 407,068
– – –
(49,704) (186,749) (236,453)
(49,704) (186,749) (236,453)
100,749 343,671 444,420
– – –
100,749 343,671 444,420
– – – –
(55,982) (216,232) (2,788) (275,002)
(55,982) (216,232) (2,788) (275,002)
Financial liabilities not measured at fair value Loans and borrowings Trade and other payables*
–
(49,704)
–
(49,704)
–
(55,982)
–
(55,982)
–
–
(2,788)
(2,788)
31 December 2024 Financial assets not measured at fair value Trade and other receivables # Cash and cash equivalents
Financial liabilities not measured at fair value Loans and borrowings Trade and other payables* Other financial liabilities
Excludes prepayments Excludes deferred income and other long-term employee benefits
Page 14 of 27
5
Financial assets and financial liabilities (cont’d)
Company
At amortised cost S$’000
Carrying amount Other financial liabilities Total S$’000 S$’000
Fair value Level 1 S$’000
Level 2 S$’000
Level 3 S$’000
Total S$’000
31 December 2025 Financial assets not measured at fair value Trade and other receivables # Cash and cash equivalents
109,965 86,366 196,331
– – –
109,965 86,366 196,331
– – –
(11,204) (83,742) (94,946)
(11,204) (83,742) (94,946)
85,617 145,658 231,275
– – –
85,617 145,658 231,275
– – –
(11,265) (70,962) (82,227)
(11,265) (70,962) (82,227)
Financial liabilities not measured at fair value Loans and borrowings Trade and other payables*
–
(11,204)
–
(11,204)
–
(11,265)
–
(11,265)
31 December 2024 Financial assets not measured at fair value Trade and other receivables # Cash and cash equivalents
Financial liabilities not measured at fair value Loans and borrowings Trade and other payables*
Excludes prepayments Excludes deferred income and other long-term employee benefits
Page 15 of 27
6
Profit before tax Profit before tax has been arrived after charging/(crediting):
6 months ended 31 December 2025 S$’000 Changes in fair value in investment properties Contributions to defined contribution plans Foreign exchange loss/(gain) (Gain)/Loss on disposal of property, plant and equipment, net Impairment loss on intangible assets and goodwill Interest expense:
- bank loans
- non-controlling interest
- lease liabilities
- others Interest income Property, plant and equipment written off Recovery of bad debts Value of employee services received for issue of share options and share awards, included in staff costs Write-off for stock obsolescence
6 months ended 31 December 2024 S$’000
Group 12 months ended 31 December 2025 S$’000
12 months ended 31 December 2024 S$’000
(4,700) 10,685 59
– 11,542 (47)
(4,700) 22,111 1,791
– 21,282 308
1
1,921
(3)
1,922
316
2,601
316
2,601
852 481 651 7 (2,898) 956 (205)
1,220 713 606 56 (4,951) 184 (160)
1,796 1,178 1,189 7 (7,333) 1,077 (851)
2,824 1,438 1,277 331 (10,247) 446 (376)
1,453 245
1,641 89
3,066 262
3,465 254
Page 16 of 27
7
Taxation The Group calculates the period income tax expense using the tax rate that would be applicable to the expected total annual earnings. The major components of income tax expense in the condensed consolidated statement of profit or loss are:
6 months ended 31 December 2025 S$’000 Current income tax expense Current withholding tax expense Deferred income tax expense relating to origination and reversal of temporary differences
Adjustment for prior years Current income tax expense – Adjustment for prior years Deferred tax expense – Adjustment for prior years Tax expense
8
12 months ended 31 December 2024 S$’000
10,751 405
9,943 629
22,357 975
23,112 1,219
242 11,398
2,150 12,722
(187) 23,145
626 24,957
(366)
(171)
(663)
67
41
(354)
41
(344)
(325)
(525)
(622)
(277)
11,073
12,197
22,523
24,680
Group 6 months 12 months ended 31 ended 31 December December 2024 2025 S$’000 S$’000
12 months ended 31 December 2024 S$’000
46,273
44,576
Dividends 6 months ended 31 December 2025 S$’000 Dividends paid: Final dividend in respect of the previous financial year of 2.5 (2024: 2.4) cents per share
9
Group 6 months 12 months ended 31 ended 31 December December 2024 2025 S$’000 S$’000
–
–
Net assets value Group Company 31 December 31 December 31 December 31 December 2025 2024 2025 2024 S$ S$ S$ S$ Net asset value per ordinary share [C]
57.52 cents
56.50 cents
60.28 cents
58.39 cents
[C] The calculation of net asset value per ordinary share was based on 1,840,160,875 shares as at 31 December 2025 (31 December 2024: 1,858,137,925).
Page 17 of 27
10
Intangible assets and goodwill Software under Customer Membership rights development Software Goodwill relationship S$’000 S$’000 S$’000 S$’000 S$’000
Total S$’000
Group Cost At 1 January 2024 Additions Write-off Effects of movement in exchange rate At 31 December 2024 Additions Write-off Reclassification Effects of movement in exchange rate At 31 December 2025
23,574 – – 135 23,709 – – – (511) 23,198
4,125 – – 14 4,139 – – – (71) 4,068
139 – (25) – 114 – – – – 114
640 704 – – 1,344 348 – (1,521) – 171
17,388 935 (54) 17 18,286 1,811 (3,568) 1,521 (87) 17,963
45,866 1,639 (79) 166 47,592 2,159 (3,568) – (669) 45,514
Accumulated amortisation and impairment losses At 1 January 2024 Amortisation* Write-off Impairment loss Effects of movement in exchange rate At 31 December 2024 Amortisation* Write-off Impairment loss Effects of movement in exchange rate At 31 December 2025
12,815 – – 2,600 84 15,499 – – 316 (366) 15,449
3,762 72 – – 14 3,848 71 – – (66) 3,853
111 – (25) 1 – 87 – – – – 87
– – – – – – – – – – –
10,335 2,334 (8) – 13 12,674 2,351 (2,777) – (46) 12,202
27,023 2,406 (33) 2,601 111 32,108 2,422 (2,777) 316 (478) 31,591
Carrying amounts At 1 January 2024 At 31 December 2024 At 31 December 2025
10,759 8,210 7,749
363 291 215
28 27 27
640 1,344 171
7,053 5,612 5,761
18,843 15,484 13,923
- During the year, amortisation charge of $849,000 (2024: $861,000) was included in ‘insurance service expenses’ in the consolidated statement of profit or loss.
For the purposes of impairment testing, goodwill has been allocated to the Group’s cash generating units (CGUs) (operating divisions) as follows:
China clinics
Group 2025 S$’000
Group 2024 S$’000
North region East region
3,875 3,874
3,938 3,937
–
335 8,210
Cambodia clinic
7,749
The recoverable amount of CGUs were based on its value in use, determined by discounting the pre-tax future cash flows to be generated from the continuing use of the CGUs.
Page 18 of 27
10
Intangible assets and goodwill (cont’d) The recoverable amounts of CGUs were based on its value in use, determined by discounting the pre-tax future cash flows to be generated from the continuing use of the CGUs. Key assumptions used in the estimation of value in use were as follows: Group 2025 %
Group 2024 %
China clinics North region Discount rate Terminal growth rate Revenue growth rate for next five years
12.1 2.0 4.0
12.6 2.0 2.2 – 2.5
East region Discount rate Terminal growth rate Revenue growth rate for next five years
13.2 2.0 4.0
14.8 2.0 1.7 – 2.0
Cambodia Discount rate Terminal growth rate Revenue growth rate for next five years
18.2 3.0 0.5
20.0 3.0 2.1
The discount rate was a pre-tax measure based on the rate of 10-year government bonds issued by the government in the relevant market and in the same currency as the cash flows, adjusted for a risk premium to reflect both the increased risk of investing in equities generally and the systematic risk of the specific CGU. Five years of cash flows were included in the discounted cash flow model. A long-term growth rate into perpetuity has been determined as the nominal GDP rates for the countries in which the CGUs operate. Revenue growth was projected based on expectation of future outcomes, taking into account the average growth levels experienced over the past five years and the estimated growth for the next five years.
11
Property, plant and equipment During the year ended 31 December 2025, the Group acquired property, plant and equipment (PPE) amounting to S$27,592,000 (31 December 2024: S$26,520,000), transferred S$17,200,000 (31 December 2024: S$ Nil), from investment property which were re-designated as premises occupied by the owner to PPE and disposed of assets amounting to S$104,000 (31 December 2024: S$5,325,000). During the six months ended 31 December 2025, the Group acquired PPE amounting to S$16,391,000 (31 December 2024: S$10,396,000), transferred S$17,200,000 (31 December 2024: S$ Nil), from investment property which were re-designated as premises occupied by the owner to PPE and disposed of assets amounting to S$87,000 (31 December 2024: S$3,967,000).
Page 19 of 27
12
Investment properties Group 2025 S$’000 Balance as at 1 January Reclassification to property, plant and equipment Changes in fair value Balance as at 31 December
2024 S$’000
246,100 (17,200) 4,700 233,600
246,100 – – 246,100
Valuation technique and significant unobservable inputs The Group’s policy is for investment property to be measured at fair value for which the Group completes property valuations at least annually by independent registered valuers at the end of the year. Investment properties that are measured at fair value are stated at fair value as at 31 December 2025 based on valuation performed by independent professional valuer, Colliers International Consultancy & Valuation (Singapore) Pte Ltd, having appropriate recognised professional qualifications and recent experience in the location and category of property being valued. The fair value measurement for investment properties of $233,600,000 (2024: $246,100,000) has been categorised as a Level 3 fair value based on the inputs to the valuation technique used. The following table shows the Group’s valuation technique used in measuring the fair value of investment properties, as well as the significant unobservable inputs used.
Valuation technique
Significant unobservable inputs
Capitalisation approach
Capitalisation rates 3.50% to 5.30% (2024: 3.50% to 5.50%)
Capitalisation and discounted cash flow approach
Capitalisation rate 4.00% (2024: 4.00%) Discount rates 7.00% (2024: 7.00%) Terminal yield rates 4.25% (2024: 4.25%)
13
Inter-relationship between key unobservable inputs and fair value measurement The estimated fair value varies inversely against the capitalisation rates. The estimated fair value varies inversely against the capitalisation rates, terminal yield rates and discount rates.
Loans and borrowings Group 2025 2024 S$’000 S$’000 Amount repayable after one year Unsecured bank loans
Company 2025 S$’000
2024 S$’000
–
49,116
–
10,000
Amount repayable within one year or on demand Unsecured bank loans
49,704
6,866
11,204
1,265
Total loans and borrowings
49,704
55,982
11,204
11,265
Page 20 of 27
14
Share capital 2025 No. of shares ’000 S$’000
2024 No. of shares ’000 S$’000
Company Fully paid ordinary shares, with no par value: At 1 January Issue of shares under share option scheme At 31 December
1,884,544 – 1,884,544
440,099 – 440,099
1,884,198 346 1,884,544
439,819 280 440,099
The total number of issued shares excluding treasury shares at 31 December 2025 was 1,840,160,875 (31 December 2024: 1,858,137,925). (i) Exercise of share options and share awards During the year, the Company utilised 2,142,850 treasury shares pursuant to the Raffles Medical Group Performance Share Plan. On 8 September 2025, options to subscribe for 10,250,000 ordinary shares at an exercise price of S$1.01 were granted to 144 eligible participants pursuant to the Raffles Medical Group (2020) Share Option Scheme. On 8 September 2025, 900,000 share awards were granted to 309 eligible participants pursuant to Raffles Medical Group (2020) Performance Share Plan. As at 31 December 2025, there were 78,707,000 (31 December 2024: 82,421,000) options outstanding in relation to ordinary shares of the Company. As at 31 December 2025, the number of shares comprised in contingent awards granted under the Raffles Medical Group (2020) Performance Share Plan which has not been released was 2,109,850 (31 December 2024: 2,136,050). (ii) Treasury shares The Company holds 44,384,050 treasury shares as at 31 December 2025 (31 December 2024: 26,407,000). Treasury shares held by the Company as at 31 December 2025 represent 2.41% (31 December 2024: 1.42%) of the total number of issued shares (excluding treasury shares). Number of treasury shares Balance as at 1 January 2025 Acquisition of treasury shares Use of treasury shares Balance as at 31 December 2025
26,407,000 20,119,900 (2,142,850) 44,384,050
Page 21 of 27
14
Share capital (cont’d) (iii) Subsidiary holdings There is no subsidiary holdings as at 31 December 2025 (31 December 2024: Nil). There were no sales, transfers, cancellation and/or use of subsidiary holdings as at 31 December 2025 (31 December 2024: Nil).
.
Page 22 of 27
Other Information Required by Listing Rule Appendix 7.2 1
Whether the figures have been audited or reviewed and in accordance with which auditing standard or practice. The financial statements of Raffles Medical Group Ltd (the Company) and its subsidiaries (the Group), which comprise the consolidated statement of financial position of the Group and the statement of financial position of the Company as at 31 December 2025, the consolidated statement of profit or loss, consolidated statement of comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows of the Group for the year then ended, and notes to the financial statements have been audited in accordance with Singapore Standards on Auditing. A copy of the Independent Auditors’ report is attached. The condensed consolidated statement of profit or loss and other comprehensive income and condensed consolidated statement of cash flows for the six-month period ended 31 December 2025 and certain explanatory notes have not been audited or reviewed.
2
A review of the performance of the group, to the extent necessary for a reasonable understanding of the group’s business. It must include a discussion of the following:(a) any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and (b) any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on. The Group reported a revenue of S$765.3 million for the financial year (FY) ended 31 December 2025, a 1.8% increase as compared to FY2024. Profit after tax and minority interests (PATMI) for the year stood at S$70.6 million, a 13.4% increase over FY2024. The increase in PATMI was attributable to improvement in performance from the hospital services and insurance businesses and fair value gain on investment properties in FY2025. The PATMI for the second half (2H) of 2025 improved by 21.7% to S$38.5 million compared to S$31.6 million in 2H2024. The Hospital Services division remained a key contributor, with revenue growing 3.5% to S$357.8 million and profit increasing 15.3% to S$41.1 million, supported by steady patient volumes, higher bill size and operational efficiencies in both Singapore and China. The Healthcare Services division also recorded revenue of S$285.9 million, with profitability remaining broadly stable. The 3% decrease in revenue is due to reduced consumption of services. In the China market, revenue increased 2.3% from CNY351.3 (S$65.3) million in FY2024 to CNY359.4 (S$65.4) million in FY2025. The RafflesHospital brand continues to gain wider recognition among patients in China, reinforcing its position as a trusted provider of quality healthcare. Cost saving measures put in place earlier are helping to improve bottomline. Strategic partnerships with Shanghai’s Renji Hospital, Zhongshan Hospital and Chongqing’s First Affiliated Hospital will enable our RafflesChinaHealthcare to better integrate our international standards with local expertise, to provide high quality patient-centred care in China. RafflesHealthInsurance (RHI), the Group’s Health Insurance Services Division, saw a 4.1% increase in revenue from S$178.0 million in FY2024 to S$185.2 million in FY2025, mainly contributed by contract repricing and new contracts. The healthcare insurance industry is generally facing a higher loss ratio as a result of medical inflation. With vigilant and watchful claims adjudication and thoughtful control of management expenses, RHl's results reflected a 50.6% improvement when compared to FY2024. On a full year basis, the Group generated S$101.3 million in cash from operating activities. Its balance sheet remains strong, with cash and cash equivalents totaling S$310.8 million as of 31 December 2025. During FY2025, the Group distributed cash dividends of S$46.3 million, acquired S$19.9 million of its own shares, acquired a minority shareholder’s share at S$16.6 million and made repayment of a loan to minority shareholder amounting to S$29.4 million. For the financial year ended 31 December 2025, the Directors are pleased to recommend a final core dividend of 3.0 cents per share, an increase of 20% year-on-year. This represents 84% of the sustainable Group PATMI for FY2025. Page 23 of 27
3
Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results. The current financial period’s results are in line with the Directors’ expectations as disclosed in the Group’s 1H2025 results announcement.
4
A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months. Global trade tensions and geopolitical uncertainties remain a challenge to the global economy. Volatility in financial markets and interest rate uncertainties will affect investor sentiments. The healthcare sector remains less cyclical because of stable demand for its services. Singapore and China both face demographic challenges of aging population and falling birth rates. The Group operates in both of these geographies and we will respond to these trends and grow services that are in demand. To address rising insurance premiums and private healthcare costs in Singapore, the Ministry of Health introduced a higher co-payment cap to a minimum of S$6,000. RHI will introduce a new rider that complies with the new regulations. The change is not expected to have a significant impact to the financials of RHI. We will expand and grow our depth and breadth of services in the 14 cities of Asia where we currently operate. Globally, technological and social changes are gathering momentum. We will monitor these changes closely. We intend to be early adopters of appropriate AI applications in healthcare, both to improve efficiencies as well as to transform care and service delivery. The RafflesHealthyLongevityCentre, scheduled to open in Q1 2026, is a physician-led, multidisciplinary service focused on helping individuals achieve healthier, longer lives. Through advanced diagnostics and evidence-based therapies, the Centre will provide personalised and preventive care tailored to each individual’s health profile. Amidst rising healthcare costs and evolving patient needs, the Group, as an integrated healthcare provider, is well-poised to provide individuals and corporates with end-to-end insurance and healthcare solutions. This year, the Group celebrates its 50th Anniversary of caring. We resolve to continue serving our patients and corporate clients with the same Compassion, Commitment, Excellence, through our Teamwork of physicians, nurses and healthcare managers adding Value to the lives of our patients (CCETV, our core values). Barring unforeseen circumstances, the Directors are optimistic that the Group will be profitable in the current financial year 2026.
5
Dividend a)
Current Financial Period Reported on Any dividend declared for the current financial period reported on? Yes Name of dividend
Proposed Final
Dividend Type
Ordinary
Dividend Amount per Share (in cents)
3.0 cents per ordinary share (one-tier tax)
Tax Rate
Tax Exempt
Page 24 of 27
5
Dividend (cont’d) (b) Corresponding Period of the Immediately Preceding Financial Year Any dividend declared for the corresponding period of the immediately preceding financial year? Yes Name of dividend
Final
Dividend Type
Ordinary
Dividend Amount per Share (in cents)
2.5 cents per ordinary share (one-tier tax)
Tax Rate
Tax Exempt
(c) Date payable The Directors are pleased to recommend a final dividend of 3.0 cents per share, amounting approximately to S$55.2 million in respect of the financial year ended 31 December 2025 for approval by the shareholders at the next Annual General Meeting to be convened on 24 April 2026. The date of payment of the proposed dividend, if approved at the Annual General Meeting, will be on 22 May 2026. (d) Books closure date Notice is hereby given that, subject to shareholders’ approval of the payment of the final dividend (Dividend) at the Annual General Meeting scheduled for 24 April 2026, the Share Transfer Books and the Register of Members of the Company will be closed on 14 May 2026, for determining of shareholders' entitlements to the Dividend. Registrable transfers received by the Company's Registrar, Boardroom Corporate & Advisory Services Pte Ltd at 1 Harbourfront Avenue, Keppel Bay Tower, #14-07, Singapore 098632, up to the close of business at 5.00 p.m. on 13 May 2026 (Record Date) will be registered for the Dividend. In respect of ordinary shares in securities accounts with The Central Depository (Pte) Limited (CDP), entitlements to the Dividend will be computed based on the shareholding position after settlement of all trades on Record Date. The Dividend will be paid by the Company to CDP which will, in turn, distribute the Dividend to holders of the securities accounts. (e) Scrip Dividend Scheme The Scrip Dividend Scheme will not be applicable to the final dividend this year. 6
If no dividend has been declared/recommended, a statement to that effect. Not applicable.
7
If the group has obtained a general mandate from shareholders for Interested Parties Transactions (IPTs), the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect. The Company did not obtain a general mandate from shareholders for IPTs.
8
Confirmation pursuant to Rule 720 (1) of the Listing Manual The Company confirms that it has procured undertakings from all its Directors and executive officers (in the format set out in Appendix 7.7) under Rule 720 (1) of the Listing Manual. Page 25 of 27
9
In the review of performance, the factors leading to any material changes in contributions to turnover and earnings by the business or geographical segments. Please refer to Item 2.
10
11
A breakdown of sales.
2025 S$’000
Group 2024 S$’000
Change %
(a)
Revenue reported for first half year
378,447
365,690
3.5
(b)
Operating profit after tax before deducting noncontrolling interests reported for first half year
32,461
30,929
5.0
(c)
Revenue reported for second half year
386,852
385,874
0.3
(d)
Operating profit after tax before deducting noncontrolling interests reported for second half year
38,610
31,353
23.1
Disclosures of incorporation of Entities, Acquisition and Realisation of Shares pursuant to Rule 706(A) of the Listing Manual On 30 October 2025, Shanghai Capital Pte Ltd (SHC), a subsidiary of the Company, completed the acquisition of the remaining 30% which it does not already hold, in the equity interest of Shanghai Qihua Hospital Co. Ltd., China (SQH), for a total cash consideration of S$16.6 million. SHC in turn holds a 100% equity interest of SQH. The net asset of the acquired shares is S$18.2 million at the acquisition date. The consideration was arrived at following arm’s length negotiations on a “willing buyer-willing seller” basis, taking into account, amongst others, the performance of SQH in the recent years, and its existing assets and operations. The consideration was fully satisfied in cash from the Company’s internal resources. With the completion of this acquisition, SQH became a wholly owned subsidiary of SHC. In January 2026, Raffles HuKan (Chongqing) Internet Hospital Co., Ltd. (RHIH), was incorporated in China as an indirect wholly owned subsidiary of the Company, with a registered share capital of CNY10 million (S$1.8 million). The principal activity of RHIH is the provision of online and offline medical services.
Page 26 of 27
12
Disclosure of person occupying a managerial position in the issuer or any of its principal subsidiaries who is a relative of a director or chief executive officer or substantial shareholder of the issuer pursuant to Rule 704(13). If there are no such persons, the issuer must make an appropriate negative statement. Family relationship with any director and/or substantial shareholder
Name
Age
Dr Loo Choon Yong
76
Father of Dr Sarah Lu Qinghui and Dr Lu Liangjian David
Dr Sarah Lu Qinghui
44
Daughter of Dr Loo Choon Yong and sister of Dr Lu Liangjian David
Current position and duties, and the year the position was held Executive Chairman of Raffles Medical Group (RMG) Ltd since 1997, having overall executive responsibility for the business direction, strategies and management of the RMG group of companies. (1) Executive and NonIndependent Director, on 1 June 2020 (2) Consultant Breast Surgeon, Raffles Hospital Pte Ltd, on 1 June 2020 (3) Executive Medical Director, Raffles Hospital Pte Ltd, on 1 February 2025 (4) Managing Director, Singapore Healthcare of RMG on 1 August 2025.
BY ORDER OF THE BOARD Kimmy Goh Company Secretary 23 February 2026
Page 27 of 27
Details of changes in duties and position held, if any, during the year Nil
Appointed Executive Medical Director, Raffles Hospital Pte Ltd on 1 February 2025 Appointed Managing Director, Singapore Healthcare of RMG on 1 August 2025 with overall responsibility for all commercial matters of the Division.
Result Announcement For the Second-Half and Full Year 2025 Audited 2H2025 (S$’m)
2H2024 (S$’m)
Change %
2025 (S$’m)
2024 (S$’m)
Change %
Revenue
386.9
385.9
0.3
765.3
751.6
1.8
EBITDA
71.3
64.4
10.7
135.0
125.7
7.4
Operating Profit
48.7
41.2
18.3
90.4
82.5
9.5
Profit After Tax
38.6
31.4
23.1
71.1
62.3
14.1
PATMI
38.5
31.6
21.7
70.6
62.2
13.4
2025 (cents)
2024 (cents)
Change %
Diluted Earnings per Share
3.81
3.34
14.1
Net Assets Value per Share
57.52
56.50
1.8
Key Highlights
Revenue grew 1.8% to S$765.3 million
PATMI for 2H 2025 and FY2025 improved 21.7% and 13.4% respectively
Diluted earnings per share increased 14.1% to 3.81 cents
Continued healthy cash position of S$310.8 million
Proposed final dividend of 3.0 cents per share, at 84% payout ratio on sustainable Group PATMI
1
MEDIA RELEASE
RafflesMedicalGroup Delivers 22% PATMI Growth to $38.5 million in 2H2025 Singapore, 23 February 2026 – RafflesMedicalGroup (RMG or the Group) delivered strong growth in the second half of 2025, with Profit After Tax and Minority Interests (PATMI) rising 22% to S$38.5 million for 2H2025, compared to S$31.6 million in 2H2024. For FY2025, PATMI increased 13.4% to S$70.6 million, driven by improved performance from the Hospital Services and Insurance businesses, as well as fair value gains on investment properties. Group revenue for FY2025 rose 1.8% year-on-year to S$765.3 million, underpinned by higher patient volumes, improved average bill sizes and operational efficiencies. The strong results reflect disciplined operational execution across the Group’s businesses and continued momentum in China. The Hospital Services Division delivered strong growth, with revenue increasing 3.5% year-on-year to S$357.8 million and profit rising 15.3% to S$41.1 million. Performance was supported by steady patient volumes, higher bill sizes, and operational efficiencies across both Singapore and China. The Healthcare Services Division generated revenue of S$285.9 million, with profitability remaining broadly stable. Together, these results demonstrate the Group’s ability to translate operational improvements into sustained earnings growth, particularly in the second half of the year. The RafflesHospital brand continued to gain recognition among patients in China, reinforcing its position as a trusted provider of quality healthcare. RafflesChinaHealthcare contributed positively to the Group’s performance, with revenue increasing 2.3% to CNY359.4 million (S$65.4 million) in FY2025, from CNY351.3 million (S$65.3 million) in FY2024. Earlier cost efficiency initiatives have improved bottomline, while strategic partnerships with Shanghai’s Renji Hospital and Chongqing’s First Affiliated Hospital continue to strengthen the integration of our international standards with local expertise to provide high quality patient care. These initiatives position RafflesChinaHealthcare for sustainable growth and a growing contribution to the Group’s overall results. 2
RafflesHealthinsurance (RHI) recorded revenue growth of 4.1%, increasing from S$178.0 million in FY2024 to S$185.2 million in FY2025, driven by contract repricing and new contracts. Disciplined claims management and prudent expense control underpinned improved profitability, reflecting a 50.6% improvement compared to FY2024, despite a higher-cost insurance environment. The Group generated operating cash flows of S$101.3 million in FY2025. Its balance sheet remained strong, with S$310.8 million in cash and cash equivalents as at 31 December 2025, providing flexibility to support strategic growth initiatives while continuing to return value to shareholders. During FY2025, the Group undertook share buybacks and acquisitions of minority interests, reinforcing its financial position while balancing growth investments with shareholder returns. For FY2025, the Board has proposed a final core dividend of 3.0 cents per share, representing approximately 84% of sustainable Group PATMI. Business Updates
Positioned for Demographic Shifts in Singapore and China Singapore and China both face demographic challenges of ageing populations and declining birth rates. The Group operates in both geographies and we will respond to these trends and grow services that are in demand.
Commitment to Caring Across Generations and Regional Expansion The Group is celebrating its 50th anniversary of caring this year. We resolve to continue serving our patients, corporate clients with the same compassion, commitment, excellence, through our teamwork of physicians, nurses and healthcare managers, adding value to the lives of our patients. We will expand and grow our depth and breadth of services in the 14 cities of Asia where we operate now. We are continually exploring and evaluating earnings-accretive businesses and assets in the Asia Pacific. The RafflesHealthyLongevityCentre, scheduled to open in Q1 2026, is a physician-led, multidisciplinary service focused on helping individuals achieve healthier, longer lives. Through advanced diagnostics and evidence-based therapies, the Centre will provide personalised and preventive care tailored to each individual’s health profile.
3
Technology Adoption and Innovative Care Delivery Globally, technological and social changes are gathering momentum. We will monitor these changes closely. We intend to be early adopters of appropriate AI applications in healthcare, both to improve efficiencies as well as to transform care and service delivery.
Proactive Response to Regulatory Changes In Singapore, rising insurance premiums and private healthcare costs have prompted the Ministry of Health to introduce a higher co-payment cap to a minimum of S$6,000. RHI will launch a new rider, that complies with the new regulations. The change is not expected to have a significant impact to RHI’s financials, demonstrating the Group’s ability to adapt efficiently to regulatory developments.
Delivering Integrated Healthcare Solutions Amidst evolving patient needs and rising healthcare costs, RMG is well-positioned as an integrated healthcare provider, delivering end-to-end healthcare and insurance solutions to individuals and corporates.
Based on the current conditions and barring unforeseen circumstances, the Board is optimistic that the Group will remain profitable in FY2026. “This year, we celebrate 50 years of RafflesMedicalGroup, a milestone that, together with our strong performance in 2025, is a testament to the strength of our foundations, the trust earned through generations of patient care, and our pledge to give our patients our very best. We are ready to enter our next phase of growth, anchored in our strengths and our commitment to excellence and value creation,” said Dr Loo Choon Yong, Executive Chairman, RafflesMedicalGroup.
For media queries, please contact Joanna Lee (Ms) Senior Manager, Corporate Communications Raffles Medical Group Email: [email protected]
4
About Us About Raffles Medical Group Founded in 1976, RafflesMedicalGroup (RMG or the Group) is one of the leading integrated private healthcare providers in the region, providing a continuum of services from primary and tertiary care to health insurance for people across Asia. A proudly Singaporean brand, RMG is listed on the mainboard of the Singapore stock exchange (SGX: BSL) and operates in 14 cities in five countries in Asia. This network includes four hospitals and over 100 multi-disciplinary clinics, offering services such as health screening, specialist care, diagnostic radiology, dental and traditional Chinese medicine. Together with about 2,900 employees, RMG brings 50 years of trusted healthcare expertise and care to more than 2.8 million patients across our network as their trusted partner for health. For more information, please visit rafflesmedicalgroup.com. About Raffles Medical RafflesMedical is the primary care network of RafflesMedicalGroup operating over 55 practices and clinics in Singapore providing family medicine, health screening and dental services. RafflesMedical also has Japanese clinics and/or clinics offering Japanese services in Singapore, Beijing Tianjin, Shanghai, Osaka, Fukuoka, and Ho Chi Minh City, servicing its Japanese patients with family medicine and dental services. In Singapore, RafflesMedical represents one of the largest networks of primary care clinics and services over 7,000 corporate clients, supporting the healthcare needs of businesses and employees. Through RafflesMedicalInternational, the Raffles brand of quality and affordable care is available to patients in 14 cities, including Singapore, Greater China, Japan as well as Cambodia and Vietnam. About Raffles Hospital RafflesHospital is the flagship private tertiary hospital offering of the Group in Singapore that currently operates a growing network of tertiary hospitals in Singapore and China, including RafflesHospitalChongqing, RafflesHospitalShanghai, RafflesHospitalBeijing and American International Hospital (AIH) in Ho Chi Minh City, Vietnam, which the Group commenced managing in January 2024. In Singapore, RafflesHospital offers a comprehensive range of medical and dental specialties as well as diagnostic services. RafflesHospital is the only private tertiary hospital in Singapore to be recognised by the Ministry of Health as Trauma Centre and is authorised to accept emergency cases from public ambulances under the Emergency Care Collaboration Scheme. The Hospital also operates more than 30 specialist centres and specialist satellite clinics, covering over 30 disciplines. Subscribing to the Group Practice model of healthcare, over 1,500 physicians, nurses and allied healthcare professionals bring the Raffles brand of quality, peer-reviewed healthcare to patients in the region. About Raffles China Healthcare RafflesChinaHealthcare is the operating division of the RafflesMedicalGroup in China, its presence in China first started in 1995 with the opening of RafflesMedicalGroup’s first overseas clinic in Hong Kong. Since then, RafflesChinaHealthcare has grown its presence and provides primary and tertiary care through its clinics and hospitals in seven cities – Beijing, Shanghai, Chongqing, Tianjin, Nanjing, Dalian and Hong Kong SAR. RafflesChinaHealthcare’s network of tertiary hospitals includes RafflesHospitalChongqing, Singapore’s first private tertiary hospital in China, and RafflesHospitalShanghai, which opened in July 2021, as well as the RafflesHospitalBeijing, bringing the Raffles brand of quality, peer-reviewed healthcare to more patients in China. About Raffles Health Insurance RafflesHealthinsurance (RHI) is the health insurance division of RafflesMedicalGroup, providing healthcare insurance to corporates and individuals in Singapore. Backed by the expertise of a trusted medical group with 50 years of experience, RafflesHealthinsurance seeks to provide healthcare financing solutions that cater to the needs of all its policy owners and members. Incorporated in 2004, RafflesHealthinsurance is a wholly-owned subsidiary of the RafflesMedicalGroup and is an Integrated Shield Plan provider appointed by the Ministry of Health in Singapore. RafflesHealthinsurance, through its partnership with Bupa Global, also offers a wider range of international private health plans, which are co-insured by RHI and Bupa, to cater to the needs of individuals and corporate clients of the international business community in Singapore.
5
1
MEDIA RELEASE
RafflesMedicalGroup Appoints
Ms Woo Yeng Yeng as Chief Financial Officer
S
ingapore, 30 September 2025 – RafflesMedicalGroup (the Group) is pleased to announce
the appointment of Ms Woo Yeng Yeng as Chief Financial Officer (CFO) with effect from 1 October
2025.
Ms W
oo Yeng Yeng
Chief Financial Officer
Raffles Medical Group
Ms Woo is a seasoned finance leader with over 20 years’
experience across real estate, hospitality and capital markets,
with expertise in financial strategy, governance and investor
relations.
Prior to joining the Group, Ms Woo was the CFO and Head of
Investor Relations of PARAGON REIT, overseeing finance
matters, corporate governance and the formulation of strategic
plans. Before that, as Head of Finance
at CapitaLand
Investment (International), Ms Woo oversaw finance
operations in Australia, Japan, Korea, Europe and USA.
Ms
Woo holds a Bachelor of Accountancy degree from Nanyang Technological University,
Singapore and a Master of Commerce (International Business) from The University of New South
Wales, Australia. She is also a Chartered Accountant of Singapore with the Institute of Singapore
Chartered Accountant.
“We are delighted to welcome Ms Woo to Raffles as we approach our 50
th
anniversary next year.
Her proven track rec
ord and breadth of international experience will contribute positively to the
Group’s s
ustainable growth in the years ahead,” said Dr Loo Choon Yong, Executive Chairman,
RafflesMedicalGroup.
For media queries, please contact Joanna Lee (Ms) Senior Manager, Corporate Communications Raffles Medical Group Email: [email protected]
2
About Us
About Raffles Medical Group
Founded in 1976, RafflesMedicalGroup (RMG or the Group) is one of the leading integrated private healthcare providers
in the region, providing a continuum of services from primary and tertiary care to health insurance for people across Asia.
A proudly Singaporean brand, RMG is listed on the mainboard of the Singapore stock exchange (SGX: BSL) and operates
in 14 cities in five countries in Asia. This network includes four hospitals and over 100 multi-disciplinary clinics, offering
services such as health screening, specialist care, diagnostic radiology, dental and traditional Chinese medicine.
Together with about 2,900 employees, RMG brings over 48 years of trusted healthcare expertise and care to more than
2.8 million patients across our network as their trusted partner for health. For more information, please visit
rafflesmedicalgroup.com.
About Raffles Medical RafflesMedical is the primary care network of RafflesMedicalGroup operating over 55 practices and clinics in Singapore providing family medicine, health screening and dental services. RafflesMedical also has Japanese clinics and/or clinics offering Japanese services in Singapore, Beijing Tianjin, Shanghai, Osaka, Fukuoka, and Ho Chi Minh City, servicing its Japanese patients with family medicine and dental services. In Singapore, RafflesMedical represents one of the largest networks of primary care clinics and services over 7,000 corporate clients, supporting the healthcare needs of businesses and employees. Through RafflesMedicalInternational, the Raffles brand of quality and affordable care is available to patients in 14 cities, including Singapore, Greater China, Japan as well as Cambodia and Vietnam.
About Raffles Hospital
RafflesHospital is the flagship private tertiary hospital offering of the Group in Singapore that currently operates a
growing network of tertiary hospitals in Singapore and China, including RafflesHospitalChongqing,
RafflesHospitalShanghai, RafflesHospitalBeijing and American International Hospital (AIH) in Ho Chi Minh City,
Vietnam, which the Group commenced managing in January 2024. In Singapore, RafflesHospital offers a
comprehensive range of medical and dental specialties as well as diagnostic services. RafflesHospital is the only
private tertiary hospital in Singapore to be recognised by the Ministry of Health as Trauma Centre and is authorised to
accept emergency cases from public ambulances under the Emergency Care Collaboration Scheme. The Hospital also
operates more than 30 specialist centres and specialist satellite clinics, covering over 30 disciplines. Subscribing to the
Group Practice model of healthcare, over 1,500 physicians, nurses and allied healthcare professionals bring the Raffles
brand of quality, peer-reviewed healthcare to patients in the region.
About Raffles China Healthcare
RafflesChinaHealthcare is the operating division of the RafflesMedicalGroup in China that provides patients with a
suite of healthcare services from primary care to tertiary care. RafflesChinaHealthcare provides primary and tertiary
care through its clinics and hospitals in seven cities in China – Beijing, Chongqing, Hong Kong SAR, Nanjing, Shanghai,
and Tianjin. RafflesChinaHealthcare’s network of tertiary hospitals includes RafflesHospitalChongqing, Singapore’s
first private tertiary hospital in China, and RafflesHospitalShanghai, which opened in July 2021, as well as the
RafflesHospitalBeijing, bringing the Raffles brand of quality, peer-reviewed healthcare to more patients in China.
RafflesChinaHealthcare has been in operation in Hong Kong SAR since 1995 with multiple medical centres across Hong
Kong SAR as well as Hong Kong International Airport where it is the exclusive medical service provider for the airport.
About Raffles Health Insurance
RafflesHealthinsurance (RHI) is the health insurance division of RafflesMedicalGroup, providing healthcare
insurance to corporates and individuals in Singapore. Backed by the expertise of a trusted medical group with over 48
years of experience, RafflesHealthinsurance seeks to provide healthcare financing solutions that cater to the needs
of all its policy owners and members. Incorporated in 2004, RafflesHealthinsurance is a wholly-owned subsidiary of
the RafflesMedicalGroup and is an Integrated Shield Plan provider appointed by the Ministry of Health in Singapore.
RafflesHealthinsurance, through its partnership with Bupa Global, also offers a wider range of international private health
plans, which are co-insured by RHI and Bupa, to cater to the needs of individuals and corporate clients of the
international business community in Singapore.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Raffles Medical Group Ltd
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| AVDS | 0.04% | 227,400 | $ 147.064K | Nov 16, 2026 |
| DXIV | 0.01% | 44,400 | $ 29.324K | Nov 12, 2026 |
| DFIS | 0.01% | 974,000 | $ 643.279K | Nov 12, 2026 |
| DFIC | 0.01% | 1,183,900 | $ 781.908K | Nov 12, 2026 |
| DISV | 0.00% | 300,200 | $ 198.267K | Nov 12, 2026 |
| DFSI | 0.00% | 47,600 | $ 31.437K | Nov 12, 2026 |
| DFAX | 0.00% | 469,511 | $ 310.089K | Nov 12, 2026 |
| DFAI | 0.00% | 528,300 | $ 348.916K | Nov 12, 2026 |
| AVDV | 0.00% | 8,600 | $ 5,561.79 | Nov 16, 2026 |